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Lentiviral (LV) vectors show promise as a gene therapy vector for cystic fibrosis (CF). The cystic 
fibrosis airway gene therapy group (CFARG) based in Adelaide, Australia have developed a 
HIV-1 based LV vector that demonstrated expression of the corrective CFTR gene up to 12 
months in the airways of CF mice. Using their two-step airway conditioning and bolus gene 
vector delivery technique, the CFARG have shown effective transduction in the airways of 
animal models such as sheep and marmosets. As this vector approaches clinical realisation 
there is a need to translate the bolus delivery regimen of this vector to an aerosol form. 
Aerosolisation would enable non-invasive and easily repeatable vector delivery, which could 
be used in future clinical trials.  
This thesis examines the efficiency of different delivery devices for aerosolising the LV vector. 
Cell culture studies showed that LV vector aerosolised using a newly developed ultrasonic 
surface acoustic wave (SAW) nebuliser produced significantly lower levels of gene expression 
than bolus delivery. This led to examination of an intra-tracheal sprayer, the MADgic™ 
atomisation device, which demonstrated promising results on delivering the vector as a spray, 
in cell culture studies. However, use of this device in human clinical studies is invasive. 
Therefore, the efficacy of delivering LV vector as an aerosol through other nebulisers was 
investigated.  
A baseline in vivo study was designed to aerosolise the LV vector into the lungs of 
mechanically ventilated mice using an Aeroneb®Pro vibrating mesh nebuliser with a 
flexiVent™ small animal ventilator. This was the first study to compare the levels of gene 
expression produced by a HIV-based LV vector delivered either as an aerosol or as a bolus 
dose into mouse lungs. Lower levels of gene expression were obtained in the trachea of 
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aerosol-treated animals compared to bolus-treated animals. However, the effect of LV 
aerosol delivery could not be determined in other conducting airways or the lung parenchyma, 
due to low power of the study produced by a substantial outlier producing a far larger than 
expected variability. The reason for the lowered gene expression observed in the trachea of 
mice treated with LV vector delivered as an aerosol through the Aeroneb®Pro-flexiVent™ 
ventilator apparatus was not conclusive.  
Further experiments investigated the cause of the low levels of gene expression observed in 
the baseline in vivo study. Bench studies with dye solution revealed that the physical dose 
volume that reached the tip of the endotracheal (ET) tube following delivery through the 
ventilator circuit was only 2% of the initial dose volume, which likely explained the low levels 
of gene expression in trachea of aerosol-treated animals. The delivery parameters were 
therefore optimised to increase the aerosol output available at the end of the delivery circuit.  
Subsequent cell culture studies examined the gene expression produced by the LV vector 
aerosolised with parameters used in the baseline in vivo study. The results demonstrated 
lowered gene expression produced by LV vector released at the end of the ventilator circuit 
compared to bolus delivery. To address this problem, different protective diluents were 
tested to try to preserve LV viability following aerosol delivery. Of these, FreeStyle™ medium 
produced higher levels of gene expression than our standard diluent, mouse serum in saline. 
On further examination, the LV vector suspended in an optimal diluent combined with 
optimal aerosolisation parameters produced higher levels of gene expression compared to 
baseline in vivo delivery parameters. However, despite these improvements the levels of gene 
expression produced by LV aerosol delivery was still significantly lower than bolus delivery. 
Hence, these studies indicate that the Aeroneb®Pro nebuliser was not ideal for aerosolising 
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the LV vector in its current formulation. 
Together the results presented in this thesis highlighted the problems associated with 
aerosolising a HIV-based LV vector using different nebulisers and through a small-animal 
ventilator circuit. Although the nebulisers investigated in this thesis were not efficient for 
aerosolising LV vector, an intra-tracheal sprayer suitable to deliver this vector for testing in 
larger animal models was identified. Future research should examine other newly introduced 
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1 INTRODUCTION  
Cystic fibrosis (CF) is an early-fatal, autosomal recessive disorder prevalent in people with 
European ancestry1. It affects one in 2,800 live births in Australia, and one in 25 people are 
non-symptomatic carriers of the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene mutation1. CF mainly affects organs with mucus secreting glands, such as the lungs, 
pancreas, gastro-intestinal tract, biliary tract, vas deferens, and sweat glands2. The 
cornerstone for CF treatment in the early half of the 19th century was pancreatic enzyme 
replacement3. Managing nutritional intake and early aggressive treatment of respiratory 
symptoms has improved life expectancy of CF patients to a median predicted age of ~37 
years4, 5. Today, the leading cause of morbidity and mortality in CF patients is lung disease6.  
1.1 CFTR gene  
The CFTR gene was first sequenced in 1989 by positional cloning and chromosome walking 
techniques7-9. This gene is present on chromosome 7q31.2 and spans approximately 190 kilo 
base (kb) pairs of genomic DNA, containing 27 exons10. This gene codes for a CFTR protein, 
consisting of 1,480 amino acids, with a mass of 168 kilo Daltons10. In healthy individuals, the 
CFTR protein functions as a cyclic adenosine 5′-monophosphate (cAMP) activated chloride ion 
channel that is present on the apical membrane of epithelial cells lining the airways, pancreas, 
intestines, reproductive organs, and exocrine glands11, 12. The CFTR protein consists of two 
halves, each with a membrane spanning domain (MSD1 and MSD2) made up of six alpha-
helices. Each MSD is connected to a nucleotide binding domain (NBD1 and NBD2) and both 




Figure 1-1: Structure of the CFTR protein showing two halves, each containing a MSD and NBD joined together 
by the R domain12. 
In healthy individuals, the CFTR channel is responsible for movement of chloride ions (Cl-) and 
bicarbonate ions (HCO3-) from within the cell to airways12. CFTR also has direct and indirect 
control over other channels within epithelial cells, such as the epithelial sodium channel 
(ENaC). CFTR down regulates ENaC, which is responsible for cell uptake of sodium ions (Na+)13. 
CFTR also controls other ion channels, such as the outwardly rectifying chloride channel, and 
calcium activated chloride channel. Thus, the CFTR channel affects overall molecular 
transport within the cell 14 and controls hydration of the epithelial surface15. 
In CF patients, absence of the CFTR protein or presence of a dysfunctional CFTR protein results 
in reduced chloride secretion and increased sodium and water absorption into tissues11, 16. 
This leads to dehydration of airway surface liquid (ASL) lining the respiratory tract, reduced 
mucociliary clearance (MCC), and accumulation of viscous mucus in the airways. This mucus 
obstruction triggers subsequent pathogenic infection, with bacteria including Pseudomonas 
aeruginosa, Staphylococcus aureus, and Haemophilus influenzae, which results in 
inflammation and reduction in lung function11, 15, 17, 18. This cycle of infection, inflammation, 
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and reduction in lung function ultimately results in respiratory failure, the leading cause of 
death in CF patients19, 20 (Figure 1-2). 
 
Figure 1-2: CF pathogenesis cascade, demonstrating that a defective CFTR gene leads to decreased chloride 
secretion and altered ionic conductance, bronchial obstruction, inflammation, and ultimately lung insufficiency21. 
Nearly 2000 CFTR gene mutations have been identified to date, and these can be categorised 
into six different classes16, 22, 23. In class I mutations CFTR protein synthesis is absent; in class 
II the protein is inadequately processed; class III demonstrates defective regulation of the 
CFTR protein; class IV shows reduced CFTR channel conductance; class V is characterised by 
reduced synthesis of the CFTR protein; and class VI presents decreased CFTR protein stability 
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20, 22, 24. Mutation classes I to III are more severe compared to classes IV to VI, as the latter 
classes retain some level of CFTR function25.  
1.2 Current treatments for CF 
Current CF treatments target downstream symptoms of the defective CFTR gene, such as 
mucus accumulation, bacterial infection, inflammation, and bronchial hydration26, 27. 
Mucolytics, like α-dornase, are administered to reduce mucus viscosity and increase MCC28. 
Osmotic agents are also prescribed to hydrate the ASL and improve MCC in CF patient 
airways26. Commonly prescribed osmotic agents include hypertonic saline and mannitol26. 
Antibiotics, such as inhalable tobramycin powder, amikacin, levofloxacin, and colistin, are 
prescribed to target infection in CF airways26. Neutrophil mediated airway inflammation is 
prevalent in CF patients for which anti-inflammatory medicine, such as prednisone (steroids) 
and ibuprofen (non-steroidal), are recommended28. Additionally, patients undergo 
physiotherapy and airway clearance techniques to assist with sputum clearance29. Despite 
these treatments, lung disease remains the main cause of mortality in CF and lung transplant 
is required for end-stage patients with severe lung disease30. 
Therapeutic drugs specific to CF mutation classes include Ivacaftor (Kalydeco®) a CFTR 
‘potentiator’, that improves CFTR channel gating and is designed to treat CF patients with 
class III mutation, such as the G551D and R117H gating mutations31, 32. CF patients with the 
G551D mutation treated with Ivacaftor have demonstrated an average 10% improvement in 
lung function32. However, patients with at least one gating mutation are rare and represent 
only 4% of CF patients31, 33, 34. Lumacaftor is a ‘corrector’ that improves processing and 
stability of CFTR with F508del, a class II mutation. In vitro studies using bronchial cells isolated 
from CF patients have shown that Lumacaftor improved maturation of CFTR F508del and 
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increased chloride secretion by four-fold. However, a combination of Lumacaftor/Ivacaftor 
(Orkambi™) improved lung function by only 3% in CF patients with F508del mutation35. 
Another drug combination used for CF patients is Tezacaftor-Ivacaftor (Symdeko™), which 
provides two correctors and one potentiator to the airways of patients36. Cell culture studies 
using this drug combination have shown restoration of >50% CFTR activity and a stage I trial 
has shown to improve lung function of CF patients with F508del mutation by 7%-12%36. Other 
modulators, such as VX-445 and VX-659 are also being examined for their effectiveness in 
improving lung function of CF patients36, 37. Despite improvement in pharmaceutical therapies 
targeted at improving CFTR function there is a need to investigate new treatment methods 
that correct the initial CF gene defect and provide long-term, therapeutic benefits to CF 
patients belonging to all CFTR mutation classes.  
1.3 CF airway gene therapy  
CF airway gene therapy is an alternative therapeutic option to overcome the underlying gene 
defect by either correcting the CFTR gene (gene-editing), or supplementing with corrected 
copies of the CFTR gene (gene-addition)6, 38. The principle of airway gene-addition therapy is 
to use a vector to deliver a correctly functioning copy of the CFTR gene to relevant cells of the 
respiratory epithelium, thereby restoring normal cellular homeostasis and lung function29, 39.  
Studies reported in the literature suggest that restoration of CFTR function in 6-10% of cells 
is sufficient to bring about phenotypic correction40, 41. The main targets for CF gene therapy 
are ciliated epithelial cells39, 42, submucosal glands42, and basal cells43 in the larger and smaller 
conducting airways. Basal cells are the airway progenitor cells for ciliated epithelial and 
submucosal cells43. Furthermore, these basal cells are also responsible for maintenance and 
repair of the human airway43. Hence, transducing basal cells could provide long-term 
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correction of the CF gene defect as they can generate corrected daughter cells thus improving 
the therapeutic benefits43. Transducing these basal airways cells using an effective single 
dose-protocol reduces the need to re-administer the viral vector formulation to patient 
airways43.  
Another type of cell that can be targeted in future studies to produce effective correction in 
the airways is the ionocytes. Recently published studies using single-cell RNA sequencing 
methods have identified that this new cell type, present in the proximal airways, expresses 
about 60% of CFTR activity in mice and humans, but represent only 1% of the airway cells 44, 
45. This makes them ideal targets for future CF gene-editing and cell therapy46. Various viral 
and non-viral vectors have been developed to deliver the therapeutic gene to the airway 
epithelium39, but efficient delivery of gene vectors to appropriate sites in the airway remains 
crucial for successful treatment39. 
1.4 Challenges for delivery to the lung 
The lung was initially thought to be an easily accessible organ for gene vector delivery because 
the vector could reach airway epithelial cells by non-invasive methods, and the possibility of 
the vector targeting other organs was reduced47. However, challenges in delivering vector 
formulations to the lung have become apparent in airway gene therapy studies16. The lungs 
have a series of intracellular and extra-cellular barriers that pose a challenge for effective 
vector administration16. Gene therapy vectors have to overcome complex host mechanisms 
that fight invasion of foreign particles in the lung, including (1) a mucus layer that can bind 
the vector and remove it via MCC mechanisms48, (2) a glycocalyx protein layer that can 
prevent binding of vector to its receptors48, and (3) host immune responses to the vector, 
which can reduce effectiveness on repeated administration48. To overcome these barriers, it 
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is important to develop an optimal gene vector and an optimal vector delivery method.  
1.5 Vector delivery methods 
Gene vectors used for CF gene therapy have predominantly been delivered as a bolus dose to 
the airways of animals and CF patients49-51. These bolus delivery studies have reported small 
but significant physiological benefits52, 53. However, delivering the vector as bolus dose can be 
invasive as the patient is likely to require sedation and a bronchoscopy procedure49, 54, 55. 
Additionally, in vivo studies have shown that delivering viral vectors as a bolus dose produces 
patchy gene expression in the airways54, 56, 57. This patchy gene expression possibly results 
from uneven distribution of the vector or pooling of the bolus dose in certain airway regions58 
and uneven coverage of the airway surfaces57. Researchers have speculated that chronic 
inflammation and injury of lung tissue could also lead to patchy gene expression59; however, 
this gene expression pattern does not inhibit the expression of a functional CFTR gene in 
animal models57. Regardless of this, the inability to easily, rapidly, and uniformly, deliver a 
gene vector to the conducting airways led to a search for alternative delivery methods.  
Aerosol delivery was considered an ideal delivery method as it is minimally-invasive, easily 
repeatable, and is likely to be a more clinically acceptable method of vector administration54, 
60. Delivering the viral vector as an aerosol has been demonstrated to produce uniform vector 
distribution in the airways of some animal models54. However, these studies highlighted 
problems associated with aerosolising viral vectors. One major issue is reduced viability of 
some viral vectors, like adenovirus (Ad) and sendai virus (SeV), during transit through the 
nebuliser58. This lowered vector viability is probably due to shear stress applied on the vector 
during transit through the nebuliser58. The process of aerosolisation can produce a change in 
temperature, concentration, and pH of the liquid formulation61-63, which can also affect the 
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biological viability of a viral vector64, 65. Hence, it is critical to use an appropriate nebuliser to 
aerosolise the viral vector to obtain a positive therapeutic outcome.  
1.6 Aerosol delivery devices 
Success of developing a viable aerosol gene therapy treatment is dependent on identifying a 
suitable vector and then delivering it using an appropriate aerosol delivery device66. There are 
many delivery devices available in clinics to aerosolise drug formulations to the airways of CF 
patients. A brief description of the devices, which have been used primarily in drug delivery 
studies and a few gene therapy studies, are described below. 
1.6.1 Dry powder inhalers  
Dry powder inhalers (DPIs) are a popular aerosol delivery device as they are small and easily 
transportable67 (Figure 1-3). The capsule containing the drug is placed in a spinning chamber, 
where it is punctured by piercing buttons68. The drug is then broken down into finer particles 
by the inspiratory force of the patient. During inhalation the drug is filtered as it passes into 
the mouth piece68. These devices are available in a single capsule-based design or multi-dose 
units68. DPIs can deliver a larger dose volume of drugs to patient airways (approximately 10% 
and 37%) compared to the 7% dose volume delivered by pressurised metered dose inhalers 
(pMDIs; see Section 1.6.2)68. Drugs such as mannitol, colistin mixed with lactose-carrying 
particles, and thrombomycin, have been delivered using DPIs to the airways of CF patients68. 
However, DPIs also pose certain disadvantages. Many drugs are not available in a powdered 
form and hence cannot be used by DPIs69. Also, elderly patients with chronic lung disease find 
it difficult to apply sufficient inspiratory force to aerosolise the drug using DPIs68. The same 




Figure 1-3: A dry powder inhaler with a single capsule-based design69. 
1.6.2 Pressurised metered-dose inhalers  
Pressurised metered-dose inhalers (pMDIs) were introduced in 1956 at Riker laboratories and 
became popular due to small size, portability, and efficiency (Figure 1-4 A). The pMDI consists 
of three main components: a canister containing the drug dissolved in liquid gas propellant; 
a metering valve, which delivers a known amount of the drug; and a spray actuator68. When 
the patient presses the canister, a mixture of propellant and drug formulation is propelled 
into the expansion chamber where it is sheared by the actuator nozzle to produce aerosols68 
(Figure 1-4 B). Despite the popularity of these inhalers, they have several disadvantages such 
as high particle delivery velocity, deposition of majority of the dose volume at the oropharynx, 
and the patient must learn the technique of coordinated actuation and inspiration67. These 
inhalers can only deliver a small quantity of the drug which was the main disadvantage in the 
case of drugs used for the treatment of CF. The pMDI is commonly used to deliver small 





Figure 1-4: (A) Parts of pMDI and (B) formation of aerosol when the formulation is propelled into the expansion 
chamber68. 
1.6.3 Jet nebulisers  
Jet nebulisers are devices that evolved along with the advent of DPIs and pMDIs. Jet nebulisers 
gained popularity in inhalation therapy as they can aerosolise a large volume of liquid 
medication70. The jet nebuliser works by releasing aerosols when a jet of compressed air is 
pushed through a small tube to disperse a thin film of liquid67 (Figure 1-5). The size of the 
primary aerosols generated are ~100 μm, which is not suitable for inhalation71. Hence baffles 
are installed within the jet nebuliser to break down larger aerosols into smaller ones (< 5 μm) 
for deposition in the bronchial and alveolar region of the lung67, 71. These nebulisers are 
efficient in delivering highly viscous formulations, such as dextrose solution72. However, one 
drawback of this nebuliser is that it increases drug concentration in the reservoir and has a 
large residual volume (1 to 1.5 ml)67. Moreover, conventional jet nebulisers operate 
continuously and result in substantial loss of drug formulation during exhalation67. This led to 
the invention of the breath-actuated jet nebuliser67.  
The breath-actuated nebulisers (also known as breath-enhanced nebulisers) are a type of jet 
nebuliser that deploys a valve system to control aerosol release during the inspiratory 
phase67. PARI LC PLUS® (PARI Gmbh, Stamberg, Germany), PARI LC SPRINT® (PARI Gmbh, 
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Stamberg, Germany), LC STAR® (PARI Gmbh, Stamberg, Germany), and Ventstream® 
(Respironics respiratory drug delivery, New Jersey) are popular devices that incorporate this 
mechanism67. There have also been various modifications to jet nebulisers such as adaptive 
aerosol delivery (AAD), which adapts to the breathing pattern of individuals and delivers the 
drug in pulses during the first half of the patient’s inspiratory phase70. Devices like 
AeroEclipse® (Trudell medical international, Canada), HaloLite® (Respironics respiratory drug 
delivery, New Jersey), and ProDose® (Respironics respiratory drug delivery, New Jersey), 
incorporate this design67. Jet nebulisers are used to aerosolise various drugs, such as 
antibiotics, mucolytics, and recombinant products, such as rhDNaSe. In CF, the jet nebuliser 
is used to deliver drugs like Pulmozyme® (Dornase alpha) and Tobramycin72.  
 
Figure 1-5: Mechanism of aerosolisation in a jet nebuliser72. 
1.6.4 Vibrating mesh nebulisers 
Recent advances in technology led to introduction of the vibrating mesh nebuliser, which 
addresses some problems associated with earlier nebulisers67. Vibrating mesh nebulisers use 
“micro-pump technology” to generate aerosols73. These nebulisers have a mesh plate 
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containing up to 1,000 dome shaped apertures and a vibrating element73 (Figure 1-6). When 
an electric current is applied the mesh moves up and down by a few micrometres, with the 
force of displacement generating aerosols73. Aerosols delivered by the vibrating mesh 
nebuliser are 1 -5 μm in diameter, which is optimal for deposition of aerosols in the bronchial 
airway and lung parenchyma73. Vibrating mesh nebulisers have several advantages, such as 
being easily portable, noise-less, and single-pass, i.e. these nebulisers do not recycle the 
formulation within the system67. Compared to jet nebulisers, vibrating mesh nebulisers 
produce high output rates, can aerosolise small volumes of drug formulation and have almost 
no residual volume72. Furthermore, they can also be breath actuated to release aerosols 
during inspiration only74. However, one disadvantage of vibrating mesh nebulisers is that they 
cannot efficiently aerosolise viscous formulations. Commercially available nebulisers 
incorporating this design are the Aeroneb® Pro and Aeroneb® Go (Aerogen Inc., Ireland), 
eFlow® rapid (PARI Gmbh, Stamberg, Germany), and Omron MicroAir® (Omron Healthcare, 
Japan). The eFlow® rapid nebulisers have been used to aerosolise aztreonam lysinate, an 
antibiotic against Pseudomonas aeruginosa infection in the airways of CF patients75. 




Figure 1-6: Vibrating mesh nebuliser showing the mesh plate with tapered holes and production of aerosols72, 75.  
1.6.5 Ultrasonic nebulisers 
The ultrasonic nebuliser is another novel device with the potential to deliver large volumes of 
drug formulations76. Ultrasonic nebulisers are small, portable, noise-less, and do not require 
compressed air to deliver aerosols77. These nebulisers contain a piezoelectric crystal that 
vibrates at high frequencies (up to 3 MHz) on the liquid surface to generate aerosols67, 77, 78. 
However, the major disadvantage of these nebulisers is the heat generated during aerosol 
delivery, which could denature biological formulations67. Also, traditional ultrasonic 
nebulisers are not suitable for delivering suspensions and protein formulations67.  
A new type of ultrasonic nebuliser, called the surface acoustic wave (SAW) nebuliser, was 
recently developed. This nebuliser uses surface acoustic waves generated when a sinusoidal 
electric field is applied to an interdigital transducer (IDT) electrode79 (Figure 1-7). The waves 
then propagate, at nanometre amplitude and MHz to GHz-order frequencies, through a 
37 
 
piezoelectric lithium niobate (LiNbO3) substrate79. Upon reaching the edge of the substrate 
the waves are refracted into the adjoining liquid medium, generating aerosols79. This 
nebuliser can effectively aerosolise plasmid DNA (pDNA)79 and stem cells80.  
 
Figure 1-7: Propagation of SAWs through LiNbO3 substrate which is then refracted into the liquid formulation to 
generate aerosols78.  
 
1.6.6 Intra-tracheal sprayers 
Intra-tracheal sprayers or nebulisation catheters are used to deliver fluid formulation as a 
spray to the airways of patients and animal models 81, 82 (Figure 1-8). These devices typically 
have a barrel in which the formulation to be aerosolised is loaded. The device tip is then 
guided to the delivery location within the airway tree with the help of a bronchoscope83. 
Constant air pressure (30 to 40 psi) applied to the bottom of the syringe results in the 
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formulation passing through the sprayer nozzle at the tip to produce a plume of aerosol 
spray83. Although placement of this device into the airway is invasive and requires sedation 
and endo-tracheal intubation of subjects84, it does enable targeted delivery of formulation to 
a particular region of the lung with a high degree of efficiency and control83. Intra-tracheal 
sprayers deliver aerosols of a large size (25 to 30 μm) to subject airways85. The majority of 
these larger sized aerosols released from intra-tracheal sprayers deposit in the tracheo-
bronchial region of rats86. The Aeroprobe™ intra-corporeal nebulising catheter (Trudell 
Medical Corporation, London, Ontario, Canada) and Microsprayer® (PennCentury, Inc., 
Wyndmoor, PA) are two intra-tracheal sprayers commonly used to deliver drug formulations 
to animals83, 85, 87. These devices have demonstrated effective delivery of shear sensitive 
formulation, such as fibroblast cells85, and liposomes83. Production of both the Microsprayer® 
and AeroProbe™ catheter has now halted (PennCentury™ closed for business in 2015, and 
Trudell discontinued the AeroProbe™ in its product line) and new sprayers like the MADgic™ 
atomisation device (Teleflex, Ireland) have been developed. 
 
Figure 1-8: Aeroprobe™ intracorporeal nebulising catheter showing the sprayer nozzle at the tip86. 
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1.7 Viral vectors for CF gene therapy 
Since the discovery of the CFTR gene in 1989, there has been extensive research to develop 
an optimal viral vector that delivers the therapeutic CFTR gene to the lungs of the CF patients.  
1.7.1 Adenoviral vectors  
Gene therapy studies in the 1990’s were carried out using recombinant adenoviral (Ad) 
vectors. Ad is a type of non-enveloped virus containing double-stranded DNA, and has a 
complex icosahedral capsid88. The Ad vector could transduce non-dividing cells and could 
accommodate the 4.5 kb human CFTR complementary DNA (cDNA) in its genome89.  
Initial gene therapy studies examined the effectiveness of delivering the Ad vector as an 
aerosol in animal models. Katkin et al. aerosolised Ad vector carrying a β-galactosidase (LacZ ) 
reporter gene to the airways of cotton rats using a raindrop jet nebuliser (Puritan-Bennett 
Corporation) and showed uniform gene expression54 (Figure 1-9 A). In comparison, patchy 
gene expression was observed when the same vector was delivered as an intra-tracheal bolus 
instillation (Figure 1-9 B)54. They also showed that approximately 22% of initial dose of the 
viable vector was recovered following delivery through the jet nebuliser54. Later studies used 
other jet nebulisers to deliver Ad vector aerosols to the lungs of larger animal models, such 
as rhesus macaques and baboons90, 91. These studies demonstrated effective transduction of 
animal airways along with dose dependent inflammation90, 91. However, a reduction in vector 
viability following delivery through an Optineb® jet nebuliser (Air Liquide, France) 
(approximately 43% of initial dose) and reduced dose volume (approximately 45% of initial 
volume) reaching the airways of the rhesus macaques was also reported91. The results 
obtained from aerosol delivery of Ad vector in animal models led to clinical studies in CF 
patients. Bellon et al. were the first to deliver aerosols of Ad-CFTR vectors to the lungs of CF 
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patients along with nasal instillations92. Expression of CFTR DNA was observed for up to 21 
days, and they also detected the presence of CFTR mRNA in patient bronchial brushings up to 
15 days with no evidence of acute inflammation in patient lungs92. The outcomes of other 
pre-clinical and clinical studies delivering Ad vector as an aerosol are given in Table 1-1. 
 
Figure 1-9: Study conducted by Katkin et al. showing lung sections of cotton rat exposed to Ad-LacZ vector 
delivered as an (A) aerosol and (B) bolus dose delivery54.  
Overall, the recombinant Ad vector utilised in CF gene therapy studies provided useful 
information on vector development and administration strategies. Gene therapy studies 
using this vector demonstrated a small but clinically insignificant correction of the CF gene 
defect93. The lowered clinical efficacy observed using the Ad vector was caused by inability of 
the vector to access receptors on the basolateral surface94. Furthermore, this vector (1) was 
non-integrating and therefore only produced transient gene expression, (2) produced dose 
dependent lung inflammation, (3) demonstrated reduced viability following delivery through 
the nebuliser, and (4) exhibited a reduced efficacy on vector re-administration95. These 




Table 1-1: Outcome of pre-clinical and clinical studies delivering Ad vector as an aerosol. 










Delivered Ad vector as an aerosol to the lungs of 
Rhesus monkeys. The researchers detected CFTR 
mRNA up to 13 days following delivery of Ad 
vector; however, pneumonia was observed in a 
few animals in the study. 
2) Jobe et 
al.96, 1996  
Low-flow prototype 
gas jet aerosoliser 
(Baxter labs) 
Lungs of rabbits treated with aerosols of Ad-
luciferase (Luc) demonstrated 30% gene 
expression in whole lung, while bolus delivery 
produced 72% gene expression. 
3) McDonald, 
RJ et al.97, 
1997 
Mini Heart breath 
actuated jet nebuliser 
(Westmed, Arizona, 
US) 
Delivered aerosols of the Ad-CFTR to the airways 
of rhesus monkeys, detected the presence of 
CFTR mRNA up to 21 days following vector 
treatment. The researchers also showed evidence 




Study Aerosol delivery 
device 
Outcome 
4) Lerondel, S 




Showed homogenous distribution of aerosolised 
Ad-CFTR vector coupled with a radio-isotope in 
the lungs of baboons. They showed that only 
42.5% of the initial dose deposited in the animal 
airway and the biological viability of the 
aerosolised vector was 45% of the initial titre.  
Clinical 
Studies: 





(Olympus America Inc, 
NY) 
 
Delivered a spray of Ad vector to CF patients and 
detected CFTR mRNA in the lungs of the patients 
lasting less than 30 days and observed mild 
inflammation from bronchial brushings. 
Intermediate cDNA gene expression was observed 
after second vector administration; however, no 
expression was observed after third dose of the 
vector.  
2) Joseph, PM 
et al.93, 2001 
Perricone MA 
et al.99, 2001 
Mini Heart breath-
actuated jet nebuliser  
The change in pulmonary function (measured as 
FEV1) was small and variable in both treatment 
groups and FEV1 levels returned to baseline, 28 
days post-treatment. Transient fever was 
experienced in patients receiving bolus dose, but 




1.7.2 Helper-dependent adenoviral vectors 
Helper-dependent adenoviral (Hd-Ad) vectors were developed to reduce the immune 
response produced by Ad vectors100. All viral coding regions of the Ad vector were deleted to 
produce Hd-Ad, hence giving it the name “gutted vector”100, 101. Hd-Ad vectors demonstrated 
enhanced gene expression compared to Ad vectors102. Researchers examined the efficiency 
of delivering this vector as a spray into the airways of animal models. Kohler et al. sprayed 
Hd-Ad vector into the lungs of rabbits using an intra-tracheal AeroProbe™ catheter81. The 
vector was formulated in 0.1% L-α-lysophosphatidylcholine (LPC), a mild surfactant naturally 
present in the lung38. LPC was used to open tight junctions between epithelial cells and allow 
viral vector access to its receptors on the basolateral surface51, 81. The researchers 
demonstrated transduction in 66% of tracheal epithelial cells and observed a mild fever and 
patchy pneumonia in vector treated animals81. Cao et al. sprayed Hd-Ad vector suspended in 
0.01% LPC into the airways of pigs using an Aeroprobe™ catheter103. They reported uniform 
gene expression in major and minor bronchial airways and respiratory bronchioles in the left 
lungs103. However, no gene expression was observed in the right lung which was used as a 
negative control103. Furthermore, there was no inflammation following aerosol delivery of the 
Hd-Ad vector in pig airways103. Despite the positive results obtained from this study, 
inflammation and acute toxicity remains the major problem associated with Hd-Ad vector104. 
Furthermore, problems producing this vector on a large scale continue to delay its clinical 
translation104.  
1.7.3 Adeno-associated viral vectors  
Another vector extensively used for CF gene therapy treatment development is the 
recombinant adeno-associated viral (AAV) vectors105. AAV is a non-enveloped virus with an 
icosahedral capsid105 enclosing a single DNA strand made up of 4,700 nucleotides39. 
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Recombinant AAV is non-integrating and has an episomal nuclear configuration after 
transduction, unlike its wild type that integrates into the human genome88. There are many 
AAV vector serotypes. The first generation AAV serotype and AAV2 serotype were used in 
initial gene therapy studies106, 107. While newer serotypes like AAV1, AAV5, and AAV9 have 
been developed to improve efficacy108.  
The effectiveness of delivering AAV as an aerosol was examined in three clinical trials. Aitken 
et al. aerosolised first generation AAV-CFTR vector using a Pari LC Plus™ nebuliser into the 
lungs of 12 CF patients exhibiting mild lung disease107. The vector dose was found to be evenly 
distributed in the bronchial airways and was tolerated well in CF patients107. Bronchial 
brushing from patients revealed copies of the CFTR DNA up to 30 days, using real-time 
polymerase chain reaction (PCR)107. Following this, Moss et al. conducted a trial in 2004 in 
which three aerosol doses of either AAV2-CFTR vector or placebo (randomised 3:1) were 
delivered to the lungs of 37 CF patients with mild lung disease, at 30-day intervals. Repeated 
administration of the vector was well tolerated in CF patients106. Encouraging improvements 
in FEV1 levels of >10% from baseline were observed in CF patients receiving the aerosolised 
vector dose compared to the placebo group at 30 days following treatment (p=0.04)106. Moss 
et al. in 2007 conducted a larger trial with 102 CF patients having mild to moderate lung 
disease109. The patients received either two aerosol doses of AAV2-CFTR vector or a placebo 
dose, administered 30 days apart109. This study showed that repeated administration of 
aerosolised AAV2-CFTR vector was safe and well tolerated in CF patients109. However, no 
significant difference in FEV1 was observed between the aerosol treatment and placebo 
groups109. In a review, Guggino et al. speculated that the different outcomes between the two 
trials conducted by Moss et al. can be attributed to reducing the number of doses 
45 
 
administered from three doses to two108, and/or including CF patients with mild lung disease. 
Also, the larger clinical trial (Moss et al. 2007) did not quantify the levels of CFTR DNA in 
patient airways thus making it difficult to compare the effectiveness of gene therapy across 
the two trials108. On closer examination of the Pari LC plus™ jet nebuliser used in all three 
clinical trials 106, 107, 109, Leung et al. observed that only 47% of the initial dose was delivered 
to patient airways110. They also reported an increase in vector concentration within the 
nebuliser as a result of evaporative losses; however, this nebuliser did not reduce the viability 
of the aerosolised vector110. 
Animal studies have examined the effectiveness of delivering the AAV vector through intra-
tracheal sprayers. Beck et al. showed that saline radiolabelled with 99mttechnetium saline 
diethylene-triamine penta-acetic acid (99mTc-DTPA) delivered using the MicroSprayer® 
resulted in higher levels of dose deposition in the lungs of rhesus macaques compared to the 
Pari-LC Plus™ jet nebuliser111. The authors sprayed AAV2-green fluorescent protein (GFP) 
vector mixed with 99mTc-DTPA saline into the lungs of macaques using the MicroSprayer® and 
demonstrated a deposition of 50.1% and 30.3% of the initial dose in the right and left lungs, 
respectively111. In the same study, Beck et al. showed that there was no reduction in vector 
viability after being sprayed with the Microsprayer®111. In contrast, Guggino et al. 
demonstrated a reduction in vector viability (reduced by 27% to 35%) following delivery 
through the Microsprayer®112. Four other studies used the MicroSprayer® to deliver a coarse 
spray of AAV vector into the lungs of animals (Table 1-2). The effect of delivering this vector 
as an aerosol through a vibrating mesh nebuliser was also examined. Guggino et al. showed 
that an Aeroneb® solo nebuliser (Aerogen Inc., Ireland) delivered only 1.2% of the initial vector 
dose to the lungs of rhesus macaques112. These aerosol delivery studies demonstrated the 
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challenges of delivering AAV vector as an aerosol and also highlighted the importance of 
pairing vector formulation with appropriate delivery devices.  
Newer AAV serotypes have been developed to better target the airway cells108, but despite 
these advances the inability of the AAV vector to integrate into the host genome remains the 
major disadvantage113. This makes it challenging or impossible to provide long-term gene 
expression from a single dose113. Hence, there is a need to investigate the effectiveness of 
other viral vectors in producing long-term gene expression. 
Table 1-2: Pre-clinical and clinical trials delivering AAV vector as an aerosol. 





1) Fischer, AC et 
al.114, 2003 
MicroSprayer® Repeated dosing of recombinant AAV2-GFP 
vector aerosols demonstrated effective 
gene transfer without inflammatory 
responses in rhesus macaques. GFP-DNA 
and mRNA were detected from the lungs of 
treated animals up to 8 weeks after vector 
treatment. The researchers demonstrated 
50.3% deposition of initial dose of 




Study Aerosol delivery 
device 
Outcome 
2) Fischer, AC 
et.115, 2007 
MicroSprayer® Aerosolised either AAV5 -CFTR vector or 
AAV5-GFP reporter gene to the lungs of 
rhesus macaques. This study detected CFTR 
DNA and mRNA in animal dosed with AAV5-
CFTR and GFP DNA expression was 
observed in the airways of AAV5-GFP 
treated animals. The expression of the 
reporter gene was also confirmed by 
confocal microscopy. 
3) Flotte et al.116, 
2010  
MicroSprayer® Conducted a dual reporter study using 
firefly luciferase (F-Luc) and Renilla 
luciferase (R-Luc) to compare the efficiency 
of AAV1 and AAV5 vectors, in the airways of 
chimpanzees. Luciferase imaging studies 
showed that expression of the AAV1 vector 
was found to be 20-fold higher than the 
AAV5 vector at 90 days. 
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Study Aerosol delivery 
device 
Outcome 
4) Steines et 
al.117, 2016 
AeroProbe™ catheter A modified AAV vector derived from the 
AAV2 serotype with 5-point mutation was 
used in this study. This modified vector was 
called the AAV2H22 vector and it had an 
evolved capsid. This vector was sprayed 
into the lungs of CF pigs. Correction of the 
CF gene defect was observed from excised 
nasal tissue two weeks following vector 
administration to the nose and lungs. 
5) Guggino et al, 
2017112 
MicroSprayer® Two groups of rhesus macaques were 
treated with a spray of either AAV1-F-Luc or 
AAV5-R-Luc vector. No significant difference 
in luciferase activity was observed in the 
lung samples of the two treatment groups, 
collected at day 45. However, further 
analysis showed that the genomes copies of 
AAV1 vector was 10 times more prevalent 
than AAV5 vector. 
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1.7.4 Sendai viral vectors 
Another gene therapy vector that has been examined is the Sendai viral (SeV) vector. The SeV 
belongs to the family of Paramyxoviruses, an enveloped virus with a negative RNA strand118. 
Griesenbach et al. showed that viability of the SeV vector was reduced to 1% of its initial level 
following delivery through the Pari LC Plus® jet nebuliser, which was probably due to shear 
stress produced during aerosol delivery58. In contrast, spraying the vector through an 
AeroProbe™ catheter resulted in a viability of 49% of the initial level58. Thus, they chose to 
use the AeroProbe™ catheter to deliver the SeV vector to sheep airways58, and reported 
uniform gene expression in the lungs of animals sprayed with the vector, compared with 
patchy gene expression in the lungs of bolus-treated animals58. One disadvantage of this 
vector is that it produces transient gene expression and repeated administration of the vector 
proved to be ineffective, rendering it unsuitable for CF gene therapy58. This led to 
investigation of other viral vectors that could provide stable, long-term gene expression for 
CF airway disease.  
1.7.5 Lentiviral vectors 
Lentiviral (LV) vectors are enveloped RNA viruses which belong to the family of Retroviridae88. 
LV vectors have been derived from a variety of viruses, such as the feline immunodeficiency 
virus (FIV), simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and 
equine infectious anaemia virus (EIAV)119. They have the ability to package up to 10 kb DNA 
thus allowing them to carry the full CFTR cDNA105. Furthermore, they can transduce both 
dividing and non-dividing cells88, and contain the integrase enzyme which helps integrate the 
vector DNA into the host genome105. The LV pre-integration complex gets imported into the 
nucleus independent of mitosis, which allows it to transduce terminally differentiated cells, 
such as ciliated epithelial cells of the airways, which are the main targets for airway CF gene 
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therapy105. Furthermore, the LV vector can transduce the progenitor cells/stem cells of the 
airway, which could facilitate long-term gene expression43.  
Aerosol delivery of LV has been challenging due to its fragile nature, as observed during vector 
production120, 121. Hence, only a few studies have examined the effectiveness of aerosolising 
LV vectors. Cooney et al. sprayed an FIV vector pseudotyped with baculovirus envelope 
protein GP64 and carrying the CFTR gene into the lungs of CF pigs using a MADgic™ 
atomisation device87. They showed partial restoration of the CF gene defect from excised lung, 
tracheal, and bronchial tissue two weeks post-treatment87. They also showed a significant 
increase in the amount of CFTR mRNA present in the treated animals compared to untreated 
animals87.  
To date, only one (lung cancer) study has delivered a HIV-1 derived LV vector as an aerosol 
into mouse airways using a patented nebuliser122. However, that study did not examine the 
efficiency of the nebuliser for delivering the HIV-1 vector to animal airways, the distribution 
of the vector in the lungs, or the vector viability following aerosol delivery. Hence, there is a 
need to investigate the efficiency of delivering these types of vectors as an aerosol.  
The studies presented in this thesis examine the effectiveness of aerosolising a HIV-1 derived 
LV vector to optimise an efficient aerosol delivery protocol for future use in pre-clinical and 
clinical studies.  
1.7.5.1 Genome of the HIV-1 virus 
The wild type HIV-1 virus is made up of 15 proteins and two RNA strands123 (Figure 1-10). The 
HIV genome is 9 kb long and codes for nine open reading frames (ORF) 123. Three of these 
frames code for the Gag, Pol, and Env proteins, which are common to all retroviruses123. The 
structural component of the core is made up of four Gag proteins; the matrix (MA), capsid 
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(CA), nucleocapsid (NC), and p6. The envelope is made up of two Env proteins: surface protein 
(SU) (also known as gp120) and transmembrane protein (TM) (also known as gp41)123. The 
enzymatic proteins present within the virus are integrase (IN), protease (PR), and reverse 
transcriptase (RT)123. The HIV-1 virus has six accessory proteins: Vif, Vpu, and Vpr that control 
the rate of production of vector particles, the essential gene regulatory functions are 
controlled by the Tat and Rev accessory proteins123, and Nef enhances the pathogenicity of 
the virus124.  
 
Figure 1-10: Structure and organisation of RNA genome of HIV-1 virus123. 
1.7.5.2 Structure of HIV-1 virion  
A mature HIV-1 virion is spherical and approximately 100 nm in diameter124. The envelope of 
the virion is made up of a lipid bilayer, which is composed of the Env proteins gp120 and 
gp41124. The envelope also has 72 knobs made up of trimers of Env proteins124. Trimers of the 
gp120 protein are anchored to the membrane by trimers of the gp41 protein. The envelope 
encloses the outer capsid membrane that is made up of the MA protein124. Within this lies 
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the conical capsid that is formed by inner capsid protein p24. The inner capsid is attached to 
the outer capsid through a linking protein124. The inner capsid encloses two identical RNA 
strands and other enzymatic proteins, such as IN, PR, and RT124. 
 
Figure 1-11: Structure of the HIV-1 virion showing two RNA strands enclosed in a conical capsid (core shell) that 
is then surrounded by the envelope (lipid bilayer)124.  
1.7.5.3 HIV-1 replication  
Replication of the wild type HIV-1 virus begins by binding of gp120 to the CD4 receptors 
present on the surface of the host cell124. This leads to fusion of viral and cell membranes, 
which then releases the viral capsid into the cytoplasm of the host cell and entry of the HIV 
RNA and various enzymes into the cell124. A single RNA strand is then reverse transcribed by 
the RT into cDNA124. The DNA-dependent DNA polymerase activity of the RT then converts 
the cDNA into a double stranded pro-viral DNA124. The pro-viral DNA along with IN (known as 
the pre-integration complex) is then taken up into the nucleus of the host through the nuclear 
pore124. The pro-viral DNA is then randomly inserted into the host cell genome by IN, and is 
later transcribed along with the host genome to produce viral proteins124.  
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1.7.5.4 HIV-1 viral vector  
Self-inactivating HIV-1 vectors were created by deleting viral genes and regions that promote 
transcriptional activity of the virus125. The regions coding for accessory viral proteins that 
increase the pathogenicity of the vector, such as Vif, Vpu, Vpr, and Nef, are not required for 
production of the vector and were deleted 126. The packaging component consists of Gag, Pol, 
Tat, and Rev genes, the transfer vector, and the envelope vector125. Additionally, a polypurine 
tract located in the central position (cPPT) and post-transcriptional regulatory elements of the 
woodchuck post-transcriptional regulatory element (WPRE) have been introduced to help 
facilitate nuclear translocation of the pre-integration complex and improve levels of 
transgene expression, respectively125.  
The wild type pro-viral DNA contains the 5’ long terminal repeats (LTR), the trans-element 
that codes viral proteins, and the 3’ LTR127. The 5’LTR and the 3’LTR are known as cis elements. 
They code for a transcriptional promoter, a primer binding site for DNA synthesis during 
reverse transcription, a signal for packaging genomic RNA, a polyadenine sequence, and other 
sequences required for reverse transcription127. To render the wild type HIV-1 virus 
replication defective the cis element of the virus is replaced with a heterologous promoter, 
and a heterologous polyadenine tail that is then packaged with the transgene126. To further 
improve the safety of the vector and minimise chances of homologous recombination, 
sequences coding for viral proteins and enzymes are separated onto different helper 
plasmids128, 129.  
The wild type HIV-1 vector does not have a tropism for the cells of the lung. However, tissue 
tropism can be broadened using different envelopes or pseudotypes, such as vesicular 
stomatitis virus G glycoprotein (VSV-G), baculovirus GP64, ebola virus (EboZ), or influenza 
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virus haemagglutinin (HA)130. Receptors for the GP64, EboZ, and HA pseudotypes lie primarily 
on the apical surface of airway epithelia, whereas receptors for the VSV-G pseudotype are 
present on the baso-lateral surface130. VSV-G is a commonly used pseudotype, which has 
demonstrated effective transduction of airway epithelial cells131. As the VSV-G receptors 
reside on the baso-lateral membrane, airway conditioning treatments, such as LPC132, sulphur 
dioxide (SO2)133, or sodium caprate134, are required to provide access to the receptors for 
optimal effectiveness. Allowing viral vectors access to the basolateral surface should also lead 
to transduction of epithelial progenitor cells, which would normally not be accessible from 
the apical surface43.Furtheremore, VSV-G vectors are also resistant to the shear forces 
present during vector production135.  
The studies conducted in this thesis used a HIV-1 derived LV vector carrying a (nuclear 
localised) LacZ reporter gene pseudotyped with an VSV-G envelope. This LV vector was 
prepared using codon-optimised Gag, Pol, Tat, and Rev plasmids136, 137 (Chapter 2). The LacZ 
nuclear localisation signal allows easy identification of transduced cells following X-Gal 
histological processing for the β-Galactosidase protein136, 138.  
1.7.5.5 Bolus delivery studies using HIV-1 derived vector  
HIV-1 derived vectors have shown promising results being delivered as a fluid bolus in the 
airways of animal models. The Cystic Fibrosis Airway Research Group (CFARG, Adelaide) have 
developed a HIV-1 derived LV vector pseudotyped with a VSV-G glycoprotein envelope132, as 
well as a two-step liquid bolus gene delivery method, in which animal airways were 
conditioned with LPC followed by the LV vector dose one hour later51, 132, 139. Limberis et al. 
instilled a bolus dose of LPC conditioning followed by a bolus dose of HIV-CFTR vector onto 
the nasal airways of CF mice and demonstrated electrophysiological correction of CF gene 
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defect up to 110 days139. In a long-term study, Cmielewski et al. demonstrated correction of 
the CF gene defect up to 12 months in the nasal airways of CF mice using the same vector and 
delivery protocol132. Reporter gene expression has also been observed in airways of larger 
animal models, such as sheep140, ferrets56, and marmosets57, treated with a bolus dose of the 
HIV vector. Animals treated with a bolus dose of the vector demonstrated patchy gene 
expression in the trachea, conducting airways, and alveolar tissue57, 140, which could be due 
to uneven distribution of the vector and pooling of the bolus dose in airways, as well as a 
mismatch between regions treated with the LPC conditioning and the LV vector dose 57, 58. 
Additionally, these bolus studies showed that the HIV vector transduced ciliated cells and 
basal cells present in airway epithelium of the conducting airways56, 57, 140. A recent study by 
Farrow et al. confirmed that basal cells present in the respiratory epithelium could be 
transduced with a HIV vector and that the transgene was passed onto future daughter cells43. 
These promising results suggest that the HIV vector is a rational and feasible candidate for 
future gene therapy trials. Hence, there is a need to optimise a non-invasive aerosol delivery 
protocol that may effectively deliver this vector to the airways of CF patients in future clinical 
trials.  
1.8 Aerosol delivery of a HIV-1 derived vector 
HIV-1 derived vectors are fragile and susceptible to shear-stress, as observed during vector 
production121, 141, 142, and exhibit reduced viability with changes in temperature, pH, and 
drying64, 141, 143. HIV-1 vectors are stable at a pH of 7 and their half-life decreases at 
temperatures above 4°C64. Hence, a nebuliser that produces minimal change in pH, 
temperature, and can effectively aerosolise shear-sensitive drug formulations, would be 
optimal for aerosolising the HIV-1 vector. Based on the analysis in Section 1.6, the most well 
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suited nebuliser is likely to be the Aeroneb®Pro vibrating mesh nebuliser, which can 
effectively aerosolise shear-sensitive biological formulations, such as liposomes and 
nanoparticles83, 144. This vibrating mesh nebuliser can aerosolise very small (μl) volumes of 
liquid formulation and can therefore be used to deliver small volumes of aerosols to airways 
of smaller animal models, such as mice and rats74, 145. This nebuliser is operated by an 
electronic controller that allows timed delivery of aerosols during the inspiratory phase of the 
subject74, reducing the wastage of expensive vector formulations.  
The flexiVent™ small animal ventilator (Scireq Scientific Respiratory Equipment Inc., Canada) 
has been commonly used in conjunction with the Aeroneb®Pro nebuliser to deliver aerosols 
to the lungs of ventilated mice146-148. This ventilator could also be used to monitor 
physiological lung function of mechanically ventilated mice149. Hence, this thesis investigated 
the effectiveness of aerosolising the HIV-1 based LV vector using an Aeroneb®Pro operated 
in conjunction with the flexiVent™ ventilator into the lungs of mice.  
1.9 Aims 
The overall aim of this program of work was to develop an optimised aerosol delivery method 
for HIV-1 derived LV vectors. This thesis has the following aims:  
(1) Determine the efficiency of the Aeroneb®Pro nebuliser for aerosolising a HIV vector 
pseudotyped with the VSV-G envelope into the lungs of mice, during mechanical 
ventilation with a flexiVent™ ventilator. Compare the distribution of the LV vector 
delivered as an aerosol or bolus dose in lungs of mice. 
(2) Quantify the volume of aerosols reaching the mouse trachea, i.e. how much aerosol is 




(3) Quantify the viability of the aerosolised LV vector at the point at which it enters the mouse 
trachea, i.e. the viability of the LV vector released at the end of the Aeroneb®Pro-
flexiVent™ ventilator circuit. 
(4) Optimise the delivery parameters to develop an effective LV aerosol delivery protocol that 
could be used in further pre-clinical studies. 
This sequence of experimental aims was designed to establish a baseline difference between 
the standard LV delivery protocol150 .The subsequent aims were designed to conclusively 
identify the causes of reduced gene expression resulting from LV aerosolisation, and develop 
methods to overcome them. This was achieved using one study designed to improve the 
physical quantity of aerosol reaching the lung, and a second study aiming to improve the 
biological quality of the LV vector reaching the lung. A series of in vitro methods were used 
instead of in vivo studies, as this allowed many optimisation tests to be performed, reduced 
the time taken to obtain useful results, minimised the quantity of LV vector required, 
prevented the use of a very large number of animals, and enabled the studies to be completed 
using the funding available for the project. Cell culture studies were then used to validate the 
improvements produced by the optimal parameters identified from the bench studies. Due 
to the relatively modest improvements in delivery efficiency an additional animal experiment 
was not warranted at the completion of the described studies. 
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2 MATERIALS AND METHODS 
2.1  Materials  
2.1.1 Chemicals and suppliers 
α-Lactose monohydrate Sigma Aldrich (USA) Cat# L2643 
0.9% sodium chloride (Saline)  Baxter Healthcare (USA) Cat# AHF7124 
Agarose, type C, gelling 40°-43°C Bio-Rad (USA) Cat# 1613102 
Anti-Sedan (5 mg/ml) Pfizer (NZ) Cat# 107264-8 
Bacto™ agar Becton, Dickinson (USA) Cat# 214010 
Bacto™-tryptone Becton, Dickinson (USA) Cat# 211705 
Bacto™-yeast extract Becton, Dickinson (USA) Cat# 212750 
Bovine serum albumin (BSA) Sigma Aldrich (USA) Cat# A7906 
Calcium chloride dehydrate (CaCl2.2H2O) Sigma Aldrich (USA) Cat# C8106 
Dimethylformamide (DMF) Sigma Aldrich (USA) Cat# D4551 
Domitor 
 
 (medetomidine HCl 1mg/ml)  
Pfizer (NZ) Cat# 107332-8 
DNA molecular marker  GeneWorks (AUS) Cat# DMW-1 
DPX Leica Biosystems (Germany) Cat# 
046430011 
Dulbecco’s modified eagle medium (DMEM) Sigma Aldrich (USA) Cat# D5796 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich (USA) Cat# EDS 
Eosin Y Australian Biostain (AUS) Cat# AEPA 
Ethanol Chem Supply (AUS) Cat# EA043 
Fetal calf serum (FCS) Bovogen (AUS) Cat# SFBS 
Dye solution (yellow) Queens (AUS) Cat# QYE50 




GelRed® nucleic acid gel stain Biotium (USA) Cat# 41003 
Gentamycin (40 mg/ml) Pfizer (NZ) Cat# 08060180 
Glacial acetic acid Chem Supply (AUS) Cat# AA009 
Glutaraldehyde, grade II (25%) Sigma Aldrich (USA) Cat# G6257 
 Glycerol Chem Supply (AUS) Cat# GA010 
Hams F12media Thermo Fischer Scientific (AUS) 
 Cat# 11765-5411765-054 
Haematoxylin (Mayer’s) ProSciTech (AUS) Cat# AMH 
HEPES Sigma Aldrich (USA) Cat# H3375 
Hydrochloric acid (HCl,32%) RCI Labscan (Thailand) Cat# RP1104 
Indian ink Windsor and Newton (UK) Cat# 1005754 
Ketamine (100 mg/ml) Ceva (AUS) Cat# E55920B 
L-Glutamine Life Technologies (USA) Cat# 21051-024 
L-α-Lysophosphatidylcholine (LPC)  
 
Sigma Aldrich (USA) Cat# 4129 
Magnesium chloride hexahydrate 
(MgCl2.6H2O) 
Sigma Aldrich (USA) Cat# M2670 
Mouse serum Life Technologies (USA) Cat# 016501 
Neutral buffered formalin (NBF) Fronine (AUS) Cat# JJ0185 
OptiPro™ SFM Life Technologies (USA) Cat# 12309-019 
Paraformaldehyde (PFA) Sigma Aldrich (USA) Cat# P6148 
PBS without calcium and magnesium Sigma Aldrich (USA) Cat# D8537 
Penicillin G (5000 U/ml)/Streptomycin 
(pen/strep) (5mg/ml) 
Life Technologies (USA) Cat# 15140-122  
Phenol chloroform isoamyl alcohol Sigma Aldrich (USA) Cat# 77618 
Polybrene (Hexadimethrine bromide) Sigma Aldrich (USA) Cat # 107689 
Potassium chloride (KCl)  Sigma Aldrich (USA) Cat# P9541 
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Potassium ferricyanide [K3Fe (CN)6] Sigma Aldrich (USA) Cat# D8537 
Potassium ferrocyanide [K4Fe (CN)6] Sigma Aldrich (USA) Cat# P3289 
Schiffs reagent Australian Biostain (AUS) Cat# ASC 
Sodium chloride (NaCl) Sigma Aldrich (USA) Cat# S3014 
Sodium hydroxide (NaOH) Sigma Aldrich (USA) Cat# S5881 
TE buffer  Usb Corp (USA) Cat# 75834 
Trypan blue  Bio-Rad (USA) Cat# 145-0013 
Trypsin  Life Technologies (USA) Cat# 12604 
Virkon  Med-con (Aus) Cat# 500607 
Water for irrigation Baxter Healthcare (USA) Cat# AHF7114 
X-gal  Progen Industries (AUS) Cat# 200-0191 
Xylene  Scharlau (Spain) Cat# X100572500 
2.1.2 Consumable and suppliers 
6-well flat bottom cell culture plate Sigma Aldrich (USA) Cat# CLS3516-50 
12-well flat bottom cell culture plate Sigma Aldrich (USA) Cat# CLS3513  
24-well flat bottom cell culture plate Costar (Corning Scientific, USA) Cat# 3524 
96-well flat bottom cell culture plate Costar (Corning Scientific, USA) Cat# 3590 
Circular cell culture plates  
(150 mm x 25 mm) 
Costar (Corning Scientific, USA)  
Cat# 430599 
Haemocytometer ProSciTech (AUS) Cat# SVZ4NIOU 
Histology cassette ProSciTech (AUS) Cat# RCH40-G 
Gel loading tips 
 
Quality Scientific Plastics (USA) Cat# 010-Q 
Micro-loader tips Eppendorf (Germany) Cat# 5242956003 
Microscope coverglass slips ProSciTech (AUS) Cat# G414 




Mustang Q acrodiscs  Pall Corporation (USA) Cat# MSTG25Q8 
Polypropylene centrifuge tubes  Beckman Coulter (USA) Cat# 331374 
T-75 flask  Greiner Lab (Germany) Cat# 658175 
Typan blue  Bio-Rad (USA) Cat# 145-00143 
Square cell culture plates (224 mm x 244 
mm)  
Costar, Corning Scientific (USA) Cat# 
4301110 
2.1.3 Bacterial strains and media 
Broth 1.5% (w/v) Tryptone, 1% (w/v) Yeast 
extract, 0.5% (w/v) NaCl in distilled water 
E. coli E. Coli (Sure cells) 
LB agar  1% (w/v) Tryptone, 0.5% (w/v) Yeast 
extract, 0.5% (w/v) NaCl, 1 M NaOH in 
distilled water 
2.1.4 Cell lines 
HEK-293T cells American Type Culture, CRL 11268 
CHO-K1 cells American Type Culture, CCL 61 
NIH3T3 cells American Type Culture, CRL 1658 





LacZ pHIV-MPSV-nlsLacZ (Figure 8-6) 
2.1.6 Plasmid kit and buffers 
Agarose gel 1% (w/v) agarose in TBE buffer 
Endofree Plasmid Mega Kit Qiagen (Germany) Cat# 12391 
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2x HeBS 0.28 M NaCl,0.05 M Hepes,1.5 mM Na2HPO4 
pH 7.04 
TBE buffer  Bio-Rad (US) Cat# 161-0770 
2.1.7 Quantitative real-time PCR assay 
2.1.7.1 PCR kits 
TaqMan universal PCR master mix Life Technologies (USA) Cat# 4304437 
TaqMan MGB probe (50,000 ρmol) Thermo Fisher Scientific (AUS) Cat# 4316032 
Wizard SV genomic DNA system Promega (USA) Cat# A2361 
20x assay mix 18 μM forward primer, 18 µM reverse 
primer, 5 μM probe in TE buffer 
2.1.7.2 Primers and probes 
Gag forward primer AGC TAG AAC GAT TCG CAG TTG AT 
Gag reverse primer CCA GTA TTT GTC TAC AGC CTT CTG A 
Gag probe 6FAM-CCT GGC CTG TTA GAA AC-NFQ 
mTransferrin forward primer AAG CAG CCA AAT TAG CAT GTT GAC 
mTransferrin reverse primer CGT CTG ATT CTC TGT TTA GCT GAC A 
mTransferrin probe 6FAM-CTG GCC TGA GCT CCT-NFQ 
NLS-LacZ 3’ primer GCC ACT TCT TGA TGG ACC ACT T 
NLS-LacZ 5’ primer CCG CCA CCG ACA TCA TCT 
NLS-LacZ probe FAM-CAC GCG GGC GTA CAT-NFQ 
2.1.8 LV LacZ titre assay 
Pre-X-gal  35 mM [K3Fe (CN)6], 35 mM [K4Fe (CN)6], 
1 mM MgCl2 in PBS 
X-gal 40 mg/ml X-gal in DMF 
2.1.9 Animal models 
C57Bl/6 mice Laboratory Animal Services, University of 
Adelaide, SA (AUS) 
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2.1.9.1 Anaesthesia  
Anti-sedan reversal  0.5 mg/ml Atipamazole (Pfizer, NZ) in sterile 
water 
Domitor: Ketamine mix 0.1 mg/ml Medetomidine (Pfizer, NZ), 7.6 
mg/ml Ketamine (Ceva, AUS) in sterile water 
2.1.10 Processing of mouse head, trachea and lung 
10% NBF 
 
10% (v/v) Formalin, 0.22 M NaH2PO4, 
 0.45 M NaH2PO4 in distilled water 
Carnoy’s fixative  60% (v/v) Ethanol, 30% (v/v) Chloroform,  
10% (v/v) Glacial acetic acid 
Decalcification solution 7% (v/v) HCl in 1.5% EDTA (w/v) in distilled 
water 
PFA/Glutaraldehyde 2% (w/v) PFA, 0.5% (v/v) Glutaraldehyde in 
PBS 
Pre-X-gal  5 mM [K3Fe (CN)6], 5 mM [K4Fe (CN)6], 1 mM 
MgCl2 in PBS 
X-gal 20 mg/ml X-gal in DMF 
 
2.1.11 Equipment 
Aeroneb®Pro nebuliser Aerogen Inc., (Ireland) 
Centrifuge Beckman Coulter (USA) Allegra™25R 
Centrifuge, TS-5.1-500 rotor 
Cell culture incubator New Brunswick, Eppendorf (Germany) Galaxy 
170 R 
ET tube BT Insyte™ (Aus) 20-gauge intra-venous 
catheter 
Compound-light microscope  Nikon (Japan) Eclipse E400 
Gel electrophoresis tank  Bio-Rad (AUS) Mini-Sub GT 7X10  
Microplate reader Bio- Rad (AUS) iMark™ absorbance reader 
Microtome Leica (Germany) RM2235 




Shaker Ratek (AUS) Orbital mixer incubator 
Stereo-microscope Nikon (Japan) SMZ1500 
qRT-PCR  Bio-Rad (USA) CFX™ Connect PCR machine 
Ultra-centrifuge Beckman Coulter (USA), SW-60 Ti rotor, 
Optima L-100XP  
Ventilator (flexiVent™) Scireq Scientific Respiratory Equipment Inc. 
(Canada)  
2.1.12 Software  
CFX™ Manager  Bio-Rad (USA) Cat# 1855201 
Flexiware 7.2 Scireq Scientific Respiratory Equipment Inc. 
(Canada)  
G* Power 3.2 Universität Düsseldorf (Germany) 
NIS-element  Nikon (Japan) Cat# MQS33000 
Prism 8 GraphPad (USA) 
2.2 Methods: In vitro  
2.2.1 Plasmid preparation 
2.2.1.1 Large scale plasmid production 
All plasmids used in this study were prepared using the Endo-free Plasmid Mega-Kit as per 
the manufacturer’s instructions. 
2.2.1.2 Agarose gel electrophoresis 
Qualitative assessment of plasmid DNA was performed using restriction digests followed by 
agarose gel electrophoresis. Plasmid DNA was digested using appropriate restriction enzymes 
and visualised using 1.2-1.8% agarose gel in 1x TE buffer, with gel red nucleic acid stain. The 
gel was submerged in 1x TE buffer and run at 100 volts, 400 mA and 100 watts. DNA fragments 
produced on digesting plasmid DNA were compared to a standard DNA molecular weight 




Plasmid DNA was quantitated using a spectrophotometer at an absorbance of 260 nm. 
2.2.2 Cell culture 
All cell culture work was performed in a class II biosafety cabinet in a PC2 laboratory using 
appropriate aseptic techniques.  
2.2.2.1 Cell culture initiation  
HEK-293T and NIH-3T3 cells were cultured using DMEM containing 10% (v/v) FCS. CHO-K1 
cells were cultured using Hams F12 medium containing 10% (v/v) FCS. A vial of frozen cells 
(stored in liquid nitrogen at -80°C) was thawed using a warm water bath at 37°C and added 
to 9 ml of appropriate pre-warmed cell culture media in a 10 ml sterile centrifuge tube. The 
cell suspension was centrifuged at 5,000 RPM at 4°C for 10 minutes. Supernatant was 
discarded, and the cell pellet was suspended in 5 ml of cell culture media. 10 µl of cell 
suspension was diluted by 50% (v/v) with trypan blue to determine viable cell count using a 
haemocytometer. The cell suspension was later transferred to a T-75 flask containing 14 ml 
of pre-warmed media and placed in a humidified incubator at 37°C supplied with 5% carbon 
dioxide (CO2) and allowed to expand. 
2.2.2.2 Cell culture expansion 
2.2.2.2.1 HEK-293T and NIH-3T3 cells 
Cells were sub-cultured for further experiments and for regular cell culture maintenance. 
DMEM present in a confluent T-75 flask was aspirated and the cell layer was rinsed with 
phosphate buffered saline (PBS) to ensure removal of remaining media. To detach the 
adherent layer of cells, 4 ml of 10% (v/v) trypsin diluted in PBS was added to the T-75 flask 
and incubated for 2 minutes at room temperature. Equal amounts of DMEM were then added 
to neutralise trypsin, and cells were pipetted to obtain a single cell suspension as observed 
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using a light microscope. Cells were passaged with media, 1:2 (v/v) to be confluent in 24 hours 
and 1:4 (v/v) to be confluent in 48 hours. Flasks were incubated at 37°C and 5% CO2 for further 
adherence and cell growth.  
2.2.2.2.2 CHO-K1 cells 
CHO-K1 cells were sub-cultured using the previously mentioned protocol with minor 
modifications. Hams F12 cell culture media was used to maintain and sub-culture CHO-K1 
cells. To detach adherent layer of CHO-K1 cells, trypsin was added to the flask and incubated 
for 7 minutes. Cells were passaged with Hams F12 media, 1: 3 (v/v) to be confluent in 24 hours 
and 1:6 (v/v) to be confluent in 48 hours.  
2.2.3 Lentiviral vector production 
2.2.3.1 Cell culture 
HEK-293T cells were sub-cultured and expanded into 8 x T-75 flasks over two days. Cells from 
eight confluent T-75 flasks were sub-cultured and seeded onto eight round plates (150 mm) 
and were then cultured overnight at 37°C and 5% CO2. Round plates with confluent cells were 
harvested and cell concentration was determined using a haemocytometer. The cell 
suspension was diluted with DMEM containing 10% FCS (v/v), penicillin and streptomycin 
(pen/strep) 1:100 (v/v), to obtain a final cell concentration of 0.375 x 106 cells/ml. Cells were 
seeded onto 8 x 245 mm square plate by pipetting 110 ml of cell suspension per plate. These 
plates were incubated for 20-24 hours at 37°C and 5% CO2. 
2.2.3.2  Lentiviral vector production  
LV vector containing the LacZ reporter gene was produced by transfecting HEK-293T cells with 
a five-plasmid system using calcium phosphate co-precipitation136. A DNA/calcium chloride 
(CaCl2) mix containing 320 µl of 2.5 M CaCl2 added to 3.2 ml of water was prepared. Plasmids 
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were added to this mixture in the ratio (per 245 mm square plate): 170 µg of pHIV-MPSVnls-
LacZ (Figure 8-6), 3.16 µg of pcDNA3Tat, 3.16 µg of phCMVRev, 2 µg of phCMVgagpol, and 7.9 
µg of pVSV-G, and the mix was gently vortexed. An aliquot of 3.2 ml of 2 x HeBS buffer was 
vortexed and an equal volume of DNA/CaCl2 mixture was added drop-wise over 5 to 10 
seconds. This mixture was vortexed for an additional 20 to 25 seconds and allowed to stand 
at room temperature for a further 90 seconds. This DNA-CaPO4 precipitate was gently added 
to the 245 mm square dish containing HEK-293T cells using a pipette and was allowed to stand 
at room temperature for 30 seconds. An even distribution of DNA-CaPO4 precipitate was 
attained by gently swirling the plate. This procedure was repeated for all 245 mm square 
plates, which were then incubated for 8 hours at 37°C and 5% CO2. A media change was 
performed using OptiPro serum-free medium, supplemented with 4 mM glutamine and 
pen/strep 1:100 (v/v). Plates were then incubated for a further 48 hours.  
2.2.3.3 Lentiviral vector purification and concentration  
LV vector obtained from supernatant of transfected HEK-293T cells was filtered and 
concentrated by ultracentrifugation. Supernatant of the 8 x 245 mm square plates was 
decanted into a 1 L bottle, which was supplemented with 0.1% (w/v) BSA. This procedure was 
carried out in a bio-safety cabinet and the 1 L bottle was transferred to a sterile bench for 
further purification. The ultrafiltration system was setup using 0.45 μm filter 
(polyethersulfone membrane) connected to two Mustang Q Acrodisc filters151, 152, as shown 





Figure 2-1: Ultrafiltration system to harvest LV-LacZ vector from supernatant. 
Supernatant was pumped through the filtration system at a flow rate of 10 ml/min. On 
completion, the filtration system was flushed with 100 ml of PBS/0.1% BSA (w/v). The LV-LacZ 
vector was eluted from the Mustang Q Acrodisc filters using 4 ml of 1.5 M NaCl into equal 
volume of 2% heat inactivated mouse serum diluted in water152. For further concentration, 
the elution was divided equally into two polypropylene ultracentrifuge tubes and 
ultracentrifuged at 20,000 RPM (SW 60 Ti rotor, Beckman Coulter) for 90 mins at 4 °C. Pellets 
containing the LV-LacZ vector were suspended into appropriate volumes of diluent and 
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aliquoted to avoid freeze-thaw. The vials were stored at -80°C.  
2.2.4 Viral titre determination  
Titre of LV-LacZ vector was obtained by quantitative real-time PCR (qRT-PCR) analysis of pro-
viral genomic DNA (gDNA), obtained by transducing NIH-3T3 cells.  
2.2.4.1 Preparation of pro-viral gDNA  
NIH-3T3 cells suspended in DMEM supplemented with 10% FCS were seeded at a 
concentration of 0.05 x 106 cells/well of a 24-well plate and incubated at 37°C at 5% CO2 for 3 
hours. Media on the 24-well plate was replaced with DMEM medium supplemented with 10% 
FCS, 4 μg/ml polybrene, and 2 μg/ml gentamycin. Cells were transfected with 1:1,000 (v/v) 
diluted LV vector and incubated for 24 hours. A media change for the 24-well plate was carried 
out using DMEM supplemented with 10% FCS and gentamycin. Cells were incubated at 37°C 
at 5% CO2 until confluent then split 1: 4 (v/v). Cells were maintained for 30 days using standard 
sub-culturing methods.  
After 30 days, the media was aspirated and cells were washed with PBS. This was followed by 
0.5 ml of 10% trypsin/PBS (v/v) for 2 minutes, which was then neutralised using equal volumes 
of 1% FCS/PBS solution (v/v). The cell suspension was centrifuged at 2,000 RPM for 5 minutes 
at 4°C. The supernatant was aspirated, and the pellet was suspended in 3 ml of PBS. This 
process of rinsing cell pellets in PBS was repeated three times in total. Pro-viral gDNA was 
isolated from the cell suspension using the Wizard® genomic DNA purification kit as per 
manufacturer protocol, and was then stored at -20°C for qRT-PCR.  
2.2.4.2 qRT-PCR analysis 
The pro-viral gDNA extract was analysed using qRT-PCR to determine titre of the LV-LacZ 
vector. For every sample two assays were carried out: one to detect presence of the gag 
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sequence and the other to identify the transferrin sequence. A non-template control was also 
included by using water in place of the gDNA sample. Each reaction contained 1 µl of 20 x 
assay mix (gag or transferrin), 10 µl of 2 x TaqMan universal PCR master mix, 4 µl of water, 
and 5 µl of gDNA sample. All samples were analysed in triplicate, which included a non-
template control and standard. Reactions were performed using the following cycling 
conditions: 50°C for 2 min, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 
1 minute. At the end of each cycle the fluorescence emitted by the reaction was read and an 
amplification plot was constructed using the CFX™ software. The cycle threshold (Ct) for each 
sample was calculated using the same software. The LV titre (infectious units/ml) was 
determined using the following formula: 
ΔCt = Ct of gag – Ct of mTransferrin for a sample 
ΔΔCt = ΔCt – 1 (or average of standard) 
1/ 2ΔΔCt = copy number per cell 
Titre= number of cells initially plated x copy number per cell x (1000/ volume in μl) 
                            dilution factor 
         = infectious units/ml 
2.2.5 Lentiviral aerosol viability assay 
A β-galactosidase assay was used to quantify the level of gene expression produced by 
aerosolised LV-LacZ vector released at the end of a nebuliser-ventilator circuit (Chapter 4, 
Figure 4-1). A T-75 flask of confluent CHO-K1 cells was split using Hams F12 media 
supplemented with 10% FCS and pen/strep 1:100 (v/v), and cells were seeded at a 
concentration of 0.05 x 106 cells/well onto a 24-well plate and incubated for 3 hours. Prior to 
LV transfection, media in wells was replaced with Hams F12 media supplemented with 10% 
FCS, pen/strep 1:100 (v/v), 4 µg/ml of polybrene, and 2 µg/ml of gentamycin. A 20 µl aliquot 
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of LV-LacZ vector diluted 1:10 (v/v) in an appropriate diluent was aerosolised using an 
Aeroneb®Pro nebuliser connected to a flexiVent™ ventilator (Figure 2-2). The Aeroneb®Pro 
nebuliser used in this study was expected to produce aerosols of 3.6 µm diameter, as 
determined by the manufacturer. The ventilator circuit consisted of: a Scireq in-line 
Aeroneb®Pro mount with an internal diameter of 0.8 mm that lies directly below the point of 
aerosol delivery, connector tube, Y-piece, endotracheal (ET) tube with an internal diameter 
of 1.1 mm, and an expiratory limb. The tip of the ET tube was immersed in 500 µl of 
supplemented Hams F12 cell culture media contained in a 1.5 ml screw capped tube, with a 
loosened lid.  
Aerosols of LV-LacZ vector released at the tip of the ET tube were collected in supplemented 
cell culture medium, which was later assayed. The ventilator circuit was cleaned between 
samples using the following protocol: aerosol delivery of 50 µl Virkon for 30 seconds, followed 
by three aerosol doses of 100 µl water, for 45 seconds each. The ventilator circuit was then 





Figure 2-2: Aeroneb®Pro nebuliser and parts of flexiVent™ ventilator circuit (scale bar=2.5 cm).  
The viability of the LV-LacZ vector released from the outlet of nebuliser (not connected to the 
ventilator circuit) was also quantified. The LV-LacZ vector of the same dilution was aerosolised 
using the Aeroneb®Pro nebuliser not connected to the ventilator circuit into wells of a 12-well 
plate containing 500 µl of supplemented Hams F12 cell culture medium. Media containing 
aerosols of LV-LacZ vector was later assayed. For a positive bolus control, LV-LacZ vector of 
the same dilution was delivered as a bolus dose to a separate well containing 500 µl 
supplemented Hams F12 cell culture medium. 
Equal volumes of samples from each group were used to transduce CHO-K1 cells on a 24-well 
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plate (200 μl/well). Transfected cells were incubated at 37°C and 5% CO2. A media change was 
carried out after 24 hours with pre-warmed Hams F12 media supplemented with 10% FCS, 
pen/strep 1:100 (v/v) and was incubated for a further 48 hours. Cells were rinsed with PBS 
and fixed with 0.05% glutaraldehyde in PBS for 15 minutes on a shaker at room temperature. 
The fixative was aspirated, and cells were washed three times with 1 mM MgCl2 in PBS for 10 
minutes each. The MgCl2 was then aspirated and 1: 40 dilution (v/v) of X-gal: pre-X-gal 
solution (Section 2.1.7) was added onto the monolayer of cells and allowed to incubate 
overnight at 37°C. Cells were rinsed twice with PBS and stored in 80% glycerol. Images of each 
well of the 24-well plates were captured at 100x magnification using a stereo-microscope. 
The number of transduced cells in each well was quantitated by image analysis (Appendix, 
Section 8.2), using a custom-written MATLAB script (The Mathworks, Natick, USA).  
2.2.6 Colorimetric assay to assess physical dose volume of aerosolised dye solution 
The physical dose volume of aerosolised dye solution deposited in different ventilator circuit 
components and released at the tip of the ET tube (located at the end of the ventilator circuit) 
was quantified using the following protocol. A 20 µl aliquot of yellow food dye diluted 50% 
(v/v) with water was aerosolised through the Aeroneb®Pro nebuliser connected to the 
flexiVent™ ventilator circuit using appropriate ventilation parameters (Chapter 4). The 
volume of dye solution was constant for all experiments, unless otherwise mentioned. 
Aerosolised dye solution was collected at the tip of the ET tube, which was immersed in 500 
μl of water contained in a 1.5 ml screw-cap tube with a loosened lid. The ventilator circuit was 
disassembled, and each ventilator circuit component was washed with 500 µl of water, which 
were collected in separate microcentrifuge tubes to be assayed later. 
The physical dose volume of aerosols released at the outlet of the Aeroneb®Pro nebuliser not 
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connected to the ventilator circuit was also quantified. The nebuliser (not connected to 
ventilator circuit) was mounted on one well of a 12-well plate containing 500 µl of water. Dye 
solution was then aerosolised using the nebuliser with appropriate delivery parameters 
(Chapter 4). Aerosols released by the nebuliser were captured by water contained in the well 
to be assayed later.  
As a bolus control, dye solution was delivered using a pipette into 500 µl of water. A 200 µl 
aliquot of sample collected from each group was then loaded into a clear 96-well plate. Two 
replicates were used per sample for all studies. 
Dye absorbance was measured at 510 nm using a Microplate absorbance reader. A standard 
curve was established by measuring the absorbance of known concentrations of dye solutions 
(where 100% represented 20 μl of dye pipetted into 500 μl of water, the starting volume of 
dye solution). The standard curve was used to quantify the dose volume of aerosols released 
at the outlet the Aeroneb®Pro nebuliser alone, end of the ventilator circuit, deposited within 
circuit components, and bolus delivery. 
2.3 Methods: In vivo 
Mice were used as cost-effective in vivo models as only a very small starting volume of the 
expensive vector formulation is required to determine the effectiveness of different delivery 
regimen. LV vector was delivered to the lungs of mice as either a liquid bolus or an aerosol.  
2.3.1 Animal care and management 
All animal experiments were approved by the University of Adelaide Animal Ethics Committee 
and Women’s and Children’s Hospitals (WCH) Animal Ethics Committee. All experiments used 
female C57BL/6 mice housed at the WCH animal house physical containment 1 (PC1) facility. 
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Following vector delivery mice were transferred to the WCH physical containment 2 (PC2) 
facility, as per Office of the Gene Technology Regulator (OGTR) guidelines. All experiments 
involving LV delivery to mice were performed in a class II biosafety cabinet under PC2 
conditions. Animals were monitored and weighed daily for one week post-LV treatment with 
additional monitoring as required.  
2.3.2 Airway pre-treatment preparation 
PBS tablets without calcium and magnesium were dissolved in MilliQ water (1 tablet/ 100 ml 
water) and sterile filtered using 0.45 µm filter. PBS solution was aliquoted and stored at -20°C 
for further use. Various concentrations of LPC were diluted in PBS solution and dissolved by 
sonication to avoid bubble formation. LPC was stored at 4oC and used within 4 weeks. 
2.3.3 Lentiviral vector delivery  
C57BL/6 mice of 8-10 weeks of age were anesthetised with 10 µl/g body weight of 
medetomidine (Domitor) (0.1 mg/ml) and Ketamine (7.6 mg/ml) formulation delivered as an 
intra-peritoneal (i.p) injection. They were then suspended by upper incisors on a vertical 
support and intubated using 20-gauge polyethylene ET tube guided into the trachea by a 
fibre-optic cable within the tube. The fibre-optic cable was then withdrawn. Mice were placed 
in a supine position, and 10 µl of 0.1% LPC conditioning solution was delivered as a single 
bolus dose using a micropipette fitted with a microloader tip via the ET tube, administered 
smoothly over 5 seconds. Mice were placed on a heating pad while anaesthetised to maintain 
optimal body temperature. 
2.3.3.1 Bolus lung instillation 
One hour after LPC conditioning, 20 µl of LV-LacZ vector was delivered as a single bolus dose 
via the ET tube, administered smoothly over 10 seconds. The ET tube was removed, and mice 
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were given an i.p injection 2 µl/g bodyweight of atipamezole (Anti-Sedan) (0.5 mg/ml) to 
reverse anaesthesia. 
2.3.3.2 Aerosol lung instillation 
One hour after LPC conditioning, the mice were connected to the Aeroneb®Pro-flexiVent™ 
ventilator circuit via the ET tube as shown in Figure 2-3. This system was designed to minimise 
the distance between the Aeroneb®Pro and the ET tube, but keep the flexiVent™ system 
outside the biosafety cabinet. The mice were mechanically ventilated for two minutes using 
the following ventilation parameters: tidal volume (VT) 10 ml/kg, respiratory rate (RR) 120 
breaths/minute, duty cycle (DC) 1 (i.e. operated at a 100% during the inspiratory phase only), 
positive end expiratory pressure (PEEP) set at 3 cmH20, and inspiratory: expiratory ratio (I: E) 
ratio ~ 1:1 (0.233 s: 0.266 s). The mice were closely observed to ensure breathing was 





Figure 2-3: Aerosols of LV-LacZ vector: (A) the Aeroneb®Pro nebuliser connected in-line with the flexiVent™ 
ventilator (scale bar = 5 cm) and (B) mouse connected to the Aeroneb®Pro-flexiVent™ ventilator circuit via the ET 
tube (scale bar = 2.5 cm). 
One hour after receiving the LPC conditioning, a 20 µl aliquot of LV-LacZ vector formulation 
was loaded onto the vibrating mesh of Aeroneb®Pro nebuliser and aerosolised. After delivery, 
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the mice were disconnected from the Aeroneb®Pro-flexiVent™ ventilator circuit and the ET 
tube was removed. All components of the ventilator circuit were thoroughly washed and 
dried prior to treatment of the next mouse. Anaesthesia was reversed as described in Section 
2.3.3.1. 
2.3.4 Assessment of LacZ gene expression  
LacZ gene expression was detected by X-gal staining the trachea and lungs of mice treated 
with the LV vector. One week after LV-LacZ treatment, mice were humanely killed by CO2 
asphyxiation. Mice were placed in a supine position and cardiac puncture was performed. The 
chest and abdomen were swabbed with 70% ethanol; an incision was made from the 
abdomen to the chin. Rings of the trachea were exposed by separating the oesophagus and 
associated connective tissue. A blunt cannula was connected to a drip apparatus containing 
fixative (2% (w/v) PFA, 0.5% (v/v) glutaraldehyde in PBS, Section 2.1.10). The trachea was 
pierced using a 23-gauge needle and the blunt cannula was then inserted into the trachea and 
secured in place using silk sutures. The peritoneal cavity was then pierced to allow the lungs 
to collapse and the drip-line was opened to inflation fix the lungs.  
Associated tissues (the oesophagus, ribs, and heart) were carefully separated, and the lungs 
were removed and placed in fixative at 4°C for 2 hours. The lungs were rinsed twice in 1 mM 
MgCl2 at 4°C for 15 minutes and stained overnight (X-gal solution diluted 1:20 with pre-X-gal 
solution, see 2.1.10) at 37°C. The staining solution was removed, lungs were washed in 0.9% 
saline, and fixed in 10% neutral buffered formalin (NBF) for 22 hours. The lungs were stored 
in 70% ethanol and en face pictures of the whole lung were taken using a stereo-microscope. 
The lung tissue was separated into the trachea, left lung, and right lung. The left lung was cut 
horizontally into two equal halves, while the four lobes of the right lung were separated. En 
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face images of dissected lungs were recorded to visualise the LacZ gene expression. 
Longitudinal sections of the trachea and whole lobes of lungs were placed in histology 
cassettes and sent to Histology Services at Adelaide Medical School (University of Adelaide, 
SA) for embedding in paraffin. For every tissue sample, two sections of 4 µm thickness were 
taken using a microtome. One was stained with haematoxylin and eosin (H & E) to visualise 
morphology and the other counter stained with Safranin O (Saf O) to quantify the number of 
LV-LacZ transduced cells. 
To measure the number of transduced cells in the tracheal section, images of the section were 
captured at 40x magnification using a compound-light microscope. The length of the trachea 
(represented as mm) was measured using NIS-element software. The number of transduced 
cells present within 4 mm of the trachea was counted from the Saf O stained sections at 400x 
magnification.  
Similarly, an image of sectioned lobes of the lung were captured using the stereo-microscope 
at 75x and the area of tissue was measured using NIS-element software. The number of 
transduced cells present in lung parenchyma and airways within the entire lobe was then 
counted under the light microscope at 400x magnification. Results were expressed as number 
of transduced cells per length of the tracheal sections and per area for lobes of the lungs.  
2.4 Statistical analysis  
Results obtained were represented as mean and standard deviation of mean (Mean ± S.D), 
with n representing sample size of the group. G-Power version 3.1 was used to calculate the 
sample size of the study with statistical significance set at, p=0.05 and power=0.80. Statistical 
analysis was carried out using GraphPad Prism (version 8). Parametric or non-parametric tests 
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were carried out based on distribution of data. Student’s T-test (for data with equal variance) 
or Welch’s T-test (for data with unequal variance) were used to compare between two 
treatment groups and one-way analysis of variance (ANOVA) was used to compare across 
multiple treatment groups. 
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3 AEROSOL DELIVERY OF LENTIVIRAL VECTOR TO 
MOUSE AIRWAYS 
3.1 Introduction 
Lentiviruses (LV) are a leading vector of choice for CF gene therapy as they can transduce 
dividing and non-dividing cells51, 132, 140, integrate into host cell genomes132, carry the large 
CFTR gene132, and are more efficient than some other viral vectors153. As mentioned in the 
introduction, the CFARG has developed a HIV-1 derived LV vector pseudotyped with a VSV-G 
glycoprotein envelope132. The two-step bolus vector delivery method developed by this group 
includes an LPC conditioning followed by the LV vector dose one hour later, to the airways of 
mice51, 132, 139. Studies by Cmielewski et al. showed that delivering a bolus of 15 μl 0.1% LPC 
conditioning solution followed by 20 μl bolus of LV-LacZ vector (8.8 × 109 gRNA copies/ml) to 
mouse airways and observed an average of 65.9 transduced cells per mm of conducting 
airway (including the trachea and the bronchial airways)150. In another study, Liu et al. 
delivered a bolus dose of 15 μl of 0.1% of LPC and a 30 μl bolus dose of LV-LacZ vector (9.36x 
107 TU/ml) to mice airways140. This study showed lower levels of gene transduction in the 
trachea (two transduced cells per mm2) and the bronchial airways (one transduced cell per 
mm2) compared to the study by Cmielewski et al. Although the titre of these two studies 
cannot be compared directly it could be a contributing factor. These published studies clearly 
suggest that it is difficult to transduce mouse bronchial airways, even when the LV is delivered 
as a liquid. The two-step bolus vector delivery method was also used to deliver LV vector 
carrying a reporter gene to the airways of larger animal models, such as ferrets56, 
marmosets57, and sheep140. Gene expression associated with bolus delivery was patchy in 
major airways and lung parenchyma possibly caused by pooling of the vector dose at those 
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regions 57, 139. Katkin et al. observed similar patchy gene expression in the lungs of cotton rats 
treated with a bolus dose of Ad vector, while uniform gene expression was observed in lungs 
of aerosol-treated animals54, suggesting that a more uniform spatial distribution could be 
obtained by aerosolising the vector.  
Aerosol delivery is attractive due to its non-invasive nature, relative ease of access to the 
airways, and its potential for uniform drug deposition. In comparison to other delivery routes, 
aerosol delivery offers immediate availability of drugs or agents at airway surfaces, which 
could trigger rapid onset of action and provide a positive clinical experience154. Aerosol vector 
delivery protocols have been well established for viral vectors, such as Ad90, 91, AAV106, 111, 112, 
114, and SeV58, 155. Current LV delivery research focuses on developing an optimal aerosol 
delivery method, which has been challenging due to the more fragile nature of the LV vector 
in comparison to other viral vectors156. In a recent study, Cooney et al. successfully delivered 
a spray of FIV derived LV vector to airways of newborn pigs using an intra-tracheal spray 
device called the MADgic™ atomisation device87. Cell culture experiments in this thesis also 
demonstrated that this device was effective in delivering a coarse spray of the HIV-1 vector 
(Appendix, Section 8.1.4.2), but the device has some limitations (Introduction, Section 1.6.6). 
The HIV-1 vector has also been delivered as an aerosol in lung cancer studies157, however the 
efficacy of aerosolising this vector has not been reported.  
A major challenge reported in the above-mentioned studies was lowered viability of certain 
viral vectors, such as Ad, and SeV, following aerosol delivery54, 58. This lowered vector viability 
was likely due to shear stress applied on the vector during the process of aerosolisation58, 158. 
Thus, it is important to find a compatible nebuliser that can retain efficacy of the viral vector 
on aerosol delivery66. Conventional nebulisers, such as jet-nebulisers, produce high shear 
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stress due to generation of an air-liquid interphase and recycling of the aerosol formulation 
multiple times within the nebuliser before release159. Ultrasonic nebulisers are known to 
damage the aerosolised formulation due to heat generated during the process of 
aerosolisation159. A newly developed ultrasonic nebuliser called the SAW nebuliser has shown 
to effectively aerosolise sensitive biological formulations80. However, this thesis showed that 
the SAW nebuliser was not effective for aerosolising the HIV-1 vector (Appendix, Section 
8.1.4.1) 
In comparison, newer delivery systems, like vibrating mesh nebulisers are a single pass device 
developed to reduce shear stress produced by recycling the aerosolised formulation within 
the nebuliser159. Vibrating mesh nebulisers have been effective in delivering drug 
formulations sensitive to shear stress and temperature159, 160, such as liposomal salbutamol 
sulphate161, and biodegradable nanoparticles144. Hertel et al. demonstrated conservation and 
stability of a protein formulation SM 101, a soluble human FcγRIIB receptor, following delivery 
through an Akita2Apixneb™ vibrating mesh nebuliser (PARI, Gmbh, Stamberg, Germany)159. In 
another study, Kleeman showed that aerosolising iloprost containing liposomes through an 
Aeroneb®Pro vibrating mesh nebuliser produced low physical damage compared to a jet 
nebuliser and an ultrasonic nebuliser162. Changes in the formulation after aerosolisation 
through vibrating mesh nebulisers has also been investigated. MacLoughlin et al. showed that 
formulation temperature increased by a maximum of 7°C at an ambient temperature of 18°C 
following three consecutive passes through the Aeroneb®Pro nebuliser, each lasting 24 
minutes74. However, the authors mentioned that this increase in temperature did not exceed 
37°C, the temperature at which many biological formulations, such as gene therapy vectors, 
DNA, and proteins, are denatured74. Moreover, vibrating mesh nebulisers also have a high 
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output rate, shorter nebulisation time, and almost no dose retained in the device following 
aerosol delivery compared to jet nebulisers72, 144, 163. Together, these features enhance 
suitability of the vibrating mesh nebuliser to aerosolise difficult to produce and expensive 
viral vectors. 
The Aeroneb®Pro vibrating mesh nebuliser was chosen for all remaining studies presented in 
this thesis as is it approved for use in humans and has been well-established in clinics164, 165. 
This nebuliser may be used in-line to deliver aerosols to lungs of mechanically ventilated 
patients166, 167 and is also easily adapted to deliver aerosols to the lungs of smaller animals, 
like rodents mechanically ventilated with the flexiVent™ ventilator146. Rodents have a low VT 
and RR, which results in a very short inspiratory time74. The time taken by the Aeroneb®Pro 
nebuliser to begin generating aerosols is 2 ms, compared to 80 ms for a jet nebuliser and 150 
ms for an ultrasonic nebuliser74. MacLoughlin et al. demonstrated that this ability of the 
Aeroneb®Pro nebuliser enabled them to deliver the maximum volume of aerosols during the 
inspiratory cycle of the rat74. The Aeroneb®Pro nebuliser has been successful in delivering 
vector formulation to the airways of rodents. MacLoughlin et al. used this nebuliser to 
aerosolise AAV vector to the airways of rats and demonstrated robust gene expression in rat 
lung168.  
3.1.1 Hypothesis and aims  
The hypothesis of this experiment was that the Aeroneb®Pro vibrating mesh nebuliser would 
be effective in aerosolising a HIV-1 derived LV vector to the lungs of mice, due to its proven 
ability to aerosolise other viral vectors168 and shear sensitive drug formulations161.  
The aim of this in vivo study was to quantify the baseline level of gene expression produced 
by aerosolising the LV gene vector into mouse lungs using an Aeroneb®Pro nebuliser operated 
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in conjunction with the flexiVent™ small animal ventilator and compare it to the level of gene 
expression obtained by delivering the LV vector as a bolus dose. This was the only complete 
in vivo study presented in this thesis, where the animals were divided into an aerosol group 
and a bolus delivery group, with n=12 in each group. 
3.2 Methods  
3.2.1 Animals 
Animals used in this study were 8 to 10 week-old C57BL/6 female mice, weighing 
approximately 22 grams. All animals were cared for and managed, as described in Section 
2.3.1.  
3.2.2 Gene vector  
The HIV-1 gene vector used in this study was pseudotyped with the VSV-G envelope, 
contained a nuclear-localised LacZ transgene driven by the myeloproliferative sarcoma virus 
(MPSV) promoter, and was produced by transfecting HEK-293T cells using a 5-plasmid system 
by calcium phosphate co-precipitation (Section 2.2.3). Pellets obtained at the end of the 
vector preparation process were suspended in a standard carrier fluid (or diluent) of 0.1% 
mouse serum in 0.9% saline (MS/saline). Four batches of LV-LacZ vector were prepared for 
this study and were pooled prior to vector administration. The LV-LacZ vector titre of 
individual vector batches was determined using qPCR methods (Section 2.2.4 ). 
3.2.3 Aerosol airways vector delivery studies  
Gene expression produced by the LV-LacZ vector in the lungs of mice following delivery as an 
aerosol was compared to that produced by vector delivered as a bolus dose (n = 12/group).  
3.2.3.1 Airway conditioning and gene vector lung dosing  
Mice in both groups (aerosol dose and bolus dose) were anaesthetised and intubated with a 
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20-gauge intravenous catheter as an ET tube. The airways of both groups were then 
conditioned with 10 μl of 0.1% LPC delivered as a bolus dose via the ET tube, one hour prior 
to vector delivery (Section 2.3.3). LPC is a mild surfactant and being of detergent-like nature 
at high concentrations it can damage the respiratory epithelium and cause pulmonary 
edema169, 170. Cmielewski et al. optimised the bolus dose of LPC conditioning solution (0.1%) 
required to efficiently transduce the lungs of mice, without much damage150. The present 
study did not deliver LPC as an aerosol because the optimal dosing protocol required to 
produce efficient gene transduction using this delivery regimen is yet to be determined and 
was not within the scope of this thesis. Delivering LPC as an aerosol could distribute it 
uniformly throughout the lungs, potentially damaging the alveolar tissue, and thus would 
need to be carefully optimised.  
3.2.3.2 Vector administration  
Intubated mice in the liquid bolus delivery group were treated with 20 μl of LV-LacZ vector 
pipetted through the ET tube into the trachea and lungs (Section 2.3.3.1). Intubated mice in 
the aerosol treatment group were connected to the Aeroneb®Pro-flexiVent™ ventilator 
circuit via the ET tube (Figure 2-3). The ventilator parameters used were: VT 10 ml/kg, RR 120 
breaths/minute, DC 1 (i.e. operated at a 100% during the inspiratory phase only), PEEP set at 
3 cmH20, and I: E ratio ~ 1:1 (0.233 s: 0.266 s). A 20 μl aliquot of LV-LacZ vector was aerosolised 
over 20 to 40 second through the nebuliser-ventilator circuit. After every aerosol delivery the 
ventilator circuit was cleaned (Section 2.3.3.2).  
After LV treatment, anaesthesia was reversed, and mice were monitored post-operatively 
(Section 2.3.1). Mice were humanely killed by CO2 asphyxiation one week later. Each mouse 
trachea, bronchial airways and lungs were dissected, stained with X-gal solution, and 
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processed for histological analysis (Section 2.3.4). The number of LacZ expressing cells present 
in trachea and lungs of mice were assessed.  
3.3 Results 
The four LV-LacZ vector batches prepared for this study had titres of 8.19 x 108 TU/ml, 1.04 x 
109 TU/ml, 3.76 x 107 TU/ml, and 6.57 x 108 TU/ml. Equal volumes of the four LV vector batches 
were pooled prior to vector administration (average titre 6.38 x 108 TU/ml). The LPC 
conditioning and LV vector dose were tolerated well by all mice in both treatment groups. 
The general behaviour of mice, including demeanour, feeding, respiratory motion, and weight, 
was within normal limits post-treatment. 
The lungs treated with a bolus dose of the vector demonstrated LacZ gene expression in the 
trachea, which extended into the bronchial airways and upper lobes of the left and right lungs 
(indicated by black arrows, Figure 3-1 A). Gene expression observed in the trachea of bolus-
treated animals was along an axial line and was more intense than that seen in aerosol-
treated animals (Figure 3-2). The en face images of bolus-treated animals revealed intense 
and patchy gene expression at the carina (Figure 3-1 A and B), although no gene expression 
was seen in bronchial airways themselves. This pattern of gene expression in tracheal and 
bronchial airways was seen in 10 out of 12 bolus-treated animals. Furthermore, a cross-
section of the left lungs in 5 of 12 animals belonging to the bolus treatment group revealed 
diffuse LacZ gene expression in major airways (indicated by black arrow, Figure 3-1 C and D) 




Figure 3-1: Bolus delivery of LV-LacZ vector: gene expression (blue-stained regions) observed from the en face 
images of (A) mouse lung showing LacZ gene expression in the upper lobes of the left and right lungs (black 
arrows), (B) magnified view of the trachea, (C) cross-section of left lung, and (D) magnified view of the sectioned 
lobe showing diffuse LacZ gene expression in the major airways (black arrow) and patchy gene expression in the 
parenchyma (blue arrow) (scale bar = 1 mm). 
En face examination of the tracheas from mice treated with aerosolised LV vector (Figure 3-2 
A and B) revealed that LacZ gene expression was primarily limited to regions near the site of 
dosing, with a few transduced cells observed in the more distal bronchial airways. Gene 
expression was not observed in the lung parenchyma of mice belonging to the aerosol 




Figure 3-2: (A) En face images of X-gal stained mouse lungs following aerosol delivery of LV-LacZ vector LacZ 
expression (blue-stained regions) is limited to site of delivery in the trachea (B) magnified view of the same 
trachea (scale bar = 1 mm).  
Transduction in of one of twelve animals in the aerosol treatment group exhibited very high 
levels of LacZ transduced cells. The en face images of this mouse showed LacZ gene expression 
in the trachea, bronchial airways, and throughout the lobes of the left and right lungs (Figure 
3-3 A). Cross sections of the left lung revealed intense and uniform transduction along the 
major airways (Figure 3-3 B).  
 
Figure 3-3 : Aerosol delivery of LV-LacZ vector: gene expression observed in the outlier animal (A) en face image 
of the whole lung (B) cross section of the left lung (scale bar = 1 mm). 
Both aerosol and bolus delivery regimens primarily targeted ciliated cells of the conducting 
airways. Histological analysis of all tracheas revealed that the mean number of LacZ-
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transduced cells in the bolus delivery group was nine-fold higher than in the aerosol delivery 
group (Figure 3-4). In addition, Figure 3-4 shows high variability in the number of transduced 
cells seen in the trachea of bolus treatment group.  
 
Figure 3-4: LacZ gene expression observed in the trachea on delivering the vector as a bolus or as an aerosol dose.  
There were very few LacZ-transduced cells in the bronchial airways of animals from both 
treatment groups (data not shown). This result suggests that it was difficult to transduce 
mouse bronchial airways using either delivery methods employed in this study.  
A histological analysis of the left lungs revealed no significant difference in the number of 




Figure 3-5: Number of transduced cells observed in the left lung of mice from each treatment group. 
Similar to the bronchial airways, the number of LacZ-transduced cells observed in the right 
lung of mice in both treatment groups was very low (Figure 3-6). Thus, other than the 
observation of poor gene expression, this study was limited in its capacity to draw conclusive 
results from LacZ gene expression observed in the right lung of mice.  
 
Figure 3-6: LacZ gene expression in the right lung produced by delivering the LV vector either as an aerosol or a 
bolus dose. 
LacZ-transduced ciliated, non-ciliated, and basal cells were observed in the trachea of mice 
belonging to the bolus treatment group (Figure 3-7). In the aerosol treatment groups, only 




Figure 3-7: H & E stained sections of a trachea from the bolus delivery group showing LacZ-transduced non-
ciliated cells (dash arrow), ciliated cells (double-lined arrow), and basal cells (solid arrow) (scale bar =10 μm). The 
LacZ staining was strong enough to bleed out of the cell nuclear region. 
In the bolus treatment group, LacZ-transduced ciliated cells were seen in conducting airways 
of the left lung (image not shown), along with transduced type 1 and type 2 pneumocytes 
(Figure 3-8 A). A small number of transduced macrophages were also observed in the alveolar 
region (Figure 3-8 B).  
 
Figure 3-8: H & E stained sections of the alveolar region present in the left lung of mice from the bolus delivery 
group, showing (A) a LacZ-transduced type 1 pneumocytes having squamous morphology (solid arrow), type 2 
pneumocytes having cuboidal morphology (dotted arrow) and (B) a LacZ transduced macrophage at the centre 
(double-lined arrow) (scale bar =10 μm).  
One animal that was transduced in the aerosol treatment group demonstrated gene 
expression in a majority of cells present in the airways of the left and right lungs (Figure 3-9 




Figure 3-9: Outlier animal from aerosol delivery group showing (A) transduced cells in the airways (scale bar = 50 
μm) and (B) magnified view of the airway showing LacZ-transduced basal (solid arrow), ciliated (dotted arrow) 
and goblet cells (dash arrow) (scale bar = 10 μm). 
3.4 Discussion  
Developing an effective vector delivery regimen is crucial for CF airway gene therapies. 
Aerosol vector delivery may be ideal for use in future CF gene therapy trials, as it is convenient 
and is thought to be more likely to distribute the vector uniformly in the lungs of animals 
compared to bolus delivery54. To my knowledge, this proof of concept in vivo study is the first 
to test the efficiency of aerosolising a HIV-1 based LV vector using an Aeroneb®Pro nebuliser 
in conjunction with a flexiVent™ ventilator circuit to the airways of mice. 
Viral vectors can be administered as an aerosol to the lungs of animal models via the nasal97 
or tracheal route112, or via (whole-body box) inhalation delivery54. In this study, the LV vector 
was delivered by the tracheal route using an ET tube, as this provides immediate availability 
of the LV formulation to the lung, and avoids loss of dose on the body surface (with whole 
animal exposure chambers) or in the nose or throat as can occur with other delivery routes171, 
172. The intra-tracheal route has also been recognised as an optimal delivery method and has 
been used to deliver formulations such as sub-unit vaccines173, cationic lipoplexes174, and 
polymeric microspheres175 to mouse lungs. 
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Results reported in the present study did not support the hypothesis that the Aeroneb®Pro 
nebuliser was effective in delivering a HIV-based LV vector to the lungs of mice when 
mechanically ventilated with the flexiVent™ ventilator. Histological analysis of the trachea 
revealed that levels of gene expression in the bolus-treatment group were nine-fold higher 
than the aerosol treatment group. The proximal conducting airway region in mice is the 
location of ciliated epithelial cells and the recently identified ionocytes that express 
approximately 60% of the CFTR mRNA in the lung44. Both the aerosol and bolus delivery 
regimens presented in the current study could transduce these cells, although this remains 
unproven and needs to be investigated in future studies. The proportion of ionocytes present 
in the mouse airway is very low (~1% of the airway cells)44, but they are clearly a very 
important population of cells in CF. This means that future studies should also examine 
whether a vector specifically designed to target ionocytes would improve outcomes in CF.  
High variability in the number of transduced cells, in the trachea, was observed in the bolus 
treatment group. In a previous study, Liu et al. found similar levels of variability in gene 
expression in the lungs of mice treated with a bolus dose of the same LV vector140. This 
variability in gene expression could be a result of different ET tube insertion depths or 
techniques, different respiratory characteristics of each mouse, or unpredictable loss of 
vector dose due to capillary action along the ET tube. The en face images of animals in both 
treatment groups also revealed intense LacZ staining along an axial line in the trachea, likely 
as a result of the flow path of the vector dose or physical disturbance of respiratory epithelium 
caused by inserting and withdrawing the ET tube. Disturbance of the epithelium by a physical 
process (e.g. ET tube insertion/withdrawal) or chemical agent (e.g. LPC conditioning solutions) 
are both known to result in higher levels of gene expression due to increased access of the 
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vector to receptors on the basolateral surface51, 176. 
An effective CF gene therapy must target the epithelial cells of the conducting airways, and in 
particular the small distal airways. This is the location of the ciliated epithelial cells and basal 
stem cells177, 178,that express the highest levels of the CFTR protein in a healthy adult 179,and 
also the region where the disease first manifests in CF patients88. However, results reported 
in this study suggest that the bronchial airways of the mice could not be transduced by either 
delivery regimen: the en face images of animals in both treatment groups showed no LacZ 
gene transduction in either region, and histological analysis revealed very low levels of gene 
expression that prevented conclusive findings. It was found that the experiment was not 
sufficiently powered to identify significant differences in this region. A one-tailed t-test 
comparing the number of LacZ transduced in the bronchial airways of the aerosol and bolus 
delivery group (A-priori effect size = 1.02, α=0.05, power =0.80) showed that a minimum of n 
= 123 animals per group was required to show a significant difference between the aerosol 
and bolus treatment groups in the bronchial airways. The large sample size estimate resulted 
from the low levels of gene expression observed in the bronchial airways, combined with the 
high variability observed within each group. Performing a study with such a large sample size 
is clearly not practical. Hence the subsequent chapters focus on optimising the vector delivery 
methods using in vitro techniques. 
The low levels of gene expression observed in both aerosol and bolus treatment groups at the 
bronchial airways could be due to low residence time and/or low physical dose volume of the 
LPC conditioning agent or LV vector at these regions. Nonetheless, these results were similar 
to findings of Liu et al140, who showed that only two transduced cells/mm2 were present in 
conducting airways and lungs of mice treated with a bolus dose of 15 μl of 0.1% LPC and 30 
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μl of the same HIV-1 vector (9.36 × 107 TU/ml) used in the present study140. Although a lower 
volume of 0.1% LPC conditioning solution (10 μl) and LV vector (20 μl bolus dose, average titre 
6.38 x 108 TU/ml) was used in the present study, the similarity in the results to that of Liu et 
al. could be because the titre of the LV vector used in the present study was higher compared 
to Liu et al. and improvement in bolus delivery methods150. In contrast, Cmielewski et al. 
demonstrated higher levels of gene expression in the conducting airways of mice-treated with 
a bolus dose of the same HIV-1 vector150. They measured an average of 65.9 LacZ transduced 
cells per mm of conducting airway following a bolus dose of 15 μl of 0.1% LPC conditioning 
solution and 20 μl LV-LacZ vector (8.8 × 109 gRNA copies/ml)150. As mentioned in the 
Introduction (Section 3.1), this elevated level of gene expression could have resulted from 
improvements in the method of administering the bolus dose of LPC conditioning solution 
and LV vector150. Thus, the results presented in this Chapter suggest that delivering LV vector 
as an aerosol was not likely to produce uniform and wide-spread transduction from the 
trachea to the smaller airways of mice. Together these results highlight the difficulties of 
efficiently transducing conducting airway tissue, a challenge faced by the entire CF gene 
therapy community.  
Further observation of en face images of bolus-treated animals showed intense LacZ gene 
expression in the upper lobes of the left and right lungs. Cross sections of the left lung 
revealed patchy transduction in the parenchyma of bolus-treated animals. This patchy 
pattern of gene transduction was also observed in airways of sheep and marmosets treated 
with a bolus dose of the LV vector57, 140. This transduction pattern could be caused by any or 
all of the following: pooling of bolus vector dose in the lungs; incomplete coverage of the area 
due to small vector volume; specificity of the LV vector for a certain cell type; or mismatch 
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between the LPC and LV-treated areas57, 58. 
In the present study, histological analysis of the left lungs showed no significant differences 
in the number of transduced cells between the two treatment groups (Figure 3-5), which was 
likely due to high variability observed in the aerosol treatment group. This high variability was 
caused by one outlier animal with higher than expected gene expression levels (Figure 3-3). 
Interestingly, the elevated level of gene expression observed in the outlier animal was higher 
than that observed in the bolus treatment group, which could be caused by dosing error. 
Delivering a larger volume of LV vector or LPC conditioning solution to the airways, such as 
twice the required dose, could explain the unexpected levels of gene expression observed in 
this animal. Additionally, insufficient cleaning of the ventilator circuit component could have 
resulted in viable LV particles being retained in the components from the previous treatment 
and therefore a higher dose of vector was delivered to the lungs of the animal. Also, the 
elevated levels of gene expression could have been caused from an inherent and unexplained 
variation of the respiratory characteristic of that mouse. Although the level of gene 
expression observed in this outlier animal was greater than bolus dose, it demonstrates what 
might be achievable in future experiments provided optimal aerosol delivery parameters can 
be identified. 
Histological analysis of the right lung showed lower levels of gene expression in both 
treatment groups, which could be due to lung and airway morphology, and the dosing method. 
In mice the right lung is divided into four lobes while the left lung has a single lobe. Aerosol 
and fluid deposition studies have shown that the morphology of the lungs (including the width 
of the airways and branching angle) heavily influences dose deposition180. The bolus delivery 
study published by Liu et al. showed contrasting results to the present study, by 
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demonstrating efficient gene expression in lobes of both the right and left lungs of mice140. 
These contrasting results may be due to a subtle difference in the bolus delivery protocol used 
by Liu et al. compared to the present study. Liu et al. suspended the mouse by its dorsal 
incisors and the mouse’s dorsal side was supported against an inclined board during LPC and 
LV vector delivery140. In contrast, in the present study mice in both treatment groups were 
placed in a supine position during LPC and vector delivery. It is possible that this difference in 
animal position during delivery could have influenced the volume delivered to specific regions 
of the lung (particularly for the liquid group) and could be the reason for the absence of gene 
expression in the right lung. However, additional studies would be needed to confirm this 
hypothesis.  
In summary, significant difference in levels of LV gene expression between the aerosol group 
and bolus treatment group was only identified at the tracheal region of mice airway. Three 
mechanisms may be responsible for the lower transduction levels seen in the trachea of the 
aerosol-treated animals compared to the bolus treated animals. Firstly, this could be caused 
by a lower physical volume of the vector reaching the trachea and lungs of animals in the 
aerosol group. This lowered dose volume could be caused by unoptimised aerosol delivery 
parameters and the design of the Aeroneb®Pro-flexiVent™ ventilator circuit in the present 
study. Delivering the vector as a bolus dose is less complicated as the dose is delivered directly 
to the ET tube via a fine polyethylene pipette, maximising the volume of fluid reaching the 
airways. The volume of aerosolised formulation that reaches the tip of the ET tube and the 
effect of aerosol delivery parameters on delivery efficiency of the Aeroneb®Pro-flexiVent™ 
ventilator circuit are examined in Chapter 4.  
The second cause for lowered gene expression in the trachea of mice treated with LV aerosols 
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could be loss of vector viability due to partial damage of the LV vector during transit through 
the nebuliser and component of the ventilator circuit. Although, the Aeroneb®Pro nebuliser 
has been proven to efficiently aerosolise shear sensitive nanoparticle144 and liposomes161, it 
is still possible that LV vector viability was affected by the process of aerosolisation in the 
Aeroneb®Pro, the turbulent flow through the Scireq in-line Aeroneb®Pro nebuliser mount, 
and the transit through the inspiratory tubing and ET tube. Chapter 5 examines the viability 
of LV aerosol delivered through the Aeroneb®Pro nebuliser and that expelled at the end of 
the Aeroneb®Pro-flexiVent™ ventilator circuit. 
The third cause of the lowered levels of gene expression observed in the aerosol treatment 
group could be the mismatch between the areas treated with a bolus dose of LPC conditioning 
agent and the aerosolised LV vector. Delivering LPC as an aerosol might enable uniform 
distribution throughout the lung that might better overlap with regions later treated with 
aerosolised LV vector, resulting in uniform transduction. However, as explained earlier 
delivering a higher concentration of aerosolised LPC could result in pulmonary oedema 
(Section 3.2.3.1). In this study LPC was deliberately delivered as a liquid rather than as an 
aerosol so that only one single variable associated with gene delivery, i.e. the method of 
delivering the LV vector, was examined. The effect of delivering LPC conditioning as an aerosol 
in conjunction with aerosolised LV vector was not examined at this point, because a much 
larger series of animal experiments would have been needed to establish all of the factors 
that cause changes in gene expression. The present chapter identified that delivering the 
vector as an aerosol produced lower levels of gene expression in comparison to bolus delivery, 
so it is suggested that delivering LPC as an aerosol should only be examined after the protocol 
for LV aerosol delivery has been optimised. 
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Although the effects of aerosolising LPC conditioning by itself has not been examined LPC has 
been formulated with other viral vectors, such as Hd-Ad, and delivered as a coarse spray in 
other gene therapy studies. Koehler et al. showed that delivering a spray of a Hd-Ad vector 
formulated with 0.1% LPC to rabbit airways enabled effective gene transduction, which was 
likely by opening tight junctions in rabbit airways81. They also demonstrated that this dose 
was tolerated well in animals81. Further studies conducted by the same group demonstrated 
that spraying vector formulated with a much lower concentration of LPC (0.01 %) produced 
effective transduction in porcine airways and was well tolerated by animals in the study103. 
Although a coarse spray of 0.1% LPC formulated with Hd-Ad vector, has been shown to 
efficiently transduce animal airways its efficacy might vary when delivered as an aerosol using 
a nebuliser103. Delivering 10 μl of 0.1% LPC (same concentration and volume used in the 
present study) as an aerosol may result in uneven distribution of LPC at the epithelial surface 
as the volume of LPC used would be too low to cover the entire airway epithelial surface in 
mice; however, this remains to be investigated in a future study. Future studies would also 
need to identify the optimal dose volume and LPC concentration for use as an aerosol, bearing 
in mind that higher concentrations of LPC will likely damage the airway epithelium rather than 
transiently open tight junctions. They should also determine how uniformly the aerosol 
delivery method distributes LPC, and whether this enables effective disruption of the tight 
junctions on the epithelial surface.  
3.5 Conclusion  
Aerosol delivery of a gene therapy vector formulation is an attractive approach as it has the 
potential to be non-invasive and could produce a uniform distribution of vector in the 
conducting airways of animals. This was the first study to investigate the effectiveness of 
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aerosolising a HIV-1 based LV vector in the airways of mice, using an Aeroneb®Pro nebuliser 
and flexiVent™ small animal ventilator. LacZ gene expression levels produced in the trachea 
of mice were significantly lower in the aerosol treatment group compared to the bolus 
treatment group. However, no significant difference in the level of gene expression between 
the two treatment groups was observed in the left lungs of mice, which was likely due to an 
outlier in the aerosol treatment group. The effect of vector delivery regimens could not be 
determined from other regions of the mouse airway, such as the bronchial airways or right 
lung, as very low levels of gene expression were observed in both treatment groups. Together, 
these results only identified the lowered efficiency of LV aerosol delivery, using the 
Aeroneb®Pro-flexiVent™ ventilator circuit, in the trachea of mice. Additionally, the reasons 
for the lowered efficiency of this nebuliser-ventilator apparatus in delivering LV aerosols was 
inconclusive. Further investigation is needed to determine the effect of this nebuliser as a 
viable option in further aerosol delivery studies. A range of factors affecting aerosol delivery 
of the LV vector through the Aeroneb®Pro nebuliser operated in conjunction with flexiVent™ 
ventilator are examined further in Chapters 4 and 5.   
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4 OPTIMISING AEROSOL DELIVERY EFFICIENCY FOR 
MECHANICAL VENTILATION OF MICE: AN IN VITRO 
STUDY 
4.1 Introduction 
Chapter 3 demonstrated lowered gene expression in the trachea of mice treated with an 
aerosol dose of the LV vector compared to those receiving a bolus dose (Section 3.3). In the 
aerosol delivery group, the LV vector was aerosolised through an Aeroneb®Pro-flexiVent™ 
ventilator. It was proposed that the lower levels of gene expression observed in this group 
could be caused by a reduced physical dose volume being delivered to mouse trachea, and/or 
a reduction in LV viability during the process of aerosolisation. This Chapter investigates the 
former reason for lowered gene expression. This study quantified the dose volume released 
at the end of the Aeroneb®Pro-flexiVent™ ventilator circuit when applying the same 
ventilation parameters that were used to deliver the LV vector to the mouse lungs (Section 
3.2.3).  
The Aeroneb®Pro nebuliser is increasingly used to aerosolise drug formulations into the lungs 
of mechanically ventilated animals146, 181, 182, but there have been consistent difficulties 
reported in delivering a volume similar to the initial dose through a ventilator circuit. Ferrari 
et al. aerosolised ceftazidime into the airways of mechanically ventilated piglets and observed 
deposition that represented 66% of the initial dose volume183. Dubus et al. demonstrated 
deposition of only 13-14% of the initial dose volume on aerosolising 99mTc-diethylene 
triamine pentacetic acid (DTPA) into the lungs of mechanically ventilated macaques184. The 
dose delivered to lungs of mechanically ventilated mice has been reported to be lower than 
that delivered to the lungs of larger animal models. Robichaud et al. aerosolised methacholine 
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to the lungs of mechanically ventilated mice using an Aeroneb®Pro nebuliser with the 
flexiVent™ ventilator and showed an extremely poor deposition efficiency of 0.1 to 0.2 % of 
the initial dose at the target site. They reported that a majority of the aerosolised dose was 
deposited in the ventilator tubing due to impactional deposition, commonly referred to as 
rainout146, providing a likely explanation for the low performance of their system. Based on 
that study, it could be hypothesised that the volume of aerosol produced at the end of the 
Aeroneb®Pro-flexiVent™ circuit is likely to be significantly lower than a bolus delivery volume. 
Hence, there is a need to optimise the aerosol delivery efficiency of this system.  
The dose volume expelled at the outlet of the ventilator circuit is dependent on nebuliser-
related factors, ventilator circuit-related factors, the chosen ventilation parameters, 
properties of the formulation, and patient (or animal)-related factors185. Amongst these, 
ventilator circuit-related factors and ventilation parameters significantly affect the delivery 
efficiency of a rodent ventilator system74. Ventilator circuit-related factors that affect delivery 
efficiency are the length and internal diameter of ventilator circuit components74, 186, the 
number and type of connectors186, the presence of tight-radius bends within circuit 
components187, and the use of corrugated tubing188.  
As mentioned earlier, deposition of aerosolised formulation within the narrow ventilator 
tubing was suspected to be the main reason for reduced delivery efficiency in a rodent 
ventilator system74, 146. The width of the ventilator tubing was also shown to influence 
deposition of the aerosolised dose in clinical studies. Pedersen et al. showed that 
approximately 4.5% of aerosolised dose was deposited within an 8 mm ET tube, which is the 
narrowest component of an adult ventilator circuit187. However, the dose deposited within a 
6 mm ET was 8.4%, under the same delivery conditions187. The researchers speculated that 
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the narrow internal diameter of the 6 mm ET tube could have constricted the aerosol flow 
path (therefore increasing the gas velocity) and given rise to turbulent airflow within the 
component187. This could have caused impaction and deposition of aerosols against the inner 
walls of the component, thus explaining increased dose deposition187. Hence, it could be 
hypothesised that using a ventilator circuit component with a larger internal diameter should 
reduce impactional deposition of aerosols within the component and improve aerosol output. 
Ventilation parameters determine the velocity of aerosol flow within the ventilator circuit, 
and hence influence dose delivered to the lungs187. Ventilation parameters, such as RR, VT, 
DC, PEEP, and I: E ratio, determine the characteristics of aerosol flow within the ventilator 
circuit, which in turn affects delivery efficiency189-191. Thomas et al. showed that using a low 
RR and high VT, while maintaining a constant respiratory minute volume [MV (ml/min) = VT 
(ml) × RR (breaths/min)], delivered optimal volume of aerosolised formulation at the tip of 
the ET tube192. Other studies have also confirmed that using a lower RR192-194, and higher VT190, 
195 released optimal volume of aerosolised formulation at the tip of the ET tube of an adult 
ventilator circuit. The researchers speculated that these ventilator settings reduced the 
velocity of the aerosol and airflow turbulence within the ventilator circuit, which in turn 
reduced deposition of aerosolised formulation in circuit components, and increased delivery 
efficiency192. Hence, it could be hypothesised that using a lower RR and higher VT will improve 
delivery efficiency of a small-animal ventilator circuit, where the largest component is 8 mm 
in diameter.  
Other ventilation parameters, such as the nebuliser DC could also influence dose delivered by 
the end of the ventilator circuit. Fink et al. reported a significant increase in aerosolised dose 
delivered to the lungs of mechanically ventilated patients when operating a pMDI at a higher 
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DC of 0.5 in comparison to a lower DC of 0.25196. However, change in DC has not shown to 
affect aerosol delivery efficiency in an in vitro model of a paediatric ventilator circuit197. 
Contrasting results were obtained on testing the effects of DC on delivery efficiency of a small 
animal ventilator. Robichaud et al. showed that a higher volume of aerosolised methacholine 
was expelled by the end of the Aeroneb®Pro-flexiVent™ ventilator on operating the nebuliser 
at a DC of 0.25 compared to a higher DC of 0.5146. Thus, it could be hypothesised that using a 
lower DC produces an increased volume of aerosol at the tip of the Aeroneb®Pro-flexiVent™ 
circuit.  
Researchers have also examined other methods to improve delivery efficiency of nebuliser-
ventilator systems. Recent developments include nebulisers that have adaptive aerosol 
delivery technology, which adapts the nebuliser output to the respiratory pattern of the 
patient and delivers aerosols in short-pulses during inspiration198. This pulsed aerosol delivery 
has been shown to reduce the velocity of aerosols within the nebuliser system, thus leading 
to a decreased deposition of aerosols in oropharyngeal regions, and increased lung 
deposition198, 199. The effect of delivering aerosols in short-pulses during mechanical 
ventilation must still be investigated. It could be speculated that delivering aerosols in short-
pulses would reduce aerosol velocity during its transit through narrow tubing of a small 
animal ventilator, and thus release a higher volume of aerosols at the tip of the nebuliser-
ventilator apparatus. 
MacLoughlin et al. demonstrated another method to improve delivery efficiency of a rat 
ventilator operated in conjunction with the Aeroneb®Pro nebuliser. They demonstrated an 
improvement in aerosol delivery efficiency from ~13% to ~41% of inhaled mass by re-
aerosolising the dose deposited in the component adjacent to the Aeroneb®Pro nebuliser; 
106 
 
however, the quality of the re-aerosolised dose material was not known74. Similar 
improvement in aerosol output could be expected on re-aerosolising the dose deposited in 
the circuit component adjacent to the nebuliser within the ventilator circuit. 
4.1.1 Hypothesis and aims 
The following hypotheses were developed based on the results from the previous Chapter 
and the previously published studies outlined above. I hypothesise that the volume of aerosol 
produced at the tip of the Aeroneb®Pro-flexiVent™ ventilator circuit ET tube will be: 
1) Lower than a bolus dose, when using the parameters from the baseline in vivo study 
(Section 3.2.3). 
2) Increased by using ventilator circuit containing components with a larger internal 
diameter, due to minimisation of deposition within the circuit.  
3) Higher when using a low RR and high VT. 
4) Improved by reducing the amount of aerosol produced during each breath.  
5) Enhanced by re-aerosolising the dose deposited in the Scireq in-line Aeroneb®Pro 
mount, the circuit component adjacent to the nebuliser. 
The aim of this in vitro study was to quantify dose volume released from the ET tube at the 
end of the Aeroneb®Pro-flexiVent™ ventilator circuit when using the same ventilation 
parameters used in the previous Chapter (Section 3.2.3), by using a dye solution as the 
surrogate dose fluid. The studies were designed to estimate the amount of fluid that is 
deposited in each part of the ventilator circuit, and to quantify the effect of making changes, 
such as replacing the Scireq in-line Aeroneb®Pro mount (the component used to connect to 
the Aeroneb®Pro nebuliser into the flexiVent™ inspiratory tubing) with one having a larger 
internal diameter (Figure 4-2), and by altering the ventilation parameters. It was also designed 
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to assess the effects of delivering aerosol in short time-controlled pulses during each breath, 
and re-aerosolising the fluid deposited in the Scireq in-line Aeroneb®Pro mount. 
4.2  Methods 
4.2.1 Aerosol delivery efficiency of the Aeroneb®Pro nebuliser  
In this in vitro experiment, the Aeroneb®Pro nebuliser (not connected to the ventilator circuit) 
was mounted to a single well of a 12-well plate containing 500 µl of water. A 20 µl aliquot of 
dye solution (diluted 50% v/v with water) was aerosolised using the same ventilation 
parameters as the in vivo study (i.e. DC 1), and aerosolised dye solution was captured in the 
water below (Section 2.2.6). 
A standard curve was prepared by plotting known concentration of dye solution against its 
absorbance, measured using a plate reader (Section 2.2.6). For this experiment, 20 µl of dye 
solution pipetted into 500 µl of water was considered as 100% of starting volume (i.e. initial 
dose of dye solution). Other concentrations prepared for the standard curve were 2.5%, 5%, 
25%, 50%, and 75% of starting volume, prepared by pipetting 0.5, 1, 5, 10, and 15 µl of dye 
solution into 500 µl of water, respectively. The volume of aerosolised dye solution released 
at the outlet of the Aeroneb®Pro nebuliser (expressed as % starting volume) was quantified 
by interpolating the standard curve.  
4.2.2 Aerosol delivery efficiency of the Aeroneb®Pro-flexiVent™ ventilator circuit 
The Aeroneb®Pro-flexiVent™ ventilator circuit uses a motor-operated piston to move air 
through the inlet valve into the inspiratory limb (Figure 4-1 A). Air then flows through the 
Scireq in-line Aeroneb®Pro mount on which the nebuliser is placed. Aerosols released by the 
nebuliser are carried into the ventilator tubing, connector tube, Y-piece, and ET tube. In this 
experiment the aerosol released from the tip of the ET tube was collected under 500 µl of 
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water in a modified Eppendorf tube (Figure 4-1 B). Aerosol not captured was then released 
into the expiratory limb which connects to the air outlet valve and a PEEP trap (Figure 4-1 B). 
When delivering aerosols to airways of mice, the PEEP trap ensures that a positive pressure 
is maintained in the airways of the animal (Section 3.2.3). 
A 20 μl aliquot of dye solution was aerosolised through the circuit (Figure 4-1 A-C) using the 
same ventilation parameters as per the previous in vivo study (Section 3.2.3). The DC, PEEP, 
and I: E ratio were kept constant for all experiments described in this Chapter, unless noted. 
Aerosolised dye solution released was collected and assayed later (Section 2.2.6). The circuit 
was disassembled to gather the fluid from each of the components, and each component was 
then washed with water, which was collected to be assayed later (Section 2.2.6). The standard 
curve was used to determine the volume of aerosols released at the tip of the ET tube for all 




Figure 4-1: Aeroneb®Pro-flexiVent™ ventilator circuit showing the (A) ventilator motor, piston inspiratory limb, 
expiratory limb, and the PEEP trap (scale bar = 5 cm), (B) Aeroneb®Pro nebuliser connected in-line to the ventilator 
circuit and ventilator circuit tubing which consists of the connector tube, Y-piece, and the ET tube half-immersed 
in 500 µl of water contained in an Eppendorf tube with a loosely-screwed cap (Scale bar 2.5 = cm), and (C) 
diagrammatic representation of the ventilator circuit.  
4.2.3 The influence of the internal diameter of the Aeroneb®Pro mount on delivery efficiency 
This experiment compared two Scireq in-line Aeroneb®Pro mounts with different internal 
diameters. The first group used a standard in-line nebuliser mount with an internal diameter 
of 8 mm (Figure 4-2 A and C, used in Section 3.2.3) as a part of the ventilator circuit. The 
second group used an in-line nebuliser mount with a larger internal diameter of 12 mm 
(Figure 4-2 B and D) with an additional connector that has smoother inner walls that should 
reduce impactional deposition of aerosols. The distance from the centre of in-line nebuliser 
mount to the adjoining connector tube was 30 mm in the first group (Figure 4-2 C) and 50 mm 
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in the second group (Figure 4-2 D). Dye solution was aerosolised through the ventilator circuit 
with the same ventilation parameters used in the earlier in vivo study (Section 3.2.3). The 
volume of dye solution deposited within the in-line nebuliser mount and aerosol output 
released at the tip of the ET tube were quantified as described earlier (Section 4.2.1). The in-
line nebuliser mount that delivered the highest aerosol output was used for the RR 
experiment described below. 
 
Figure 4-2: Top-view of the (A) standard Scireq in-line Aeroneb®Pro mount with an internal diameter of 8 mm 
(blue arrow) and (B) another Scireq in-line Aeroneb®Pro mount with the larger diameter of 12 mm (blue arrow). 
Side view of the (C) standard in-line nebuliser mount, distance from the centre to the tip was 30 mm (yellow 
arrow) and (D) the in-line nebuliser mount with a larger internal diameter. The distance from the centre to the 
tip was 50 mm (yellow arrow). 
4.2.4 Effect of altering ventilation parameters  
4.2.4.1 Respiratory rate 
This experiment tested four respiratory rates (RRs); the first group (standard group) used an 
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RR of 120 breaths/minute, as used in the previous in vivo study (Section 3.2.3). This was 
compared to three other groups with RRs of 60 breaths/minute, 90 breaths/minute, and 150 
breaths/minute. The VT was adjusted so that each group had the same MV of 1.2 ml/min/g, 
which was the typical MV of C57BL/6 mice200. Hence, the VT used for the standard group was 
10 ml/kg and other groups were 20 ml/kg, 13.2 ml/kg, and 8 ml/kg respectively. All other 
parameters remained the same as the baseline experiment (Section 3.2.3). The RR of the 
group that produced the highest volume of aerosolised dye solution at the tip of the ET tube 
along with other ventilation parameters used in the baseline in vivo study (Section 3.2.3) was 
used for the next experiment.  
4.2.4.2 Tidal volume 
The three VT tested in this experiment were 10 ml/kg, 13.2 ml/kg (standard group), and 15 
ml/kg. The RR (identified from Section 4.2.4.1) was maintained constant for all groups. The 
dye solution was delivered through the nebuliser-ventilator circuit using appropriate 
ventilation parameters. The VT that produced the highest volume of aerosolised dye solution 
by the end of the ventilator circuit, optimal RR identified from earlier experiment (4.2.4.1), 
and other ventilation parameters from baseline in vivo (study 3.2.3) was used for the 
subsequent experiment.  
4.2.5 Effect of reducing amount of aerosols provided per breath 
The amount of aerosols produced per breath could be reduced by either reducing the DC 
supplied to the nebuliser or delivering the aerosols in short pulses, which were examined in 
two separate experiments given below.  
The duty cycle (DC) of the nebuliser is percentage of time during which the device was active 
during each respiratory cycle and is altered by changing the on/off periods of the square wave 
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electrical signal (at a frequency of 25 Hz) applied to the Aeroneb®Pro controller. A DC of 1 (i.e. 
100%) means the nebuliser is always on during inspiration, whereas a DC of 0.5 results in the 
unit producing aerosol for half of the inspiration146. The four DC values tested in this 
experiment were 0.25, 0.50, 0.75, and 1 (standard group, used in earlier in vivo study, Section 
3.2.3). The dye solution was aerosolised through the ventilator circuit with the appropriate 
DC. The optimal ventilation parameters RR and VT identified from previous experiments 
(Section 4.2.4.1 and 4.2.4.2, respectively) were used in this experiment. The DC that produced 
the highest volume of aerosolised formulation at the tip of the ET tube was then used in the 
subsequent experiment.  
An alternative strategy for reducing the amount of aerosol produced in each breath is using a 
single short pulse of aerosol at DC 1. Also, reducing the DC below 0.25 (the lowest DC used in 
the above study) is not necessarily effective due to the start-up time required to produce 
aerosol. This in vitro experiment had four groups, the standard group consisted of the 
nebuliser being operated at an optimal DC determined by the previous experiment, as well as 
groups aerosolising dye solution in pulses of 10 ms, 15 ms, and 30 ms duration per breath. 
Previously identified ventilation parameters RR (Section 4.2.4.1) and VT (Section 4.2.4.2) were 
used to aerosolise dye solution through the ventilator circuit. The pulse parameter that 
produced the highest aerosol dose at the tip of the ET tube was chosen for the next 
experiment.  
4.2.6 Effect of re-aerosolising dose deposited in the ventilator circuit  
Two groups were used in this experiment. In Group 1, dye solution was aerosolised with 
ventilation parameters previously identified to release optimal volume of aerosols at the tip 
of the ET tube (Sections 4.2.4.1, 4.2.4.2, and 4.2.5). In Group 2, dye solution was aerosolised 
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through the ventilator circuit with the same ventilation parameters as Group 1, but the fluid 
deposited in the Scireq in-line Aeroneb®Pro mount was collected using a pipette, returned to 
the Aeroneb®Pro, and then re-aerosolised. The volume of the aerosolised dye collected at the 
tip of the ET tube was then compared to Group 1.  
4.3 Results 
4.3.1 Aerosol delivery efficiency of the Aeroneb®Pro nebuliser  
This in vitro experiment measured the volume of aerosol released following delivery through 
an Aeroneb®Pro nebuliser, without being connected to the ventilator circuit. The volume of 
aerosols collected after delivery through the Aeroneb®Pro nebuliser was significantly lower 
than bolus delivery by 13.4% (Figure 4-3).  
 
Figure 4-3: Volume of dye delivered as a bolus dose delivery vs an aerosol dose through the Aeroneb®Pro 
nebuliser. 
4.3.2 Aerosol delivery volume efficiency of the Aeroneb®Pro-flexiVent™ ventilator circuit 
This experiment quantified the volume of aerosolised fluid deposited in ventilator circuit 
components and aerosols released at the tip of the ET tube. The majority of aerosolised dye 
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solution released from the outlet of the nebuliser deposited at the Scireq in-line Aeroneb®Pro 
mount (83.7% of initial dose volume) (Figure 4-4). Smaller volumes of dye solution were 
deposited in other components of the ventilator circuit, such as the inner walls of the 
Aeroneb®Pro nebuliser (10.1% of initial dose volume), connector tube (2.7% initial dose 
volume), Y-piece (2.1% initial dose volume), and expiratory limb (0.6% initial dose volume) 
(Figure 4-4). The volume released at the tip of the ET tube was found to be only 2.1% of the 
initial dose (Figure 4-4). 
 
Figure 4-4: Volume of aerosolised dose deposited in different ventilator circuit components and that expelled at 
the tip of the ET tube.  
4.3.3 The influence of the internal diameter of the Aeroneb®Pro mount on delivery efficiency 
The effect of replacing the in-line Aeroneb®Pro mount of 8 mm internal diameter with a larger 
internal diameter of 12 mm, was examined in this experiment. There was no significant 
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difference in volume of dye solution deposited within the in-line nebuliser mount between 
the two groups (Figure 4-5 A). However, aerosol output obtained at the tip of the ET tube 
when using the in-line nebuliser mount with 8 mm internal diameter was 1.7-fold higher than 
that with 12 mm internal diameter (Figure 4-5 B). As a result, the in-line nebuliser mount with 
an internal diameter of 8 mm was used for further studies.  
 
Figure 4-5: Comparison of in-line Aeroneb®Pro mount with 8 mm internal diameter vs. 12 mm internal diameter 
on the (A) dose deposited at the in-line nebuliser mount and (B) volume of aerosols expelled at the tip of the ET 
tube.  
4.3.4 Effect of altering ventilation parameters  
4.3.4.1 Respiratory rate 
The impact of changing the RR, while maintaining a constant MV, on aerosol delivery 
efficiency during mechanical ventilation was investigated. The volume of aerosolised dye 
solution released at the tip of the ET tube with RR 60 breaths/minute was 1.6-fold higher than 
RR 120 breaths/minute, the standard group (Figure 4-6). However, no significant difference 
was observed in the aerosol output between the RR 120 (standard group) and RR 90 breaths/ 
minute, and RR 150 breaths/minute (Figure 4-6). 
Although the optimal aerosol output was obtained using the lowest RR of 60 breaths/ minute, 
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this RR may not be suitable for in vivo studies. Wolthuis et al. demonstrated ventilator 
induced lung injury in mice using RR as low as 70 breaths/minute201. Hence, the second lowest 
RR 90 breaths/minute was used for further experiments. 
 
Figure 4-6: The impact of changing RR in breaths/minute, while maintaining constant MV, on the volume of 
aerosols released at the tip of the ET tube. 
4.3.4.2 Tidal volume 
This experiment investigated the effect of changing VT, while maintaining constant RR, on the 
aerosol delivery efficiency of the Aeroneb®Pro-flexiVent™ ventilator. Results showed no 
significant change in dose volume expelled at the tip of the ET tube on changing VT, while 




Figure 4-7: Effect of VT, while maintaining constant RR in ml/kg, on the volume of aerosols released at the tip of 
the ET tube. 
4.3.5 Effect of reducing the amount of aerosols released per breath  
Reducing the volume of aerosols produced per breath by supplying a lower DC to the 
nebuliser resulted in higher aerosol output at the end of the circuit (Figure 4-8). Aerosol 
output produced was two-fold higher when the nebuliser was supplied with DC 0.25 
compared to DC 1 (standard group) (Figure 4-8 ). However, no significant difference in aerosol 
output was observed using higher DC settings of 0.5 and 0.75. Hence, DC 0.25 was chosen for 




Figure 4-8: The impact of DC on the volume of aerosols released at the tip of the ET tube. 
Reducing the amount of aerosols released per breath by delivering aerosols in short pulses 
also demonstrated an increased aerosol output. The volume of aerosolised dye solution 
released at the tip of the ET tube was 2.8, 1.9, and 1.9 folds higher on delivering aerosols in 
short-pulses of 10 ms, 15 ms, and 30 ms, respectively, compared to DC 0.25 (standard group) 
(Figure 4-9 ). As the highest aerosol output was obtained on delivering aerosols in pulses of 
10 ms, this delivery parameter was used in the next experiments. 
 
Figure 4-9: The influence of pulsed aerosol delivery on the volume of aerosols expelled at the tip of the ET tube. 
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4.3.6 Effect of re-aerosolising dose deposited within the Scireq in-line Aeroneb®Pro mount 
Re-aerosolising the dose deposited within the Scireq in-line Aeroneb®Pro mount released 
approximately 21.6% of initial dose volume at the tip of the ET tube, which was 1.3-fold higher 
compared to delivering aerosols in pulses of 10 ms (Figure 4-10).  
 
Figure 4-10: Effect of re-aerosolising dose deposited at the Scireq in-line Aeroneb®Pro mount on the physical dose 
volume of aerosols expelled at the tip of the ET tube.  
4.4  Discussion 
The experiments in the present Chapter quantified the physical dose volume released at the 
tip of the ET tube, located at the end of the Aeroneb®Pro-flexiVent™ ventilator circuit, when 
aerosolising dye solution using the same ventilation parameters as the previous Chapter 
(Section 3.2.3). Unsurprisingly, the results showed that only 2.1% of initial dose volume was 
expelled at the tip of the ET tube, validating the first hypothesis. Additionally, a majority of 
the aerosolised dye solution was deposited in the Scireq in-line Aeroneb®Pro mount (83.7% 
of initial dose volume). The design of the Scireq Aeroneb®Pro mount was such that air from 
the ventilator enters the inlet pipe and travels upwards to the base of the nebuliser (Figure 
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4-11). The gas entering this chamber mixes with the aerosol, which then flows down the 
outlet pipe where it changes direction by 90° to pass into the adjoining connector tube. The 
change in the direction of aerosol and gas flow, the high velocity of the aerosol, and the 
narrow width of the of outlet pipe likely results in impaction and deposition of aerosolised 
fluid at the bottom of the outlet pipe. A review of literature reported similar deposition of 
aerosolised formulation in the component placed adjacent to the nebuliser. Dubus et al. 
aerosolised 99mTc-DTPA to the lungs of mechanically ventilated macaques and observed 
similar deposition of the aerosolised dose in the T-piece piece, a nebuliser mount with a larger 
internal diameter compared to the one used in the present study184. MacLoughlin et al. also 
demonstrated deposition of aerosolised formulation in the T-piece of the ventilator circuit 
used for rats74. They suspected this dose deposition was caused by the narrow internal 





Figure 4-11: A diagrammatic representation of the Scireq in-line Aeroneb®Pro mount showing the direction of 
aerosol flow. 
The next experiment examined the second hypothesis, that using a circuit component with a 
larger internal diameter would minimise deposition within the component and increase 
aerosol output. However, the results did not support the second hypothesis as similar levels 
of aerosolised fluid were deposited within the standard 8 mm internal diameter in-line 
Aeroneb®Pro mount and that with a larger internal diameter of 12 mm. Deposition in both 
in-line nebuliser mounts was possibly caused by the 90° bend in the component187. Hence, it 
is possible that a change in internal diameter would not be effective unless the component is 
re-designed to have a lower angle for smoother transition of airflow. Results also show that 
aerosol released at the tip of the ET tube, using the in-line nebuliser mount with a larger 
internal diameter, was lower than the standard nebuliser mount. This was probably because 
the additional connector attached to the in-line nebuliser mount with a larger internal 
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diameter was 20 mm longer than of the standard (Figure 4-2), which led to the nebuliser being 
placed further away from the Y-piece and the tip of the ET tube (aerosol collection point). An 
in vitro study by Ari et al. also showed that position of the nebuliser in the ventilator circuit 
had a significant impact on aerosol delivery efficiency. They demonstrated higher delivery 
efficiency when placing the Aeroneb®Pro nebuliser closer to the Y-piece in the inspiratory 
limb in comparison to placing it closer to the ventilator or between the ET tube and Y-piece202.  
The effect of changing ventilation parameters (RR and VT) was examined next, as these 
parameters have been demonstrated to impact aerosol delivery efficiency74. The third 
hypothesis stated that a higher RR and VT would produce optimal volumes of aerosols at the 
end of the ventilator circuit. The results partly support the third hypothesis and show that a 
lower RR of 60 breaths/minute, while maintaining a constant MV, delivered a higher volume 
of aerosolised dye solution at the tip of the ET tube. A lower RR would have reduced the 
aerosol velocity within the narrow circuit components thus reducing impaction and 
deposition of aerosols in circuit components. These results are consistent with previously 
published studies analysing a human ventilator circuit192, 193. The experiments where VT was 
changed, while maintaining constant RR, show similar volumes of aerosolised dye solution 
released at the tip of the ET tube (Section 4.3.4.1). This result was in partial agreement with 
an in vitro study by Berlinsky et al. who showed that the aerosol delivery efficiency of a 
paediatric ventilator circuit was not affected by changing VT, when the vibrating mesh 
nebuliser was placed closer to the ventilator203. However, when the vibrating mesh nebuliser 
was located closer to the Y-piece aerosol delivery efficiency increased with a decrease in VT 
203.  
The next experiment examined the fourth hypothesis, which stated that reducing the volume 
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of aerosols delivered per breath, by supplying a lower DC to the nebuliser and delivering 
aerosols in short pulses, would improve aerosols released at the end of the ventilator circuit. 
The results supported this hypothesis as a low DC of 0.25 produced higher volumes of 
aerosolised dye solution at the tip of the ET tube compared to DC 1. The results obtained in 
this experiment were in agreement with Robichaud et al. who also showed a DC of 0.25 was 
optimal for aerosol delivery to the airways of ventilated mice146. An explanation for the effect 
found in the present Chapter is that the lower DC of 0.25 produced lower volumes of aerosol 
during each respiratory cycle, thus resulting in lower deposition in circuit components and a 
higher delivered dose volume. The following experiment also supported this hypothesis as 
delivering aerosols in 10 ms pulses significantly increased aerosol output compared to 
operating the nebuliser at DC 0.25. Pulsed 10 ms aerosols could have lowered volumes of 
aerosols produced during the respiratory cycle and reduced the aerosol flow rate at the initial 
part of the ventilator circuit i.e. within the nebuliser mount. This could have subsequently 
reduced deposition of aerosolised fluid in nebuliser mount and other circuit components 
leading to increased aerosol output.  
The last experiment examined the fifth hypothesis that stated re-aerosolising the dose 
deposited in the in-line nebuliser mount would improve aerosol output. Results support this 
hypothesis and show an increase in aerosol output from 16.8% to 21.7% of initial dose volume. 
This result was similar to the findings of MacLoughlin et al. who demonstrated an 
improvement in aerosol delivery efficiency from ~13% to ~41% of inhaled mass after re-
aerosolising the dose deposited in the T-piece, using an Aeroneb®Pro- ventilator circuit for 
use in rats74.  
Other factors that influence aerosol delivery efficiency during mechanical ventilation are 
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aerosol size and I:E ratio74, 187. Aerosol delivery efficiency is dependent on aerosol size as it 
dictates the impaction and deposition of aerosols through a ventilator circuit74. MacLoughlin 
et al. reported that using an Aeroneb®Pro nebuliser that produced the lowest aerosol size of 
3.38 µm (as per manufacturer’s specifications) was more efficient than nebulisers producing 
large aerosol sizes (5.21 µm and 4.29 µm), in a small-bore ventilator circuit used for rats74. In 
another study, Raabe et al. reported that aerosols smaller than 3 µm deposited in the 
bronchial airways and lungs of mice, while those larger than 3 µm deposited in the naso-
pharynx region204. As the size of the aerosols generated using the Aeroneb®Pro nebuliser 
(3.61 µm as per manufacturer’s specifications) was close to the optimal size for delivery 
through a small-bore ventilator circuit and deposition in mice airways, this parameter was not 
investigated in this Chapter. The I:E ratio also has a significant impact on aerosol delivery 
efficiency during mechanical ventilation. MacLoughlin et al. compared the effect of different 
I: E ratios (1:1, 1:2, and 2:1) and reported that an I:E ratio of 2:1 and RR of 45 breaths/minute 
was optimal for aerosol delivery through a rodent ventilator74. As the optimal I:E ratio for 
aerosol delivery efficiency for a small animal ventilator circuit was demonstrated by 
MacLoughlin et al.74 this parameter was not investigated in this Chapter.  
Extensive research has been carried out to improve delivery efficiency of adult and paediatric 
ventilator circuits. Longest et al.205 showed that using streamlined ventilator circuit 
components improved the dose produced distal to the ET tube by 1.5-fold in an adult model 
of a ventilator circuit205. Using streamlined components minimises the changes in the 
direction of the airflow, and use of a constant diameter path minimises disruptions in airflow 
due to sudden expansion and contraction of the flow path205. Together, this likely maintains 
aerosol velocity and reduces impact deposition. With modern 3D printing techniques 
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becoming mainstream, it should be possible to design and produce a Scireq in-line 
Aeroneb®Pro nebuliser mount based on these principles of smooth airflow. In another study, 
Holbrook et al. demonstrated a 26-fold improvement in delivery efficiency through a 
paediatric ventilator circuit with streamlined components on aerosolising electrostatically 
charged aerosols206. Hence, future studies could investigate the effect of delivering 
electrostatically charged aerosols through streamlined circuit components, once they 
become available (or can be custom manufactured) for a small animal ventilator.  
4.5 Conclusion  
This in vitro study showed that the volume of aerosolised dye solution expelled from the tip 
of the ET tube with the same ventilation parameters used in the earlier in vivo study (Section 
3.2.3) was only 2.1% of the initial dose volume. Additionally, most of the aerosolised dose was 
deposited within the Scireq in-line Aeroneb®Pro mount that lies immediately downstream 
and adjacent to the nebuliser in the ventilator circuit. Optimising the ventilation parameters, 
such as VT, RR, and DC, increased the volume of aerosolised dye solution released at the tip 
of the ET tube. However, the greatest improvements in aerosol delivery efficiency were 
observed when delivering the dye solution in pulses of 10 ms, and by re-aerosolising any fluid 
that deposits within the in-line nebuliser mount. These optimised delivery parameters and 
pulsed aerosol delivery could be applied in future experiments with larger animals and clinical 
studies. However, re-aerosolising drug formulation seems less practical for use in larger 
animal models, as this would require disassembling and re-assembling the ventilator circuit, 
which may not be feasible. 
This study optimised a range of parameters to improve aerosol delivery efficiency of the 
Aeroneb®Pro-flexiVent™ ventilator circuit. These improvements should be helpful for studies 
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using the same nebuliser-ventilator apparatus to deliver aerosols to the lungs of mice. 
However, delivery might also be affected by the physio-chemical characteristics of the 
aerosolised formulation, and further studies with the particular agent of interest will be 
needed.  
The experiments reported in this Chapter provide significant insight on the methods of 
improving aerosol delivery efficiency of an Aeroneb®Pro-flexiVent™ ventilator circuit used for 
small animal models, such as mice. The next Chapter investigates how these optimised 
delivery parameters can influence aerosolisation of LV gene vector through the Aeroneb®Pro-




5 OPTIMISING AEROSOL DELIVERY OF A LENTIVIRAL 
VECTOR FOR MECHANICAL VENTILATION OF 
MICE: AN IN VITRO STUDY 
5.1 Introduction 
Aerosol delivery of LV-LacZ vector produced lower levels of gene expression in the trachea of 
mice compared to bolus delivery (Chapter 3, Section 3.3). Further examination revealed that 
only 2.1% of the physical dose volume reached the tip of the ET tube located at the end of 
Aeroneb®Pro-flexiVent™ ventilator circuit. Additionally, a majority of the aerosolised dose 
volume (i.e. approximately 97% of the initial dose) was found to deposit within the ventilator 
circuit components (Chapter 4, Section 4.3.2). The combination of delivering aerosols in 
pulses of 10 ms, using optimised ventilation parameters, and re-aerosolising the dose 
deposited within the Aeroneb®Pro nebuliser mount (Chapter 4, Section 4.3.5 and 4.3.6), 
resulted in an increase in the delivered dose volume from the initial 2.1% to 21.6%. The 
present Chapter quantifies the biological factors that influence the gene expression of the LV 
vector fraction that reaches the tip of the ET tube (i.e. would be available for lung delivery).  
The effectiveness of any aerosol gene therapy depends on the viability of the vector reaching 
the respiratory epithelium. While some viral vectors like AAV are stable110, others such as the 
Ad54 and SeV vectors58 demonstrate reduced viability on aerosol delivery. Viral viability is 
influenced by the vectors’ ability to withstand changes that occur during aerosol delivery 64, 
207, such as changes in temperature, pH, concentration, viscosity, and shear stress58, 208, 209. 
For example, AAV vectors are stable at a wide range of temperatures, ranging from 4°C to 
55°C, and at a pH of 5.5 to 8.5210. However, other viral vectors, such as Ad and LV vectors, are 
only stable at temperatures lower than 4°C65 and a narrow pH range 64, 65, which may explain 
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their reduced viability following aerosol delivery.  
Due to these factors, the type of nebuliser used will influence the viability of the aerosolised 
vector. Griesenbach et al. showed that aerosolising SeV vector through a Pari LC® jet nebuliser 
reduced viability of the vector to 1% of the initial dose58. However, delivering the vector using 
an AeroProbe™ catheter resulted in vector viability being reduced to 49% of initial dose58. 
Reduced vector viability in both groups was thought to be due to susceptibility of the vector 
to shear stress produced by the nebulisers during aerosol delivery58. Although there are few 
reports of successful aerosol delivery of LV vectors, this vector type is known to be fragile, as 
observed during vector production141, 142, 211. One approach to combatting this problem has 
been pseudotyping the LV vector with a VSV-G envelope to improve its stability212.  
The physical and chemical stability of viral vectors has a significant impact on their 
transduction efficiency65. Bolus delivery studies have shown that suspending a viral vector in 
a protective diluent can improve the physical stability of the vector65, 213. SIV- and FIV-based 
LV vectors have been suspended in diluents containing α-lactose buffer87, 214 to improve 
stability215. However, recent studies have shown that the presence of protein or serum during 
vector preparation increases immunogenicity of the LV vector, which further reduces its 
transduction efficiency64, 216. This led to development of serum-free and protein-free cell 
culture growth media for LV vector production. One such commercially available medium is 
the FreeStyle™ 293 expression medium (FreeStyle™ medium)217. It is a chemically-defined 
serum-free and protein-free medium developed to culture 293F cells for LV vector 
production217. In a recent study, Alton et al. suspended an SIV based LV vector in FreeStyle™ 
medium and reported efficient transduction in mice airways following delivery as a bolus 
dose218. Using this medium as a diluent could improve vector viability as this media contains 
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GlutaMAX™ supplement known to reduce ammonia build up and improve cell viability217, 219. 
The effectiveness of suspending a HIV-derived LV vector in protective agents such as 
FreeStyle™ medium is yet to be examined and is one focus of this Chapter.  
The present Chapter also investigates the efficacy of pulsed delivery of the LV vector through 
the Aeroneb®Pro-flexiVent™ ventilator circuit. Pulsed aerosol delivery has been used to 
deliver biological formulations that are susceptible to shear stress, such as viral vectors and 
pDNA to the airways of animals81, 220. Hoggard et al. showed that delivering pDNA as a coarse 
spray in pulses of 20 ms through an AeroProbe® catheter did not affect pDNA viability220, so 
it could be speculated that delivering LV vector in short pulses (here, 10 ms) would also not 
affect LV viability. Moreover, results obtained from Chapter 4 showed that delivering aerosols 
in 10 ms pulses, as well as recycling the dose deposited in the in-line Aeroneb®Pro mount, 
improved volume of aerosols expelled from the tip of the ET tube, compared to the output 
using baseline delivery parameters of the in vivo study (Chapter 3, Section 3.2.3). The present 
Chapter examines whether these changes also result in improved transduction levels, by 
quantifying LV gene expression following delivery using pulses of 10 ms and re-aerosolising 
the dose deposited within the Scireq in-line Aeroneb®Pro mount. 
5.1.1 Hypothesis and aims 
The following hypotheses are based on results from previous Chapters and the previously 
published studies detailed above. I hypothesise that the amount of viable LV vector reaching 
the tip of the ET tube at the end of the Aeroneb®Pro-flexiVent™ ventilator circuit will be; 
1) Lower than from a bolus dose, or when using the aerosolisation parameters from the 
baseline in vivo study (Section 3.2.3).  
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2) Improved when using 10 ms pulsed vector delivery with the optimised ventilation 
parameters (Chapter 4, Section 4.2.5).  
3) Further increased when using the additional step of re-aerosolising the vector that 
deposits at the Scireq in-line Aeroneb®Pro mount (Chapter 4, Section 4.2.6). 
4) Increased when the LV vector is suspended in protective diluents such as α-lactose 
buffer or FreeStyle™ medium. 
The first aim was to quantify the levels of LV gene expression that results when using the 
baseline aerosol delivery parameters (Section 3.2.3), or bolus delivery. The second aim was 
to quantify the gene expression when using the optimised delivery parameters (Chapter 4, 
Section 4.2.5 and 4.2.6). The third aim was to examine how suspending LV vector in 
FreeStyle™ medium, α-lactose buffer, or standard diluent MS/saline prior to aerosol delivery 
affects transduction levels. The final aim was to quantify the levels of gene expression 
produced when delivering the LV vector with both the optimised parameters as well as best 
diluent (both identified from experiments conducted within this Chapter). 
5.2 Methods 
5.2.1 Aerosol delivery of LV vector 
In this experiment, the Aeroneb®Pro nebuliser was mounted on a single well of a 12-well plate. 
The well contained 500 µl of cell culture medium supplemented with 10% FCS, pens/strep 
1:100 (v/v), 4 µg/ml of polybrene, and 2 µg/ml of gentamycin. A 20 µl aliquot of LV-LacZ vector 
diluted 1:10 (v/v) in MS/saline was delivered using the baseline in vivo study parameters 
(Section 3.2.3) and aerosols were collected in the cell culture medium present in the well.  
The nebuliser was then connected to the ventilator circuit and LV-LacZ vector was aerosolised 
using the same parameters. Aerosolised vector that reached the tip of the ET tube was 
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collected under 500 µl of supplemented Hams F12 cell culture medium (Section 2.2.5). The 
ventilator circuit was then disconnected, each component was separately washed with 500 
µl of supplemented cell culture medium (Section 2.2.5), and wash fluid was collected to be 
assayed later. For a positive bolus-volume control, 2 µl aliquot of the LV-LacZ vector was 
diluted 1:100 (v/v) in MS/saline and pipetted directly into 500 µl of supplemented cell culture 
medium which was then stored at 4° C until samples from aerosol treatment group were 
collected.  
To quantify gene expression produced by the LV vector, 200 µl samples of aerosolised vector 
collected a) at the outlet of the Aeroneb®Pro nebuliser unit; b) at the tip of the ET tube; c) 
wash of ventilator parts; or d) as a bolus control (Section 2.2.5) were added to CHO-K1 cells 
on a 24-well plate. Each sample was analysed in duplicate. Three replicates containing 
untreated CHO-K1 cells were used as a negative control in all experiments. Transfected cells 
and untreated CHO-K1 cells were incubated at 37°C and 5% CO2, with a media change after 
24 hours using cell culture media. After each experiment all components of the nebuliser-
ventilator circuit were disconnected and cleaned with Virkon and then with water (Section 
2.2.5). 
Two days later, samples were processed with standard X-gal solutions and incubated 
overnight at 37°C. The cell culture plate was placed on a grid that had four squares located in 
the centre of each well and away from the edges to avoid spurious results. Each square had 
an area of 2.5 mm2, while the total area of each well was 191 mm2. Images of samples in each 
square of the well was individually captured by a digital camera attached to a stereo- 
microscope at 100x magnification (Section 2.2.5). The number of transduced cells per area of 
field of view (2.5 mm2) was quantified by image analysis using the MATLAB script (Appendix, 
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Section 8.2). The average number of transduced cells per field of view was reported as gene 
expression. In the present Chapter, the functional titre of the LacZ vector was calculated after 
aerosolisation through the nebuliser by counting the number of transduced cells per field of 
view. This method was chosen because it was essential to assess how much functional vector 
was present after aerosolisation, and other titre assessment methods (e.g. PCR-based) would 
have likely overestimated this by including non-functional vector particles damaged by the 
aerosolisation process.  
5.2.2 Effect of aerosol delivery parameter on LV gene expression  
LV-LacZ vector was aerosolised through the ventilator circuit using the three different aerosol 
delivery parameters listed in Table 5-1. The amount of gene expression obtained in each 
group was quantified using previously described methods (Section 5.2.1). Ventilation 
parameters identified (from this study) to produce improved gene expression were used in 









 Table 5-1: Aerosol delivery parameters used in this experiment. 
 
5.2.3 Effect of diluents on LacZ gene expression of aerosolised vector  
5.2.3.1 Aerosol delivery via nebuliser alone  
Concentrated LV-LacZ vector (suspended in PBS following vector harvest) was diluted 1:10 
(v/v) with either MS/saline, FreeStyle™ medium, or α-lactose buffer (40 mg/ml in PBS). The 
vector was then aerosolised through the nebuliser alone. The nebuliser was operated with 
the parameters identified as producing the highest levels of gene expression in the previous 
experiment (Section 5.2.2).  
Aerosolised vector was collected under 500 μl of supplemented cell culture medium, which 
was then used to transduce CHO-K1 cells. The number of transduced cells obtained in each 
group was quantified using the previously described method (Section 5.2.1). The diluent 
producing the highest levels of gene expression was then chosen for use in subsequent 
experiments.  
Groups Aerosol delivery parameters 
1. Baseline in vivo (Section 3.2.3) VT 10 ml/kg, RR 120 breaths/minute, DC 1. 
2. Optimal aerosol volume (Section 
4.2.5) 
Aerosols delivered in pulses of 10 ms, VT 
13.2 ml/kg, RR at 90 breaths/minute. 
3. Optimal aerosol volume combined 
with re-aerosolisation of 
Aeroneb®Pro mount captured 
volume (Section 4.2.6) 
Same aerosol delivery parameters as the 
previous group (group 2) + re-aerosolising 




5.2.3.2 Aerosol delivery through the ventilator  
LV-LacZ vector diluted with either MS/saline, or the optimal diluent identified from the 
previous experiment (Section 5.2.3.1), was aerosolised through the ventilator circuit with the 
optimal aerosol delivery parameters (Section 5.2.2). Two modifications were made in the 
delivery apparatus used in this study; the collection tube was fitted with an O-ring that held 
the ET tube firmly to prevent aerosol loss, and the tip of the ET tube was immersed in 700 μl 
of supplemented cell culture medium (Figure 5-1), rather than 500 μl used previously (Section 
5.2.1), to better capture of the aerosols released. Consequently, the assay volume used to 
transduce CHO-K1 cells was also increased from 200 μl (used in earlier experiments) to 300 
μl. The level of LacZ expression was revealed using standard X-gal processing (Section 2.3.4) 
and quantified as above (Section 5.2.1). The diluent that produced the highest gene 
expression at the end of the ventilator circuit was then used for the next study.  
 
Figure 5-1: The nebuliser-ventilator circuit setup with new modifications. 
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5.2.4 Effect of optimised parameters on LV aerosol delivery during mechanical ventilation  
There were two groups in this experiment; in the first group, the LV-LacZ vector suspended in 
MS/saline was aerosolised through the ventilator circuit, using the baseline parameters noted 
in the in vivo study (Section 3.2.3). In the second group, the vector was suspended in the 
optimal diluent (Section 5.2.3.2) and aerosolised using the optimal delivery parameters 
identified earlier (Section 5.2.2). As a positive bolus control, 2 μl of LV vector diluted 1:100 
(v/v) with appropriate diluent was pipetted into 700 μl of supplemented cell culture medium. 
In both groups, aerosols were collected under 700 μl of supplemented cell culture medium. 
CHO-K1 cells were transduced with 300 μl of fluid in the Eppendorf tube from group 1 or 
group 2 (containing the vector), or from the bolus control solution. The CHO-K1 cells were 
cultured for 48 hours and stained with X-gal (Section 2.2.5), and levels of gene expression 










5.3 Results  
5.3.1 Gene expression produced by aerosolised LV vector  
Gene expression produced by aerosolised LV vector collected from the outlet of the nebuliser 
alone was 90.5% lower than bolus delivery (Figure 5-2).  
 
Figure 5-2: LV gene expression produced by bolus delivery vs aerosol delivery through nebuliser alone. 
Different volumes of aerosolised LV vector released from the outlet of the Aeroneb®Pro 
nebuliser deposited in different circuit components, which again contained varying amounts 
of viable LV vector (Figure 5-3). Gene expression produced by the LV vector present in the 
wash of the in-line nebuliser mount wash was higher than vector released from the nebuliser 
outlet (Figure 5-3), which could be a result of evaporation of the vector and impactional 
deposition of the vector within this component. Also, the wash of the expiratory limb 
demonstrated negligible gene expression, which suggests that the Eppendorf tube containing 
cell culture medium was effective in trapping almost all LV vector aerosolised at the end of 
the ET tube (Figure 5-3). 
The gene expression of LV vector obtained from the wash of the in-line nebuliser mount was 
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only 12.9 % of gene expression produced by bolus delivery. LV gene expression observed from 
the wash of the circuit components, such as the inner walls of the Aeroneb®Pro nebuliser, 
connector tube, and Y-piece, was 1.3%, 0.01%, and 0.01%, of bolus gene expression levels, 
respectively. Finally, the gene expression from the fluid obtained at the tip of the ET tube was 
only 0.02% of gene expression produced by bolus delivery.  
 
Figure 5-3: Gene expression produced by LV-LacZ aerosol following delivery through the Aeroneb®Pro-flexiVent™ 
ventilator circuit. The results show the number of LacZ gene expressing cells produced by transducing CHO-K1 
cells using the collected fluid from the wash of ventilator circuit components, or the vector collected at the tip of 
the ET tube. Components of the circuit are shown in Figure 4-1. 
5.3.2 Effect of aerosol delivery parameters on LV gene expression 
Gene expression obtained from the fluid collected at the tip of the ET tube when delivering 
the vector in 10 ms pulses was 83.7% higher than obtained using the baseline in vivo delivery 
parameters (Figure 5-4). This result suggested that delivering vector in pulses of 10 ms 
improved the levels of gene expression of the LV vector released at the tip of the ET tube 
compared to baseline delivery parameters. Hence this delivery parameter was used in the 
subsequent study aerosolising LV vector through the ventilator circuit. 
 In contrast, no significant difference was observed on delivering vector in 10 ms pulses with 
the additional step of re-aerosolising the dose deposited (approx. 2 µl) within the in-line 
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nebuliser mount compared to baseline in vivo delivery parameters (Figure 5-4). Additionally, 
high variability in LV gene expression was observed within the 10 ms pulse group and re-
aerosolising LV vector group. To reduce variability observed within these aerosol delivery 
groups a few modifications were made. The ET tube was fitted with an O-ring and volume of 
cell culture media was increased to 700 μl in the subsequent experiment (Section 5.2.3.2). 
Studies using dye solution showed that these modifications reduced the variability in the dose 
volume of food dye solution collected at the tip of the ET tube (15.8% ± 3.2% of initial dose 
volume) compared to the standard ventilator circuit (15.3% ± 6.2% of initial dose volume). 
 
Figure 5-4: Comparison of LacZ gene expression obtained after aerosolising the vector with baseline delivery 
parameters to 10 ms pulsed delivery or to pulsed delivery with re-aerosolisation of vector deposited within the 
nebuliser mount.  
5.3.3 Effect of diluents on LacZ gene expression of aerosolised vector  
5.3.3.1 Aerosol delivery through nebuliser alone 
This experiment examined the effect of different diluents on LV gene expression, when 
delivered by the nebuliser alone. The LV vector was delivered in pulses of 10 ms, as this 
delivery parameter produced the best results in the previous experiment (Section 5.3.2).  
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Gene expression produced by the vector suspended in FreeStyle™ medium was 49.5% higher 
than vector suspended in standard diluent MS/saline (Figure 5-5). Additionally, gene 
expression produced by vector suspended in FreeStyle™ medium was also higher than vector 
suspended in α-lactose buffer (Figure 5-5). However, no significant difference in gene 
expression was observed on aerosolising vector suspended in α-lactose buffer compared to 
vector suspended in MS/saline (Figure 5-5). 
 
Figure 5-5: Gene expression produced by aerosolised LV vector suspended in standard diluent MS/saline, 
FreeStyle™ medium, and α-lactose buffer.  
5.3.3.2 Aerosol delivery through the ventilator circuit 
The effect of delivering LV vector suspended in either FreeStyle™ medium or MS/saline 
suspension through the ventilator circuit was examined, using the optimal delivery 
parameters identified in the previous experiment (Section 5.3.2), i.e. 10 ms pulsed delivery. 
Gene expression produced by the vector suspended in FreeStyle™ medium was 59% higher 




Figure 5-6: Gene expression of LV vector suspended in either FreeStyle™ medium or MS/saline after aerosol 
delivery through the ventilator circuit. 
The combined effect of using these optimal aerosol delivery parameters (i.e. 10 ms pulsed 
delivery) (Section 5.3.2) and optimal diluent (i.e. FreeStyle™ medium) (Section 5.3.3.2) on LV 
gene expression obtained at the end of the ventilator circuit was then compared to baseline 
delivery parameters. Gene expression using optimal delivery parameters was substantially 
higher than when using the baseline delivery parameters (Figure 5-7).  
 
Figure 5-7: Gene expression produced by delivering the LV vector using baseline in the original in-vivo study 
parameters vs optimal delivery parameters.  
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Also, the effects of using optimal diluent and aerosol delivery parameters was compared to 
bolus delivery. The results showed that despite optimising diluent and aerosol delivery 
parameters, gene expression obtained from LV vector collected at the tip of the ET tube was 
still significantly lower than bolus delivery (Figure 5-8).  
 
Figure 5-8: Gene expression produced by delivering the LV vector either as a bolus dose or as an aerosol using 
optimal aerosol delivery parameters.  
5.4 Discussion  
Chapter 4 demonstrated that the poor transduction in the trachea of mice treated with 
aerosolised LV vector was a result of the small proportion of the dose volume being delivered 
to that region (Section 4.3.2). The present Chapter examined the factors affecting aerosolised 
gene expression through the ventilator circuit to explore how vector viability combined with 
dose volume is affected as the vector transits through the nebuliser and ventilator circuit. 
The first experiment of the present Chapter showed that the levels of gene expression 
produced by LV vector collected at the tip of the ET tube was 0.02% of bolus delivery 
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expression levels, thus supporting the first hypothesis. Similar levels of relative reduction in 
dose volume was observed in Chapter 4, which reported that only 2.1% of the initial volume 
of aerosolised dye solution reached the tip of the ET tube (Section 4.3.2). Together, these 
results explain the lowered gene expression levels seen in the trachea of aerosol-treated 
animals in the baseline in vivo study (Chapter 3, Section 3.3). 
The first experiment also examined LV gene expression following delivery with the nebuliser 
alone (not connected to the ventilator circuit). The gene expression produced by aerosolised 
LV vector collected at the outlet of the nebuliser was 90.5% lower than bolus delivery gene 
expression levels. In comparison, the results from Chapter 4 showed that the volume of 
aerosols released after delivery through the nebuliser alone was only 13.4% lower than bolus 
delivery. The reduced gene expression was likely caused by shear forces acting on the fragile 
LV vector during transit through the nebuliser. 
LV vector production reports highlight the fragile nature of LV vectors compared to other 
vectors, such as AAV. They suggest that shear forces imposed on the vector as it is passed 
through an ultrafiltration membrane may result in loss of biological activit121. LV vector 
production methods are typically designed to limit shear stress by pumping fluids at low 
speeds, minimising bubbles, and utilising low pressures where possible217. Other studies have 
sought to examine the part of the LV vector that makes it shear sensitive, and shown that the 
envelope of the LV vector influences its viability221, with the VSV-G envelope being more 
stable than other envelopes during vector production222. Furthermore, Kim et al. 
demonstrated that subjecting a HIV-1 vector pseudotyped with VSV-G envelope to 
ultracentrifugation resulted in survival of 70% of the vector particles223They also found that 
after ultracentrifugation the number of functional particles of a HIV-1 vector with a VSV-G 
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envelope was five-fold higher than a murine leukemia virus (MLV) vector pseudotyped with 
the same VSV-G envelope, thus demonstrating that the core of the viral particle also 
determines its stability223. Regardless of the cause, this shear sensitivity during production 
suggests that care must also be taken during delivery to not render the LV vector biologically 
inactive. 
As discussed in Section 1.6.4, vibrating mesh nebulisers such as the Aeroneb®Pro contain a 
mesh that is vibrated up and down by a few micrometres during operation, with the force of 
displacement generating aerosols. This rapid displacement likely generates shear stresses on 
the LV vector. Challenges associated with aerosolisation of shear-sensitive substances are not 
limited to LV vectors. A previously published study showed that when a shear and 
temperature sensitive protein solution, L-Lactic dehydrogenase, was passed through a 
vibrating mesh nozzle, (similar to the Aeroneb®Pro nebuliser design) used to spray dry the 
protein formulation, a loss of 78% of enzymatic activity was recorded224. The results from that 
study showed that the reduction in enzymatic activity was due to heat and shear stress 
produced by the vibrating nozzle and due to circulation of fluid within the pores of the 
nozzle224. Hence, it could be speculated that similar shearing of the LV vector occurs as it 
passes through the vibrating mesh plate of the Aeroneb®Pro nebuliser. Future studies should 
concentrate on developing novel LV shear reduction methods for preventing this degradation 
during aerosolisation. Therefore, the results presented in this Chapter demonstrate 
significant reduction in vector viability along with small reduction in dose volume following 
aerosolisation through the nebuliser. These findings agree with previously published studies 
that showed aerosolising viral vectors, such as Ad and SeV, resulted in lower vector viability 
following delivery through a nebuliser54, 58. 
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To identify any sources of reduction of LV gene expression within the ventilator circuit, 
samples of deposited LV aerosol were drawn from each circuit component for analysis. Gene 
expression produced by the fluid collected at the in-line nebuliser mount was only 12.9 % of 
gene expression produced by bolus delivery, which could be due to impactional deposition of 
LV aerosols within this component. However, results from Chapter 4 reported deposition of 
approximately 83.7% of initial dose volume within the in-line nebuliser mount (Section 4.3.2). 
Together, these results suggest that although deposition of the majority of the dose volume 
occurs within the nebuliser mount, reduction in LV gene expression due to deposition within 
this component was minimal.  
Vector recovered from other circuit components also demonstrated reduced LV gene 
expression as a result of impactional deposition of aerosolised vector within the circuit 
components. LV gene expression collected from the wash of inner walls of the nebuliser, 
connector tube, and Y-piece, was 1.3%, 0.01%, and 0.01%, of bolus gene expression levels, 
respectively. However, results from chapter 4 demonstrated deposition of dose volume 
within the inner walls of the nebuliser, connector tube, and Y-piece to be 10.1%, 2.7%, and 
2.1% of initial dose volume, respectively (Section 4.3.2). Together these results suggest that 
the lowered delivery efficiency of the Aeroneb®Pro-flexiVent™ apparatus when delivering LV 
vector was caused primarily by reduction in the vector viability following aerosol delivery 
through the nebuliser and secondly by deposition of viable vector within circuit components. 
To address the problem mentioned above, the second experiment examined the effect of 
aerosolising the vector with the optimal delivery parameters that were shown to reduce 
deposition of aerosolised fluid within circuit components (identified in Chapter 4). Delivering 
LV vector in pulses of 10 ms and with optimised ventilation parameters (Section 4.2.5) 
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produced higher levels of gene expression from the fluid collected at the tip of the ET tube 
compared to the baseline in vivo study parameters (Section 3.2.3), thus supporting the second 
hypothesis. Delivering the vector in short pulses lowers the dose volume released per 
respiratory cycle, which in turn may reduce impaction against the inner walls of the circuit 
component and result in higher amount of viable vector delivered to the tip of the ET tube 
compared to baseline in vivo study parameters, hence explaining the above result. 
Many CF gene therapy studies have used this method of pulsed vector delivery to the airways 
of animal models and CF patients. Kohler et al. delivered a Hd-Ad vector formulated in LPC 
and PBS in pulses of 1 s followed by 0.1 s of air-only pulse using an AeroProbe™ catheter to 
the lungs of rabbits and reported transduction of 66% in tracheal epithelial cells81. However, 
the authors did not compare the effect of pulsed delivery to non-pulsed delivery on vector 
viability. In another study, Harvey et al. delivered a first-generation Ad-CFTR vector in pulses 
of 2 s using a bronchoscope and demonstrated 5% of CFTR mRNA expression in the airways 
of CF patients, which was transient, lasting between 4 to 30 days98. The researchers also did 
not compare the effect of pulsed vector delivery vs non-pulsed delivery on vector viability. 
The pulse used in the above-mentioned studies were 100 to 200 times longer than the 10 ms 
pulse used in the present Chapter. This leads to the speculation that the LV vector would still 
be viable when pulsed for a longer period of time (i.e. >10 ms); however, this might reduce 
the dose volume delivered at the tip of the Aeroneb®Pro-flexiVent™ ventilator apparatus 
(Section 4.3.5) and hence remains to be investigated.  
Chapter 4 reported that re-aerosolising the dose deposited within the Aeroneb®Pro mount 
significantly improved dose volume expelled at the end of the ventilator circuit (Section 4.3.6). 
However, the present study showed that the levels of gene expression produced by re-
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aerosolising the vector deposited within the in-line nebuliser mount was similar to the 
baseline in vivo study, thus not supporting the third hypothesis. This result suggests that re-
aerosolising the vector could have reduced LV viability as the reintroduced vector was subject 
to nebuliser shear forces and impactional forces against the inner wall of the circuit 
components for a second time, thus reducing the amount of viable vector produced at the tip 
of the ET tube. As re-aerosolising the vector did not produce any significant difference in gene 
expression studies compared to baseline in vivo study it was not used further.  
In an attempt to overcome reduced vector viability associated with aerosolisation through 
the nebuliser, the vector was suspended in different diluents to assess whether they would 
protect vector particles during aerosolisation. In support of the fourth hypothesis, vector 
suspended in FreeStyle™ medium produced increased levels of gene expression when 
delivered through the nebuliser alone (Section 5.3.3.1) as well as through the ventilator circuit 
(Section 5.2.3.2), compared to vector suspended in α-lactose buffer or the standard diluent 
MS/saline. The increased gene expression with FreeStyle™ medium may be a result of its 
GlutaMAX™ and Pluronic F-68 components (see Section 5.1 for an explanation why 
GlutaMAX™ improved viability of the HIV vector). Pluronic F-68 is a non-ionic surfactant 
commonly used to reduce shear stress produced in culturing cells in bio-reactors for vector 
production217, and could also have contributed to improved LV gene expression.  
Aerosolising the LV vector when suspended in an optimal diluent and using optimal aerosol 
delivery parameters produced higher levels of gene expression than when parameters of the 
baseline in vivo study were used. However, gene expression produced by the vector collected 
at the end of the ventilator circuit using these optimal parameters remained significantly 
lower than bolus vector delivery. Although not conducted within the same experiment, the 
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gene expression produced by the LV vector suspended in optimal diluent (FreeStyle™ medium) 
following delivery through the nebuliser alone (Figure 5-5) was still significantly lower than 
bolus delivery (Figure 5-8). These results suggest that an aerosolised vector would be unlikely 
to match gene expression efficiency produced using a bolus dose in the airways of mice. 
Further speculations could be drawn on what might happen if the initial aerosol dose volume 
was increased to match the bolus dose. With improvement in the optimal delivery parameters, 
the starting volume of the aerosol sample delivered would need to be increased 117 times 
(i.e. 20 μl to 2.4 ml) to deliver the same number of functional particles as a bolus dose. 
However, this is not feasible because delivering a large volume of fluid through the 
Aeroneb®Pro flexiVent™ ventilator circuit would result in substantial fluid deposition within 
the narrow tubes of the delivery circuit, resulting in blockage and delivery failure. Simply 
increasing the starting volume loaded into the Aeroneb®Pro to match the LV bolus dose is 
clearly not a practical solution. This is far too much vector to use per animal, and it would still 
be unlikely to result in comparable transduction levels. Furthermore, production of the large 
volumes of expensive vector formulations required would not be feasible or justified. 
Finally, results of the experiments conducted in this Chapter, along with those of Chapter 3 
and 4, suggest that aerosolising a HIV-based LV vector through the Aeroneb®Pro nebuliser 
was not effective in producing similar levels of gene expression as bolus delivery. Although a 
review of literature had proposed that this nebuliser would be ideal to deliver expensive 
vector formulation compared to other nebulisers (Section 1.6 and 3.1) and was effective in 
aerosolising other shear sensitive biological formulation144, 161 results reported in this study 
highlight significant drawbacks that could limit its effectiveness, such as reduction in vector 
viability. The low gene transduction efficiency of this nebuliser alone might not be suitable to 
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deliver LV vector to the airways of larger animal models; however, this would need to be 
further investigated. As this nebuliser was shown to not be effective in delivering enough 
viable LV vector particles as bolus delivery, there is a need to investigate alternative delivery 
systems that could successfully aerosolise viral vector formulation or other shear-sensitive 
biological formulations. 
5.5 Conclusion 
The work described in this Chapter covered a range of experiments designed to quantify the 
gene expression of LV vector aerosolised through a ventilator circuit designed for use in mice, 
using the delivery parameters derived from the baseline in vivo study. Aerosolisation of LV 
vector resulted in lower gene expression than bolus delivery. The literature indicates that this 
lowered gene expression is primarily due to shear stress imposed on the vector during aerosol 
delivery and secondly, impaction of the vector against the inner walls of the ventilator circuit. 
Short pulses of vector increased gene expression compared to that achieved using baseline 
ventilation parameters. This suggests that pulsed vector delivery was effective and could be 
used for future studies aerosolising LV vector or other viral vector through a delivery circuit. 
This Chapter also identified FreeStyle™ medium – a serum-free, and protein-free formulation 
– as an optimal diluent that protected viral vector particles during aerosol delivery and could 
possibly overcome immune response problems caused by using serum containing medium217. 
For these reasons, the effectiveness of this serum-free medium for use in CF gene therapy 
studies needs to be investigated further. Despite efforts to improve gene expression of the 
aerosolised LV vector through the Aeroneb®Pro-flexiVent™ ventilator circuit, results showed 
that it was still lower than bolus delivery. Although this nebuliser had been shown to 
effectively aerosolise other shear-sensitive biological formulations144, 161, the results from this 
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thesis demonstrated that the Aeroneb®Pro vibrating mesh nebuliser was not effective in 
producing enough viable HIV-based LV vector to produce similar levels of gene expression as 
bolus delivery. The low gene transduction efficiency of the Aeroneb®Pro nebuliser further 
suggests that it might not be effective in delivering sufficient viable LV vector to the airways 
of larger animal models.  




One of the current challenges that affects therapeutic outcomes of gene therapy is the vector 
delivery regimen. Although the lungs are readily accessible, delivering vector formulation to 
them has been challenging48. In past clinical trials, vector formulation was delivered either as 
a liquid/bolus dose delivered via a bronchoscope49 or as an aerosol using a nebuliser93. 
Alternatively, a vector formulation has also been delivered as a coarse spray to the lungs of 
CF patients, using an intra-tracheal sprayer98. The relative ease of delivering vector 
formulation and uniform distribution of the vector when delivered as an aerosol makes it an 
attractive delivery option54, 60. However, only six of 27 gene therapy clinical trials have 
incorporated aerosol delivery regimens to transfer viral vector to the airways of CF patients92, 
93, 98, 99, 106, 107, 109. These clinical trials, along with other pre-clinical studies, reported that the 
primary difficulty in delivering a viral vector as an aerosol was it produced inadequate levels 
of gene expression54, 58. Hence, developing an optimal delivery regimen is dependent on using 
appropriate nebulisers to aerosolise sensitive vector formulations66. Advances in nebuliser 
technology have led to production of delivery systems that effectively deliver shear-sensitive 
and temperature-sensitive formulations. A recently developed ultrasonic nebuliser, the SAW 
nebuliser, has been shown to aerosolise sensitive biological formulations like stem cells and 
proteins80, 225. However, aerosolising the LV vector using the SAW nebuliser produced lower 
levels of gene expression than bolus delivery (Appendix, Section 8.1.4.1), suggesting that this 
nebuliser was also not efficient in delivering viable aerosols of LV vector. As a result, further 
work with this nebuliser in this thesis was abandoned. Further studies examined the effect of 
delivering LV as a coarse spray (rather than an aerosol) using the MADgic™ atomisation device. 
Results demonstrated similar levels of gene expression on spraying the vector compared to 
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bolus delivery (Appendix, Section 8.1.4.2), which suggests that this coarse sprayer is effective 
in delivering the LV vector and warrants further investigation. However, there are certain 
drawbacks in using this device as its use in patients would be invasive and a minimal volume 
of 1 ml is required to deliver a spray (30 to 100 µm) of the vector formulation. In spite of this 
result, an optimal nebuliser to deliver fine aerosols of the LV vector is yet to be identified and 
was the main goal of this thesis. 
Another type of nebuliser that has been shown to retain stability of shear-sensitive biological 
formulations following aerosol delivery is the vibrating mesh nebuliser159. The Aeroneb®Pro 
is one such commercially available vibrating mesh nebuliser that has been approved for 
clinical use and is currently utilised to deliver drug formulations to the airways of mechanically 
ventilated patients166, 167. Additionally, this nebuliser has also been used to deliver aerosols 
to the airways of mice mechanically ventilated with a small animal-ventilator (flexiVent™)146, 
226. This allows the delivery efficiency of expensive and shear-sensitive vector formulations 
through a clinical grade nebuliser to be tested in a smaller animal model. It also permits 
development of scalable-aerosol delivery protocol at a reduced cost, which could be further 
used in larger animal models.  
HIV-based LV vectors are promising as they transduce both dividing and non-dividing cells and 
have shown to produce long-lasting gene expression132. The CFARG group in Adelaide have 
developed a LV vector delivery protocol that has been demonstrated to correct the CF gene 
defect for up to 12 months in CF mice132. Bolus delivery studies using this vector 
demonstrated effective gene transduction in the airways of animal models57, 132, 140. There is 
a necessity to translate this bolus vector delivery regimen to an aerosol form for clinical 
realisation, because aerosol delivery regimen is more likely to be non-invasive and enable 
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uniform distribution of the vector in patient airways. HIV-based LV vectors have been 
successfully aerosolised in lung cancer studies122; however, the efficiency of aerosolising this 
vector has not been quantified for CF airway delivery. 
Hence, the aims of this thesis were to: (1) determine the efficiency of the Aeroneb®Pro 
nebuliser for aerosolising a HIV vector pseudotyped with the VSV-G envelope into the lungs 
of mice, during mechanical ventilation with a flexiVent™ ventilator and compare distribution 
of the LV vector delivered as an aerosol or bolus dose in lungs of mice; (2) quantify the viability 
of the aerosolised LV vector at the point at which it enters the mouse trachea, i.e. the viability 
of the LV vector released at the end of the Aeroneb®Pro-flexiVent™ ventilator circuit; (3) 
quantify the volume of aerosols reaching the mouse trachea, i.e. how much aerosol is 
released at the end of the Aeroneb®Pro-flexiVent™ ventilator circuit compared to bolus 
delivery; and (4) optimise the delivery parameters to develop an effective LV aerosol delivery 
protocol that could be used in further pre-clinical studies. 
Chapter 3 investigated the first aim, which was to determine the efficiency of delivering the 
LV vector as an aerosol in the lungs of mechanically ventilated mice. In this study, two groups 
of mice were pre-treated with a fluid dose of LPC conditioning solution (i.e. a bolus dose) 
followed by an aerosol dose of LV vector to one group of mice and bolus dose of the vector 
to the other group. The results demonstrated significantly lower levels of gene expression in 
the trachea of aerosol-treated mice compared to those receiving a bolus dose. However, the 
comparative effect of the two delivery regimens in other regions of mice airways were not 
conclusive due to one outlier. It was hypothesised that the lowered gene expression in the 
trachea was caused by the reduced dose volume reaching the animal, and/or lowered viability 
of aerosolised vector delivered. These possibilities were investigated in Chapters 4 and 5, 
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respectively. Additionally, delivering LPC as a fluid dose prior to LV aerosol delivery could be 
another cause of lowered gene expression, as there could be a mismatch in the areas treated 
with LPC fluid and LV vector aerosol doses. To overcome this problem, LPC could be delivered 
as an aerosol, which would distribute it uniformly in the airways and would ideally overlap 
with regions treated with aerosolised LV vector. However, delivering higher concentrations 
of LPC can damage the respiratory epithelium and cause oedema169, 170, and examining the 
effect of LPC aerosol was not within the scope of this thesis.  
Another drawback was that the distribution of LV aerosols in the airways of mice could not 
be examined due to the low gene expression produced by this delivery regimen compared to 
bolus delivery. The airways of bolus-treated mice demonstrated patchy gene expression 
similar to other studies reported in the literature57, 140. Together, results from Chapter 3 
identified lowered transduction efficiency of delivering LV aerosol using the Aeroneb®Pro-
flexiVent™ apparatus compared to a bolus delivery group in the trachea of mice; however, 
the effectiveness of the LV aerosol delivery in other regions of the lung was not conclusive. 
As a result, additional studies were carried out to examine aerosol delivery efficiency of this 
nebuliser-ventilator circuit.  
Chapter 4 investigated the second and fourth aims, which were to quantify the volume of 
aerosols released from the ventilator circuit ET tube (using in vivo baseline ventilation 
parameters) and to optimise the delivery parameters to develop an efficient LV aerosol 
delivery protocol. This study showed that only 2.1% of the starting dose volume reached the 
tip of the ET tube and a majority of the aerosolised dose was deposited within the Scireq in-
line Aeroneb®Pro mount. This result likely explained the low levels of gene expression 
observed in the trachea of aerosol-treated mice in Chapter 3. This study demonstrated the 
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problems associated with impactional deposition of aerosolised fluid within a small-bore 
ventilator circuit and the challenges in adapting a human clinical-grade Aeroneb®Pro 
nebuliser for use with a small laboratory animal. These findings supported results obtained 
by other researchers who also demonstrated lowered delivery efficiency of the Aeroneb®Pro 
nebuliser used in conjunction with a rodent ventilator74, 146. Hence, to improve the delivery 
efficiency of the nebuliser-ventilator circuit the parameters that control aerosol production 
and airflow were examined. Significant improvement in aerosol output was observed on 
changing some ventilation parameters, delivering aerosols in short time-controlled pulses, 
and re-aerosolising the dose deposited at the ventilator circuit component. These results 
suggested that optimising delivery parameters could control aerosol flow and deposition 
within the ventilator circuit that could in turn impact the delivery efficiency of the system. 
The only limitation was the process of re-aerosolising, which required disassembling and re-
assembling the ventilator circuit, and might not be practical for use in a larger animal model 
or clinical studies. Thus, the experiments conducted in Chapter 4 contributed to the 
understanding of aerosol delivery efficiency through a small-bore ventilator circuit used for 
mice. The optimised aerosol delivery parameters identified in Chapter 4 could also be 
applicable for other studies using the same ventilator circuit. However, further testing may 
be required as results may vary depending on the physio-chemical nature (e.g. viscosity, etc) 
of the drug formulation.  
Chapter 5 examined aims three and four, which were to investigate LV gene expression 
following delivery through the nebuliser and the ventilator circuit, and to optimise delivery 
parameters to develop an efficient delivery protocol. Results demonstrated that the levels of 
LacZ gene expression from the vector collected at the nebuliser outlet was lower than bolus 
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delivery by 90.5%. The low levels of gene expression could be due to lowered viability of the 
LV vector as a result of destructive shear forces produced by the nebuliser and the lowered 
volume of the LV vector fluid collected at the nebuliser outlet compared to bolus delivery. 
Although this nebuliser was thought to produce reduced levels of shear stress on the 
aerosolised formulation, it could have been sufficient to damage the fragile LV vector. 
Additionally, wash of the circuit components also revealed deposition of small quantities of 
viable LV vector (< 15% of viable vector) within the circuit, although Chapter 4 had shown that 
majority of the dose volume (i.e. approximately 97% of the initial dose) deposits within the 
circuit components due to impactional deposition. Furthermore, the gene expression 
produced by the fluid collected at the end of the delivery circuit was only 0.02% of bolus 
delivery, which could explain the low levels of gene expression observed in the trachea of live 
mice exposed to LV-LacZ aerosols (Chapter 3). Together these results from Chapter 5 
demonstrate the challenges in aerosolising the LV vector through the vibrating mesh 
nebuliser and a small-bore ventilator circuit.  
Chapter 3 reported elevated levels of gene expression observed in the lungs of the outlier 
animal. The reasons for the drastically high levels of gene expression in the outlier animal may 
have been due to a dosing error in the volume of LPC delivered to the lung of the animal, 
improper cleaning of the ventilator circuit tubing, or an inherent and unexplained variation in 
respiratory characteristics of that mouse, rather than delivering twice the dose of the LV 
vector. As described in Chapter 5 (Section 5.4), it is likely that increasing vector volume would 
still result in very low levels of viable LV vector produced at the outlet of the nebuliser and 
produces an additional set of challenges.  
To improve efficiency of the nebuliser-ventilator system, used in mice, in delivering the LV 
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vector it was aerosolised using the optimal delivery parameters identified in Chapter 4. The 
levels of gene expression improved when delivering the LV vector in pulses; however, re-
aerosolising the LV vector trapped in the in-line nebuliser mount did not increase gene 
expression compared to baseline parameters. Re-aerosolising the vector could subject it to 
additional shear-forces that damage the vector, and with a second impaction against the 
inner walls of the circuit components these effects together could have caused this finding.  
Other experiments in Chapter 5 examined methods to preserve vector viability during aerosol 
delivery, such as suspending LV vector in protective diluents. Suspending LV vector in 
Freestyle™ medium produced higher levels of gene expression than the standard diluent 
MS/saline following delivery through the nebuliser alone and delivery circuit. These efforts to 
preserve the viability of the LV vector during mechanical ventilation and increase the amount 
of aerosol reaching the ET tube tip improved the total transduction level, but it was still 
significantly lower than bolus delivery. 
The results from Chapter 5 suggest that the Aeroneb®Pro-flexiVent™ ventilator circuit was 
not effective in delivering sufficient quantities of viable LV vector to produce similar levels of 
gene expression as a bolus dose. Although these studies were conducted in a small-animal 
ventilator circuit, it highlighted the practical challenges of aerosol delivery regimen that could 
be expected in large animal models and clinical studies. Chapter 5 also showed that delivering 
the LV vector in short pulses improved vector viability. However, to deliver a larger volume of 
LV vector to the airways of humans and larger animal models the pulse length would likely 
need to be increased for practical reasons (so that delivery time is not overly long). Such an 
increase in the pulse length would likely reduce LV viability. However, if further improvements 
in nebuliser design, to reduce shear stress, were to occur these could drastically improve the 
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LV viability released from the nebuliser. To overcome problems associated with LV viability, 
future research could also investigate pseudotyping the LV vector with other viral vector 
envelopes resistant to shear stress and/or encapsulating the vector with a protective chemical 
agent, such as polyethylene glycol. 
Combined with improvements to the delivery circuit to reduce LV deposition an aerosol 
delivery system could still potentially be used to deliver larger volume of vector formulation 
to the airways of large animals and humans. The Aeroneb®Pro nebuliser was initially designed 
for use in humans and has been used in clinics to deliver antibiotic formulations inline, such 
as colistin, to the airways of CF patients227. It has also been shown to be effective in delivering 
drug formulation to the airways of larger animals, such as non-human primates228Thus, 
delivery of larger volumes of vector formulation is possible, provided the nebuliser design and 
delivery route are optimised. 
 Another factor that needs to be examined in the future is delivery an LV vector carrying the 
larger therapeutic CFTR gene (~4.4 kb)108 in place of the LacZ gene (~3.1 kb) used in this thesis 
(Section 8.3). A previous study has shown that titre of the LV vector decreased with increasing 
size of the transgene229 as this affects the packaging efficiency of the virions. However, 
aerosolising either a LV-CFTR vector or a LV-LacZ vector of the same titre through a nebuliser 
could be speculated to produce similar number of viable LV particles, because the physical 
properties (particle size and envelope) are not altered by the transgene that is packaged. 
Nonetheless, this remains untested. In conclusion, regardless of the results from Chapter 5, 
the question of “which is the optimal aerosol delivery system or nebuliser to aerosolise the 
HIV-based LV vector?” remain unanswered. Hence, there is a need to seek new delivery 
systems that have shown to aerosolise shear-sensitive biological formulation so as to test 
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their effectiveness in delivering the LV vector.  
While the search for an optimal fine particle nebuliser remains ongoing, there is a need to 
optimise other methods to deliver LV vector for the first clinical trial in CF patients. This thesis 
identified that the LV vector could be delivered as a coarse aerosol using the 
MADgic™atomisation device (Appendix, Section 8.1.4.2). The MADgic™atomisation device 
was more effective in delivering the LV vector than either the Aeroneb®Pro nebuliser or SAW 
nebuliser, which may be due to the aerosol generation mechanism. As explained in Section 
8.1.1, the MADgic™atomisation device generates coarse aerosols through the atomiser, 
located at the tip of the device, by applying manual pressure to the bottom of the syringe that 
pushes the liquid formulation through the tubing. In the Aeroneb®Pro nebuliser, electric 
current is supplied to the mesh plate with finely tapered holes on which the formulation was 
placed. This results in vibration of the mesh plate and generation of aerosols, as described in 
Section 1.6.4. The mechanism of SAW nebuliser involves an electric signal supplied to the 
interdigital transducer (IDT), which generates travelling SAW waves that aerosolises the liquid 
delivered to the substrate via a capillary tube, as explained in Section 8.1.1. 
The frequency of the vibrating mesh of the Aeroneb®Pro nebuliser was 128 kHz230 and the 
frequency of the SAW waves employed in the SAW device was 10 to 100 MHz80, while there 
are no vibrations produced by the MADgic™atomisation device. Using these high frequency 
vibrations (in the MHz range) could be the source of the shear stress that likely destroys some 
of the LV particles during the aerosolisation process. Additionally, the heat generated at the 
point of aerosolisation within the SAW nebuliser (Section 8.1.5) could have also further 




Future studies should optimise the design of the Aeroneb®Pro nebuliser-flexiVent™ ventilator 
circuit to reduce the deposition of the aerosolised dose within the circuit. Published studies 
have shown that using streamlined ventilator circuit components downstream of the 
nebuliser reduces dose deposition within the circuit and thus enhances vector delivery205. 
Streamlined circuit components reduce sudden changes in the diameter of tubing, turbulence, 
and have adequate flow separation resulting in uniform flow of aerosol within the 
component205. Longest et al. showed that using a streamlined T-piece component, which is 
placed adjacent to the nebuliser in the delivery circuit, reduced deposition within this 
component by a factor of four205. 
The design of the Aeroneb®Pro nebuliser and SAW nebuliser could also be improved to enable 
effective delivery of shear-sensitive biological formulation, such as gene therapy vectors. The 
mesh plate of the Aeroneb®Pro nebuliser could also be re-designed using different metallic 
alloys that are compatible to deliver LV vectors. In a study by Choi et al., a vibrating mesh 
plate nebuliser was fabricated using a bio-compatible palladium–nickel alloys and showed 
effective delivery of mouse fibroblast and human basal epithelial cells231. The effectiveness of 
these types of modifications on LV vector delivery remains unknown. 
Heat produced by the SAW nebuliser was suspected to be an obstacle in its efficient delivery 
of LV vectors. To overcome this, experiments could examine the effectiveness of different 
heat-sinks, such as copper or aluminium alloys, in absorbing the heat generated. Also, the 
SAW nebuliser could be operated in a cooled chamber (at 4°C) to further reduce the heat 
generated. Another method to capture the heat generated by the SAW nebuliser is by using 
Peltier cooling plates. A study conducted by Hertel et al. showed that attaching a micro Peltier 
cooling plate attached to the nebuliser reservoir reduced the average temperature of the 
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reservoir by 8°C232. This reduction in temperature enabled the effective aerosol delivery of a 
thermolabile protein through the nebuliser. Until such improvements in nebuliser design and 
ventilator circuits occur research efforts should focus on the optimisation of the 
MADgic®atomisation device, combined with alterations to the vector diluents to improve 
stability and reduce sensitivity, as an optimal delivery device for further pre-clinical LV gene 
therapy studies. 
Further cell culture studies could examine the effectiveness of the MADgic™atomisation 
device for delivering LV vector suspended in optimal diluents, delivered in short-pulses, and 
priming the device with protective agents prior to vector delivery. Additionally, future studies 
would also need to examine the distribution of the vector in animal airways and effectiveness 
of this vector delivery regimen in CF animal models. A major drawback of using the 
MADgic™atomisation device is that the patient needs to be sedated and undergo endo-
tracheal intubation. In spite of this drawback, it could be used in the first clinical trial to 
uniformly distribute the HIV-based LV vector to the airways of CF patients, provided it 
produces promising results in the aforementioned studies. Other research groups, like the UK 
Cystic Fibrosis Gene Therapy Consortium have also examined similar intra-tracheal sprayers 
to deliver SIV vector218. They demonstrated successful delivery of the SIV vector through a 
Trudell AeroProbe® catheter and a metered nasal spray device that could be used in the first 
CF gene therapy trial using this vector218. 
In the event that LV aerosol/spray experiments produce unfavourable results, the LV vector 
could be delivered as a bolus dose via a bronchoscope. Although this method might not result 
in uniform spatial distribution of the vector in the lung, and requires sedation of the patient, 
it has been effective in delivering other viral vectors, such as AAV, to the airways of CF 
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patients55. FIV based LV vector has been effectively delivered to the airways of pigs using a 
bronchoscope233. A pilot study conducted by Liu et al. demonstrated low gene expression 
levels after delivering a HIV-based LV vector as a bolus dose to the lungs of sheep using a 
bronchoscope140. The researchers speculated that low gene expression could have resulted 
from the low volume of LV vector delivered to the lungs of sheep and small size of the study140. 
However, a recent study by the CFARG confirmed that the HIV-based LV vector could be 
effectively delivered through a miniature bronchoscope, where it produced effective and 
lobe-specific gene transduction in the lungs of rats234.  
As the realisation of using an LV vector for CF gene therapy draws closer, there is an urgent 
need to identify optimal methods to deliver expensive vector formulations to the airways of 
patients. Besides vector stability, there are other challenges that affect delivery of vector 
formulations to appropriate sites in airways. These challenges include bacterial colonisation 
and mucus obstruction235 that could limit vector deposition at appropriate sites in airways236. 
Immune response produced against the viral vector or transgene products could also result 
in reduced efficacy on vector re-administration236 as well as other clinical complications such 
as pulmonary inflammation and pneumonia105. Therefore, the effect of aerosolised 
antibacterial and mucolytic agents alongside LV vector treatment need to be investigated in 
the airways of CF animal models. The effect of drugs for suppressing the immune response 
and LV vector delivery should also be examined, because the safety of using these agents 
combined with a gene therapy treatment is still relatively unknown. Targeting vector 
treatment to certain regions of the lung also needs to be investigated as this could reduce the 
burden of producing expensive vector formulations. Finally, there is a need for newer, more 
non-invasive nebuliser designs that could efficiently aerosolise shear-sensitive LV vector 
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formulations to the airways of CF patients. Hence, there is still much work that needs to be 
done to successfully deliver a HIV-based LV vector to correct or prevent disease in the airways 
of CF patients.   
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7 CONCLUSION  
This thesis aimed to identify an ideal nebuliser capable of effectively delivering a HIV-based 
LV vector pseudotyped with a VSV-G envelope developed by the CFARG in Adelaide. The 
effectiveness of a recently developed SAW nebuliser in delivering aerosols of this vector was 
examined in an in vitro study. Results demonstrated significantly lowered gene expression 
compared to bolus delivery, which could be due to the fragile nature of the virus. In contrast, 
the next study showed that the MADgic™atomisation device was effective in delivering the 
HIV-based LV vector as a coarse spray because levels of gene expression obtained were similar 
to bolus delivery. However, using this device could be invasive and requires the sedation of 
patients. Therefore, there is a need to examine other nebulisers that could be non-invasive 
and effectively deliver fine aerosols of the LV vector to patient airways. 
Further experiments examined a commercially available vibrating mesh nebuliser, the 
Aeroneb®Pro, which has been shown to effectively aerosolise shear-sensitive formulations. 
To my knowledge, this was the first study to examine the effect of aerosolising this LV vector 
using the Aeroneb®Pro nebuliser into mouse airways. This study highlighted the challenges in 
delivering aerosol formulation to the narrow airways of mice and the fragile nature of 
delivering the LV vector as an aerosol. Further bench studies documented the effect of 
ventilation parameters, pulsed aerosol delivery, and re-aerosolising dose deposited within 
circuit components on delivery efficiency of the Aeroneb®Pro-flexiVent™ ventilator used for 
smaller animal models. This knowledge could also be useful in other aerosol delivery studies 
using the same ventilator apparatus. Subsequent cell culture studies elucidated the effect of 
aerosol delivery parameters of LV vector through the ventilator circuit and identified the use 
of serum-free FreeStyle™ medium as a suitable diluent that improves vector LV gene 
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expression following aerosol delivery. Further investigation is warranted for using this 
medium as a diluent for clinical studies. Despite optimising delivery parameters, the 
Aeroneb®Pro-flexiVent™ ventilator apparatus was found to be ineffective in delivering 
enough viable LV vector to produce similar gene expression levels as bolus delivery.  
Research efforts to identify an optimal nebuliser to effectively aerosolise the HIV-based LV 
vector remain ongoing. Future research effort needs to focus on delivering this vector as a 
spray or bolus dose. The effectiveness of the MADgic™ atomisation device in delivering the 
HIV-based LV vector as a spray has been reported in this thesis. This result provides initial 
data for future studies that could examine the effectiveness of this device in delivering LV 
vector formulations to the lungs of animal models. Such research effort could be comparable 
to other research groups, like the UK Cystic Fibrosis Gene Therapy Consortium, who have also 
examined the effectiveness of a similar intra-tracheal sprayer (Trudell AeroProbe ® catheter) 
to deliver the SIV vector in preparation for the first CF gene therapy trial 218.  
Besides the above-mentioned studies, research is also needed to examine the effect of 
aerosolising the LPC airway conditioning treatment prior to aerosolising the LV vector. Other 
issues that might severely limit the outcomes of aerosol gene therapy treatment, such as 
mucus obstruction in the airways of CF patients and immune responses to the vector, also 
need to be addressed. The experiments reported in this thesis highlight the advantages and 
disadvantages associated with LV aerosol delivery. Much work still needs to be done to 
develop a non-invasive, and effective vector delivery method for use in the first CF gene 





8.1 Aerosol delivery of the LV vector using other types of nebulisers 
8.1.1  Introduction 
As discussed in previous Chapters, aerosol delivery of a HIV-based LV vector is challenging, 
due to the fragile nature of the vector156. The Aeroneb®Pro nebuliser was chosen in these 
studies to aerosolise the LV vector due to its record of successful aerosolisation of shear-
sensitive formulations, such as proteins and liposomes160, 161, 237 (Introduction, Section 1.6.4). 
However, prior to examining the Aeroneb®Pro nebuliser other new delivery devices were 
briefly assessed. This Appendix investigates the effectiveness of two devices; a prototype 
Surface Acoustic Wave (SAW) nebuliser, and the commercially available MADgic™ 
atomisation device. 
8.1.1.1 SAW nebuliser  
Advances in engineering technology have led to development of the SAW nebuliser238. This 
nebuliser has been successfully used to aerosolise drug formulations such as β2 agonist 
salbutamol sulphate and shear sensitive biological formulations, such as proteins225, pDNA79, 
and stem cells80, suggesting that it might also be suitable for LV vector delivery. The SAW 
nebuliser (Figure 8-1) makes use of transverse-axial polarised electroacoustic waves, also 
known as SAW waves, which have a displacement amplitude of a few nanometres. SAW 
waves are generated by applying a sinusoidal electric field to the interlaced fingers of an 
interdigital transducer (IDT). These waves then travel along the adjacent piezoelectric lithium 
niobate (LN) substrate that helps contain most of the energy generated. The travelling SAW 
waves give rise to capillary waves along the surface of the liquid placed on the substrate, 
these waves then lead to liquid breakup and formation of aerosols239. The size of aerosols 
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produced by this device range from 1 to 10 μm, depending on characteristics of the liquid 
formulation240. On inhalation, larger aerosol particles (5 to 10 μm) deposit in the central 
airways of patients241 (the primary region targeted by CF gene therapy), which might make 
this a suitable nebuliser for use in future clinical studies42. 
The frequency used in the SAW nebuliser ranges from 10 to 100 MHz, which sets it apart from 
the 10 kHz-1 MHz frequency range of traditional ultrasonic nebulisers225. Other nebulisers like 
the Aeroneb®Pro, use a much lower frequency range of 128 kHz to aerosolise a liquid 
formulation242. The frequency used in the SAW nebuliser induces vibrations with a shorter 
time period than the molecular relaxation time scale of large molecules in liquid, thereby 
reducing the possibility of denaturing molecules of the drug formulation225. As this could 
translate to less shear forces, the present Chapter reports on pilot experiments to determine 
whether the SAW nebuliser could be an effective method for delivering the LV gene vector.  
 
Figure 8-1: SAW waves generated by applying a sinusoidal electric field to the finger of an interdigital transducer 
(IDT) placed on the lithium niobate (LN) substrate1. 
8.1.1.2 Intra-tracheal sprayers 
Intra-tracheal sprayers or nebulisation catheters deliver a coarse spray of drug formulation to 
the airways of patients98 and animal models58, 81, 103. To deliver a drug formulation, the 
nebulising catheter needs to be guided to the trachea using a bronchoscope58. Although this 
procedure is invasive and requires sedation of the subject81, 103, it has significant advantages, 
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as majority of the drug formulation reaches the bronchial airways and lungs, reducing the 
dose deposited at other regions like the pharynx and vocal cords98, and maximising the 
potential effectiveness of expensive drug formulation243. The Microsprayer® (PennCentury, 
Philadelphia, USA) and the AeroProbe™ (Trudell Corporation, USA) catheter are two intra-
trachea devices commonly used to deliver viral vectors in many CF gene therapy studies81, 103, 
111, 114, 116. As mentioned in the introduction, the production of both the Microsprayer® and 
AeroProbe™ catheter have been halted (PennCentury™ closed for business in 2015 and 
Trudell discontinued the AeroProbe™ in its product line), so new sprayers like the MADgic™ 
atomisation device (Teleflex, Ireland), have been developed (Figure 8-2 A). 
8.1.1.3 MADgic™ atomisation device 
The MADgic™ atomisation device has been used in clinics to deliver topical anaesthesia to the 
airways of patients244, 245 (Figure 8-2 A). The device comprises of an atomiser with tiny holes, 
located at the tip of 28 cm of tubing, to allow its use in intubated patients (Figure 8-2 A and 
B). It also has separate tubing to allow oxygen delivery to the lungs of patients. One drawback 
of this device is that it can only spray a large volume of liquid formulation (1 ml to 5 ml) and 
cannot to be used to deliver smaller volumes (μl) of formulation, like that used for mice. 
Hence, in this in vitro study the starting volume of vector formulation was increased to 1 ml 
by diluting the vector with standard diluent and delivered it as a coarse spray. To deliver a 
spray of the liquid, the formulation is loaded into a 5 ml syringe that is then attached to the 
tubing of the atomiser. Manual pressure is then applied to the bottom of the syringe to push 
the liquid formulation through the tubing to reach the atomiser situated at the tip of the 
device (Figure 8-2 C). The bolus formulation goes through the atomiser, which contains 
microscopic holes (Figure 8-2 D) to generate aerosol droplets that range from 30 to 100 µm246. 
A study using a similar trachea-bronchial sprayer (Microsprayer®), which delivers aerosol 
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droplets of the same size, has demonstrated deposition of the AAV vector in rhesus macaque 
major conducting airways111, which is also the target region for human CF gene therapy42.  
The MADgic™ atomisation device was recently used to deliver vector formulation in a CF gene 
therapy study. Cooney et al. were the first to use this device to effectively deliver an FIV based 
LV vector carrying the therapeutic CFTR gene to the airways of CF pigs87. They demonstrated 
partial correction of the CF gene defect two weeks later in the excised bronchial and tracheal 
airways of the treated animals87. Hence, this pilot study was designed to examine the 
effectiveness of the MADgic™ atomisation device in delivering coarse aerosols of the LV 




Figure 8-2: (A) MADgic™ atomisation device consisting of a 5 ml syringe with the atomiser at its tip and separate 
tubing to enable oxygen delivery to the lungs of intubated patients247, (B) magnified view of 5 ml syringe attached 
to tubing with the atomiser at the tip (scale bar =1 cm), (C) magnified view of the tip (scale bar = 0.5 cm), and (D) 
diagrammatic representation of the atomiser tip showing microscopic holes through which the liquid formulation 
is pushed to generate coarse aerosols (scale bar = 30 µm).  
8.1.2 Hypothesis and aims 
The hypothesis of the present study was based on the results of previously published studies 
described in Section 8.1.1. I hypothesised that delivering a HIV-based LV vector as an 
aerosol/spray through the: 
1) SAW nebuliser would produce similar levels of gene expression as bolus delivery.  
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2) MADgic™ atomisation device would produce gene expression levels comparable to 
bolus delivery. 
The aim of this pilot study was to quantify the gene expression produced by the LV vector 
following aerosol delivery through the SAW nebuliser or the MADgic™ atomisation device and 
compare that to the gene expression obtained by delivering the vector as a bolus dose.  
8.1.3 Methods 
8.1.3.1 Aerosol delivery using the SAW nebuliser  
The SAW nebuliser was mounted onto a metal base to provide support. A hole was made in 
the cap of a 50 ml Falcon tube and was fitted with an O-ring. This cap was then mounted on 
top of the SAW nebuliser to direct the plume of aerosols downward towards the cells (Figure 
8-3 A and B).  
Two aspects of the SAW nebuliser were examined in this study. The first experiment 
quantified how much of the original dose was retained by the nebuliser during aerosol 
delivery, using coloured dye solution. The second experiment examined the effectiveness of 
the nebuliser for delivering a LV vector and compared it to bolus delivery. Results of the first 
experiment were used to adjust the starting volume of the LV vector dose delivered by the 




Figure 8-3: (A) SAW nebuliser apparatus used in the present study (B) diagrammatic representation of the SAW 
nebuliser delivering aerosols onto CHO-K1 cells in a 24-well plate.  
8.1.3.2 Quantifying the residual dose volume retained by SAW nebuliser on aerosol delivery 
A 10 µl aliquot of dye solution (diluted 50% v/v with water) was loaded onto the capillary tube 
and aerosolised by supplying the SAW nebuliser with an electric potential of 100 mV. The 
combined weight of the paper strip and capillary tube was measured before and after aerosol 
delivery was complete (n=5). The difference in weight of the paper strip and capillary tube 
represented the dose volume retained by the SAW nebuliser.  
8.1.3.3 Quantifying the gene expression of LV vector aerosolised using the SAW nebuliser 
A 10 µl aliquot of diluted LV-LacZ vector (diluted 1:250 in PBS, v/v), along with additional dose 
volume of formulation retained by the SAW nebuliser identified from the previous 
experiment (Section 8.1.3.2), was loaded into the capillary tube (unlike previous experiment 
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that used a starting vector dose of 20 µl, the present study used 10 µl of LV vector because 
the maximum volume held by the capillary tube was 15 µl). A thin film of the vector 
formulation was then transferred to the edge of the SAW nebuliser via the paper strip due to 
capillary force within the tube. A plume of LV aerosols released by the SAW nebuliser was 
then directed towards the 0.25 x106 CHO-K1 cells placed in the well. A fresh paper strip was 
used for each sample. Between aerosolisation samples the entire SAW nebuliser setup (Figure 
8-3) was rinsed once with 5 ml of Virkon solution and three times with 5 ml of water and was 
then dried. As a control, 10 µl of diluted LV-LacZ vector was delivered as a bolus dose onto 
CHO-K1 cells using a pipette (n=3/group). Three wells containing untreated CHO-K1 cells were 
used as negative controls. The cells were cultured for 48 hours and then stained with X-gal 
overnight (Section 2.2.5). Three random images of each well were captured using a digital 
camera attached to a stereo-microscope at 40x magnification. The number of transduced cells 
per area of field of view (5 mm2) was quantified using the MATLAB image-analysis script 
(Section 8.2). Gene expression was reported as the number of transduced cells per field of 
view. 
8.1.3.4 Quantifying gene expression of LV vector sprayed using the MADgic™ atomisation 
device 
The MADgic™ atomisation device needed a minimum of 1 ml starting dose volume to 
generate coarse aerosols. Therefore, the LV vector formulation was diluted 1:10,000 with 
MS/saline (v/v) and 1 ml of this diluted vector formulation was used in this study (rather than 
1:250 dilution used in the previous experiment, Section 8.1.3.3). Also, unlike earlier studies, 
the starting volume of vector formulation of the present study was high (i.e. 1 ml compared 
to 20 μl used in previous studies) and delivering 1 ml of vector formulation could flood the 
cells; hence, the vector formulation was not directly sprayed onto the cells in the well. 
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The diluted LV vector was loaded into the barrel of the device and a coarse spray was 
generated by depressing the syringe plunger for a duration of three to four seconds. The 
coarse aerosols of the LV vector were collected in a 15 ml tube. The vector formulation 
retained in the tubing of the device was collected separately and weighed. A 20 µl aliquot of 
the sprayed vector was then used to transfect CHO-K1 cells cultured on a 24-well plate. As a 
replicate, the same volume of the sprayed vector was used to transduce cells in another well 
on the 24-well plate. After each sample, the apparatus was rinsed once with 2 ml of Virkon 
solution and three times with 5 ml of water. As a bolus control, 20 µl of the diluted LV-LacZ 
vector was delivered onto CHO-K1 cells (n=5/ group) using a pipette. Cells were cultured for 
48 hours, X-gal stained overnight, and four random images of each well were captured at 100x 
magnification (Section 2.2.5). The number of transduced cells per area of field of view (2.5 
mm2) was quantified using the MATLAB image-analysis script (Section 8.2). Gene expression 
was reported as number of cells present per field of view. 
8.1.4 Results 
8.1.4.1 SAW nebuliser  
This pilot study (n=3) quantified how much of the 10 μl original dye dose (i.e. 10 mg) was 
retained in the SAW nebuliser during the delivery process. The average combined weight of 
the paper strip and capillary tube before and after delivering dye solution was 17.15 ± 1.6 mg 
(mean ± S.D) and 18.51 ± 1.6 mg, respectively. The maximum weight of the dye solution 
retained in the capillary tube and paper strip following aerosol delivery was 1.5 ± 0.1 mg, 
which was approximately 15% of the initial dose volume. As the maximum dose retained by 
the device was 1.5 mg (i.e. equivalent to 1.5 μl) the volume of the LV vector aerosolised using 
the SAW nebuliser in the subsequent cell culture experiment (Section 8.1.3.3) was set higher 
at 11.5 μl (10.0 μl + 1.5 μl) to account for the dose expected to be retained in the nebuliser. 
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Results showed that gene expression obtained on delivering the LV vector through the SAW 
nebuliser was only 0.16% of bolus delivery (Figure 8-4). Additionally, the number of 
transduced cells in the bolus group of the present study cannot be compared to the bolus 
studies performed later in other experiments (Section 5.3.1 and 5.3.3.2), as the titre of the LV 
vector used in the present study was different to the vector used in the Chapter 5. 
 
Figure 8-4: LacZ gene expression obtained on delivering the LV vector as a bolus dose or as an aerosol using the 
SAW nebuliser. 
8.1.4.2 MADgic™ atomisation device 
The efficiency of delivering the LV vector as a coarse spray using the MADgic™ atomisation 
device was then examined. After aerosolisation of 1 ml of vector formulation, 0.09 ± 0.02 g 
(i.e. equivalent to 90 μl) of the dose was retained in the MADgic™ atomisation device, i.e. 
approximately 9% of the dose volume. Unlike the previous study using the SAW nebuliser, no 
correction for the retained dose was made because delivery volume was far larger (1 ml) than 
the SAW nebuliser and Aeroneb®Pro nebuliser experiments (10 to 20 µl). Similar levels of 
gene expression were observed on delivering the LV-LacZ vector through the MADgic™ 
atomisation device compared to the bolus delivery group (Figure 8-5). This result shows that 
the MADgic™ atomisation device could be an effective way to deliver a coarse spray of the LV 
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vector. Similar to the previous study, the number of transduced cells per field of view in the 
bolus delivery group of the present study was also higher than the bolus delivery group in 
Chapter 5 (Section 5.3.1and 5.3.3.2).  
Unlike the previous study of the SAW nebuliser (section 8.1.4.1), the titre of the LV vector 
used in Chapter 5 and the present study were the same, and so it was possible to make further 
comparisons. The difference in gene expression level was due to differences in the time taken 
to deliver the LV vector onto CHO-K1 cells between experiments reported in Chapter 5 and 
the present study. The time taken to spray the LV vector through the MADgic™ atomisation 
was 3 to 4 seconds; as a result, samples from both aerosol and bolus treatment groups were 
delivered to CHO-K1 cells under 30 seconds. However, time taken to deliver the LV vector 
through the Aeroneb®Pro-flexiVent™ ventilator circuit was 6 to 7 minutes; therefore, samples 
from both treatment groups were delivered to CHO-K1 cells under 8 minutes. During 
aerosolisation experiments, samples from the bolus treatment group were stored at 4° C until 
used. Higashikawa et al. had shown that the half-life of HIV-based LV vector decreases when 
stored at 4° C (and above)64, which could help explain the difference in the number of 






Figure 8-5: LacZ gene expression obtained on delivering the vector as a bolus dose or as a coarse spray using the 
MADgic™ atomisation device. 
8.1.5 Discussion  
The characteristics of two additional aerosol delivery devices with potential for delivering a 
LV vector were examined in this Appendix. The first experiment with the SAW nebuliser 
identified the volume of initial dose retained by the nebuliser; however, one limitation of this 
study was that it did not examine whether increasing the initial dose volume compensated 
for the retained dose losses. Nonetheless, this likely had little impact because the results from 
the subsequent experiment demonstrated negligible levels of gene expression are achieved 
after aerosolising the LV vector through the SAW nebuliser compared to bolus delivery (Figure 
6-4). Thus, the first hypothesis was not supported. One flaw in the design of this experiment 
was that there were no replicates for samples reported in the above experiment (Section 
8.1.3.3). These preliminary studies were observational and while they cannot be used to 
uncover factors controlling the level of gene expression observed, the work of others can 
provide clues to explain the negligible gene expression associated with LV aerosol delivery 
through the SAW nebuliser. One factor may be increased temperature in the LV vector 
formulation during SAW operation and aerosol delivery. Jugo et al. showed that aerosolising 
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a liquid formulation through the SAW nebuliser increased temperature of the formulation to 
50˚C248; and temperatures well below this level known to inactivate HIV-1 based LV vectors 
like that used in the present study64. Shear stress produced during the transfer of vector 
formulation from the loaded capillary tube into the adjoining SAW nebuliser section may also 
be a factor, although shear stresses in the SAW nebuliser are thought to be minimal79, 238. A 
third factor could be that LV vector particles were retained in the paper strip during aerosol 
delivery. Analysis and quantification of vector retention in the paper strip was not performed 
in this study but will be an important facet of future SAW nebuliser development for LV vector 
aerosolisation. Thus, this pilot study showed that the SAW nebuliser in its current form was 
not effective in delivering viable aerosols of the LV vector for use in mouse studies. 
In contrast, the coarse spray produced by the MADgic™ atomisation device demonstrated 
similar levels of gene expression to bolus delivery. This result supports the second hypothesis 
and was consistent with what is known about the MADgic™ atomisation device. The device 
probably imposes minimal shear stress, so the sprayed LV vector would remain largely viable. 
The size of the aerosols produced by this device (30–100 µm) would also have played a role. 
Delivering aerosols of a larger size may have reduced the number of vector particles on the 
surface of the aerosol that were exposed to shear stresses or other factors affecting viability. 
However, the effect of aerosol size on biological viability of LV vector, even through other 
aerosol delivery devices, remains unknown. As the MADgic™ atomisation device was recently 
introduced for use in gene vector delivery studies, researchers are yet to fully assess the 
efficiency of this device in delivering viral vectors.  
Chapter 5 showed that suspending the LV vector in protective diluent improved levels of LV 
gene expression following delivery through the Aeroneb®Pro nebuliser (Section 5.3.3). Thus, 
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similar experiments could be conducted to further increase efficiency of the MADgic™ 
atomisation device in delivering the LV vector. Cmielewski et al. demonstrated that the 
viability of a HIV-based LV vector was improved during transit through a 15 mm tube by 
priming the tube with bovine serum albumin56. Thus, future studies could also examine the 
effectiveness of priming the MADgic™ atomisation device (or any other device identified to 
effectively aerosolise LV vector) with protective agents, such as FreeStyle™ medium.  
A major limitation of the MADgic™ atomisation device for gene therapy research 
development is that it requires a minimum of 1 ml of fluid formulation to deliver a coarse 
spray of aerosols, which restricts the use of this device in small animal models such as mice. 
The large size of aerosol spray delivered by this device (30–100 µm) would not be suitable for 
aerosol delivery to the airways of mice. This is because the size of aerosols in studies using 
mice should lie between 0.5 to 5 µm to achieve effective deposition in mice airways and 
lungs249. However, this device could be used to deliver vector to the airways of larger animal 
models, such as pigs and sheep, where larger volumes are essential to reach sufficient 
portions of the airway or lung; the literature suggests volumes from (0.45 to 5 ml) would be 
needed103, 140, 233. In a recent gene therapy study, Cooney et al. instilled 2 ml of FIV vector to 
the airways of newborn pigs using the MADgic™ atomisation device87. The volume of 
aerosolised vector formulations used in the airways of patients in past CF gene therapy trials 
varied between 1 to 5 ml, depending on the type of vector, nebuliser, concentration of the 
vector formulation, patient lung capacity, and so on92, 93, 250. As the MADgic™ atomisation 
device can deliver up to 5 ml of formulation247 it has the capacity to be used in coarse spray 
delivery of LV vector for future clinical trials, and hence warrants further investigation.  
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8.1.6 Conclusion  
The ability of two novel aerosol delivery devices to deliver viable LV vector was examined in 
this Appendix. Results from this preliminary study show that in its current form the SAW 
nebuliser does not effectively aerosolise the LV vector formulation in an in vitro setting, 
despite previously being successfully used for aerosolising other biological formulations, such 
as pDNA79 and stem cells80. While these findings resulted in this nebuliser not being used in 
further in vivo LV vector delivery studies in this thesis, it is a novel aerosolisation method with 
potential still to be fully realised. The MADgic™atomisation device, in contrast, provided 
levels of gene expression very similar to that of bolus LV delivery. To the knowledge of the 
author, this is the first in vitro study to demonstrate effective delivery of a HIV-based LV vector 
using the MADgic™ atomisation device and the success suggests further in vitro and in vivo 
studies are warranted to better understand the benefits and limitations, and to optimise LV 
aerosol delivery in animals.  
8.2 Image analysis – MATLAB script  
The levels of gene transduction in a 12-well or 24-well plate were quantitated using images 
taken at 40x or 100x magnification via stereo-microscope. The characteristic blue colour 
observed in each well of the cell culture plate is indicative of successful gene expression by 
the LV-LacZ vector. The intensity of blue colour and number of cells present on the cell culture 
plate producing that colour was quantitated using the MATLAB script given below.  
start_path = 'L:\Equipment Data\Microscope\Harsha\'; 
input_format = 'jpg'; 
output_format = 'jpg'; 
Hmin = 0.4;     % Colour (ie blue) 
Hmax = 0.6; 
Smin = 0.15;    % How saturated the colour is 
Vmax = 1;      % How bright it is 
numpixels = 5;   % Number of pixels in cluster required for detection 




% Load the blank file 
[blank_name,blank_path] = 
uigetfile([start_path,'\*.',output_format],'Select the blank image'); 
blank = imread([blank_path,'\',blank_name]); 
  
% Get the folder to process 
folder_name = uigetdir(start_path,'Select the folder containing the files 
to process'); 
files = dir([folder_name,'\*.',input_format]); 
  
% Process each image 
for i = 1:length(files), 
   
  % Load the input file 
  input_name = files(i).name 
  input = imread([folder_name,'\',input_name]); 
   
  % Perform the normalisation with the blank image 
  normalised = double(input)./double(blank); 
 
  % Convert from RGB to HSV color space 
  hsv_image = rgb2hsv(normalised); 
   
  % Select regions of the image that meet the Hue and Saturation max/min 
criteria 
  BW = (hsv_image(:,:,2) > Smin) & (hsv_image(:,:,1) > Hmin) & 
(hsv_image(:,:,1) < Hmax & (hsv_image(:,:,3) < Vmax)); 
   
  % Clean up the results 
  BW = bwareaopen(BW, numpixels); 
   
  % Mark the detected cells 
  STATS = regionprops(BW, 'Centroid'); 
   
  if ~isempty(STATS), 
  im = 
insertMarker(normalised,cat(1,STATS.Centroid),'x','Size',markerSize,'Color'
,'red'); 
  end 
  
  % Count the number of cells 
  cells = num2str(length(STATS)); 
  proportion = num2str(sum(sum(BW)) / (size(BW,1) * size(BW,2)) * 100); 
   
  % Display images and save the output image 
  figure(1), imshow(input); title('Input'); 
%   figure(2),imshow(hsv_image(:,:,1)); title('Hue'); impixelinfo 
%   figure(3),imshow(hsv_image(:,:,2)); title('Saturation'); impixelinfo 
%   figure(4),imshow(hsv_image(:,:,3)); title('Value'); impixelinfo 
  figure(5),imshow(BW); title('Mask'); 
%   figure(6),imshow(BW); title('BW') 
  figure(7),imshow(im);  
  titletext = ['Detected ', cells, ' cells (', proportion, '% area)']; 
  title(titletext); 
 
  % Save the output image 
  imwrite(im,[folder_name,'\',input_name(1:length(input_name)-4),' - 
',titletext,'.',output_format]); 





8.3 Plasmid map of pHIV-MPSV-nlsLacZ  
The plasmid map of pHIV-MPSV-nlsLacZ used in this thesis is shown in Figure 8-6. 
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